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Heather A. Cooke and Professor Steven D. Bruner (Research Advisor) 
Abstract 
 The enediyne antitumor antibiotics are produced by complex biosynthetic 
machinery in acetomycetes.  This dissertation will focus on the study of three enzymes 
involved in key steps in the biosynthesis of two enediynes, neocarzinostatin and C-1027. 
Neocarzinostatin is biosynthesized by a number of enzymes that synthesize and 
decorate the enediyne core and the peripheral moieties.  NcsB1 is one enzyme involved 
in functionalizing the naphthoic acid portion of neocarzinostatin, a key group involved in 
binding to target DNA duplexes.  The enzyme has been shown to be a promiscuous (S)-
adenosylmethionine-dependent O-methyltransferase responsible for methylating a variety 
of hydroxynaphthoic acids.  Multiple crystal structures of NcsB1 cocomplexed to 
substrate and/or cofactor have been solved.  These structures revealed a displacement of 
the C-terminal domain when not bound to substrate, a movement that likely opens up the 
active site for naphthoate binding.  Additionally, the ternary complex structure of 1,4-
dihydroxynaphthoic acid, (S)-adenosylhomocysteine, and NcsB1 was solved and showed 
a rotation of this alternate substrate in the binding pocket, allowing for methylation.  
These results led us to probe NcsB1 activity using active site mutants, demonstrating 
altered substrate specificity and revealing key residues in substrate binding.   
The final step of neocarzinostatin biosynthesis involves multiple enzymes that 
convergently assemble the multiple biosynthetic intermediates to form the chromophore.  
 NcsB2, originally proposed to catalyze the attachment of the naphthoic acid moiety to the 
enediyne core, has been characterized in vitro.  Studies into its substrate specificity as an 
adenylation domain led to a revised biosynthetic pathway of 2-hydroxy-7-methoxy-5-
methyl naphthoic acid.  Instead of catalyzing the attachment of an enzyme bound 
naphthoic acid to the enediyne core, NcsB2 was found to act as a CoA-ligase, activating a 
variety of naphthoic acids and forming a naphthoyl-CoA intermediate.  The results of 
these studies present an outstanding opportunity to produce novel analogs of 
neocarzinostatin by manipulating its biosynthesis. 
 C-1027 is an architecturally similar enediyne that is also biosynthesized in a 
convergent route. C-1027 is a member of a class of enediynes that contains a 
functionalized !-tyrosine derived from L-tyrosine.  The first catalytic step towards this !-
tyrosine moiety is achieved by SgTAM, a tyrosine aminomutase that catalyzes a 2,3-
amino shift on L-"-tyrosine to form (S)-!-tyrosine.  The first X-ray crystal structure of 
SgTAM was recently solved by our group, revealing structural homology to ammonia 
lyases.  Through site-directed mutagenesis, X-ray crystallography, and biochemical 
analysis, residues that influence the mechanism by which SgTAM catalyzes this difficult 
transformation were explored.  From these studies, the enzymatic base and other pertinent 
residues involved in catalysis have been identified.  In addition, residues that close the 
tunnel leading to the active site, thought to play a key role in mutase activity, were 
probed.  Further study of rational mutants of SgTAM will allow us to engineer its activity 
to alter its substrate specificity and the type of product it produces. 
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Chapter 1  
History, Activity, and Biosynthesis of Enediyne Antitumor Antibiotics 
 2 
1.1 Overview 
Enediyne antitumor antibiotics are a class of highly cytotoxic secondary 
metabolites.  They are characterized by a core motif consisting of two acetylene units 
conjugated to a Z-olefin within a larger nine- or ten-membered ring.  Additionally, many 
enediynes have a DNA recognition unit and a nucleophilic component that triggers the 
formation of the active species.  The active form of an enediyne is a diradical species, 
which acts as a “warhead” causing single and/or double stranded DNA breakage, leading 
to apoptosis.  Enediynes have gained popularity because of their potent antitumor 
activity.  Their biosynthetic machinery can likely be cloned and reproduced using E. coli 
as a heterologous host, adding to their value as drugs (1).  Still, the extreme cytotoxicity 
of these structurally complex necessitates control of their reactivity for use as 
therapeutics (2).  The nine-membered subfamily of enediynes are composed of a small 
molecule chromophore bound to an apoprotein, which sequesters and stabilizes the 
reactive enediyne and aids in delivery to target cells (3).  The biosynthetic gene clusters 
of multiple enediynes from actinomycetes have recently been sequenced and annotated, 
allowing detailed investigation into their complex biosynthesis (4-9). The pathways 
utilize diverse enzymology to construct the natural products, including the use of 
polyketide synthase (PKS) and nonribosomal peptide synthetase (NRPS) machinery. 
Alteration of the peripheral moieties surrounding the enediyne core may be a way to 
mediate the reactivity and specificity of these therapeutically useful compounds (2).  This 
dissertation will focus on structural and mechanistic studies into the biosynthesis of two 
enediyne antitumor antibiotics, neocarzinostatin (NCS) and C-1027 (Figure 1.1).   
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1.2 Discovery of enediynes 
 In 1965, Ishida et al reported evidence for the first enediyne from extracts of 
Streptomyces carzinostaticus (10).  The two-component complex showed substantial 
activity against a variety of gram-positive bacteria.  Additionally, the complex was 
effective against a strain of leukemia cells but was found to spare non-cancerous cells.  
The remarkable ability of this compound to target cancer cells that were typically 
impenetrable by the current therapeutics of the time made this natural product a 
compound of interest.   Unfortunately because of its instability, it was not until 20 years 
later that the chemical structure of the NCS chromophore was elucidated (Figure 1.1).  It 
was found to contain a novel bicyclo[7.3.0]dodecadiynene ring system (11), which was 
decorated with a deoxyamino sugar and a naphthalene moiety, making it the archetypal 
member of the soon to be growing class of nine-membered endiynes.  The absolute 
stereochemistry of NCS was determined in subsequent studies (12).  The discovery of 
two additional classes of enediynes, the calicheamicins from Micromonospora 
echinospora ssp. calichensis (13, 14) and the esperamicins from Actinomadura 
verrucosospora (15, 16) (Figure 1.1), sparked further interest into this now growing class 
of natural products.  The calicheamicins and esperamicins differ significantly from NCS 
in that they both possess a bicyclo[7.3.1]tridecadiynene system, and constituted a new 
class of antitumor antibiotics: the ten-membered enediynes.  Both are decorated with 
deoxyamino sugars and are functionalized with a trisulfide responsible for converting the 
enediyne core to its active species.  A fourth structural was isolated in 1989; dynemycin 
A (17) was the third ten-membered enediyne to be added to this class.  Since then, 
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additional members of the nine-membered enediyne class have been discovered, 
including C-1027 (18, 19), kedarcidin (20), and maduropeptin (21) (Figure 1.1). 
Figure 1.1: Nine- and ten-membered enediyne chromophores. 
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1.3 Apoprotein and peripheral moieties 
Unlike ten-membered enediynes, nine-membered enediynes readily 
cycloaromatize to their active, diradical species and therefore require an outside source of 
stabilization so that they are not toxic to the producing organism.  NCS naturally occurs 
in complex with a 147 amino acid protein, called the NCS apoprotein (NcsA).  Early on, 
it was realized that the biological activity of NCS is imparted by the chromophore and the 
role of the apoprotein is to modulate activity by stabilizing, sequestering, and transporting 
the chromophore.  Studies towards exploitation of the apoprotein to improve the stability 
and delivery of NCS have been reportd (22). 
C-1027, isolated from Streptomyces globisporus in 1988 (23-25) and initially 
structurally characterized in 1993 (18, 19), also belongs to the chromoprotein class of 
antitumor antibiotics.  Like NCS, the enediyne core of C-1027 is also decorated with 
peripheral moieties, including a benzoxazolinate, a functionalized  !-tyrosine, and a 
deoxyamino sugar and is bound to the 119 amino acid apoprotein CagA.  CagA and 
NcsA share 40% sequence identity.   
Both the benzoxazolinate from C-1027 and the naphthalene unit from NCS play a 
role in binding to the apoprotein (26-30).   From structural studies of both apoproteins, 
the enediynes rely on crucial !-stacking interactions, which preclude the enediynes from 
cyclizing (30-32).  Upon release from the apoprotein and following binding to DNA, the 
chromophores convert to their corresponding active diradical species.  The apoprotein of 
NCS also acts to sequester the chromophore from endogenous thiols, which trigger the 
electronic rearrangement required to form the reactive diradical species.   
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1.4 Mechanism of action 
 The reactive agent of all enediynes is a carbon-centered diradical species.  The 
general mode of action to form this species begins with the enediyne binding to DNA.  
Diradical formation occurs automatically or following an electronic rearrangement, 
which then causes DNA lesions via single-stranded and double-stranded cleavage.  The 
mechanism by which individual enediynes reach this species varies slightly and 
mechanisms for C-1027 and NCS will be discussed here.   
 C-1027 is released from the apoprotein and intercalates DNA via its 
benzoxazolinate moiety.  Because the apoprotein is no longer stabilizing the enediyne 
core through !-stacking interactions, there is sufficient orbital overlap for a Bergman 
cyclization to occur, forming the active benzenoid diradical species, which in turn 
abstracts hydrogens from target DNA (Figure 1.2).    
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Figure 1.2: Mechanism for C-1027 activity.  Upon release from the apoprotein, the enediyne 
intercalates DNA.  Next, the enediyne rapidly undergoes a Bergman cyclization, forming a 
benzenoid diradical species, which is responsible for hydrogen abstraction from the deoxyribose 
sugar of DNA. 
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Contrarily, NCS requires activation via an endogenous thiol to affect a Myers-
Saito rearrangement (Figure 1.3).  The NCS chromophore intercalates into the minor 
groove of DNA via its naphthalene unit, positioning the enediyne core for hydrogen 
abstraction from the deoxyribose backbone (33).  Upon nitrogen-assisted (from the 
deoxyamino-sugar moiety) nucleophilic attack by a thiol at C12 (30), the enediyne core 
rearranges, resulting in opening of the epoxide and cumulene formation.  At this point, 
the diradical species is formed by rapid cycloaromatization, followed by hydrogen 
abstraction from the DNA backbone. 
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Figure 1.3: Mechanism for NCS activity.  Release from the apoprotein and intercalation of DNA 
leads to a Myers-Saito cyclization triggered by nucleophilic addition of a thiol into C12.  Electronic 
rearrangement of the enediyne core results in formation of a cumulene intermediate, which rapid 
collapses to the active diradical species. 
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 In both cases, hydrogen abstraction occurs at the deoxyribose sugar of the DNA 
strand, resulting in the formation of deoxyribose carbon-centered radicals.  Rapid 
reaction with molecular oxygen results in the production of abasic sites and strand 
breakage, producing DNA fragments (Figure 1.4) (34).  Double-stranded DNA breaks in 
particular are difficult to repair by the host cell and therefore are highly detrimental, 
causing apoptosis.  NCS cleavage occurs primarily at ACT/AGT trinucleotide sites, with  
80% of hydrogen abstraction occurring at the C5' of A and T residues (35-37).  Less than 
20% of DNA strand breaks are a result of abstraction from C4' and C1'.  C-1027 usually 
causes breakage at the penta-nucleotide site GTTAT/ATAAC (38, 39).  Hydrogen 
abstraction typically occurs at the C4' and C5' hydrogen atoms of the A from GTTAT and 
ATAAC, respectively. 
1.5 Therapeutic applications 
While enediynes are highly toxic, they still can be of therapeutic benefit.  The 
producing organisms are able to control their toxicity by coproducing them with an 
apoprotein and by decorating the highly reactive enediyne core with peripheral moieties 
Figure 1.4: DNA cleavage products.  Hydrogen abstraction occurs primarily at C5’ and 
sometimes at C4’ and C1’.  
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that can modulate their reactivity.  Also, studies of their DNA cleaving activity 
demonstrate that they do not act randomly and that DNA binding instigates diradical 
formation.  This controlled reactivity is very important for the development of drugs, but 
the ability to target cancer cells is far more crucial.  Enediynes have been successfully 
used as anticancer drugs in covalent conjugation to a stabilizing agent or a drug carrier.  
NCS was the first enediyne to be manipulated in such a manner.  The poly(styrene-co-
maleic anhydride)-conjugated form of NCS (SMANCS) was approved for use in Japan in 
1993 for treatment of liver cancer (40-42).  Due to their higher stability, ten-membered 
enediynes have also found utility as chemotherapeutics.  Calicheamicin conjugated to a 
CD33 monoclonal antibody (mAB) is now approved for use in the United States under 
the name Mylotarg (43).  CD33 is expressed in most leukemia cells and therefore the 
calicheamicin conjugate targets these cells and is substantially less toxic to normal cells.  
C-1027 also showed some early success an as antihepatomic agent as a mAB-C-1027 
conjugate (44). More recently C-1027 has been shown to be an effective radiomimetic 
that can specifically cause DNA strand breaks by targeting hypoxic cancer cells (45). 
1.6 Biosynthesis 
Despite efforts in developing total synthetic routes to these compounds, nine-
membered enediynes are particularly difficult to access through standard organic methods 
due to their structural complexity and chemical instability when not in complex with an 
apoprotein.  The biosynthetic gene clusters of C-1027 and NCS have been sequenced and 
annotated (5, 7) and both have been found to utilize interesting chemistry in order to 
access these complex natural products (Figure 1.5).  The C-1027 gene cluster contains 
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sgcE, which encodes for SgcE, a novel type I polyketide synthase (PKS) (7).  A 
homologous gene is found in the NCS gene cluster, ncsE.  Both genes encode for 
enzymes that are responsible for producing the unsaturated polyene that makes up the 
carbon scaffold of the respective enediyne cores of the two natural products (46, 47).  In 
the C-1027 gene cluster, a variety of open reading frames (ORFs), sgcE1 to sgcE11, were 
identified and share sequence homology to genes within the NCS biosynthetic gene 
cluster (ncsE1 to ncsE11) but were not homologous to any proteins of known function 
(5).  These enzymes, along with the epoxide hydrolase SgcF (and the corresponding 
enzymes for NCS, NcsF1 and NcsF2), are likely responsible for producing an enediyne 
intermediate of C-1027 (Figure 1.5A).  PCR amplification of PKSs from known gene 
clusters has resulted in a high-throughput method to access minimal PKS gene cassettes 
from organisms previously not known to produce enediynes (4). 
 In addition to genes responsible for encoding proteins involved in production of 
the enediyne core, for C-1027 six enzymes were assigned to produce the D-glucose 
derived deoxyamino sugar (SgcA to SgcA5), five enzymes for the functionalized !-
tyrosine (SgcC to SgcC4), and six enzymes for the benzoxazolinate (SgcD to SgcD5).  
Additionally, each peripheral moiety was assigned a gene responsible for encoding an 
enzyme that would catalyze its attachment to the C-1027 enediyne core (SgcA6, SgcC5, 
and SgcD6) (Figure 1.5A).   
Similarly for NCS, six enzymes were assigned to produce the deoxyamino sugar 
(NcsC to NcsC5), three enzymes for the functionalized naphthoic acid (NcsB, NcsB1, 
and NcsB3), followed by two additional enzymes (NcsB2 and NcsC6) that
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catalyze the addition of the two moieties to the enediyne core (Figure 1.5B).   
The goal of this dissertation is to study specific enzymes involved in the 
biosynthesis of these two enediynes.  Their convergent biosynthesis could be exploited to 
produce enediyne analogs with altered antitumor properties by engineering one or more 
Figure 1.5: Early proposed convergent assembly. A) C-1027 requires three enzymes, SgcD6, 
SgcA6, and SgcC5, to attach the benzoxazolinate, deoxy-aminosugar, and !-tyrosine to the 
enediyne core.  B) NCS is assembled with NcsB2 and NcsC6 catalyzing the attachment of the 
naphthoate and deoxy-aminosugar moieties to the core scaffold. 
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of the enzymes involved in the production or attachment of the peripheral moieties.  The 
three enzymes that will be discussed in the following chapters are all candidates for 
rational engineering.   
Chapter 2 will be a discussion of studies into the SAM-dependent O-
methyltransferase NcsB1, which is involved in the biosynthesis of the naphthoate moiety 
of NCS (48, 49).  Studies into the specificity of NcsB1 have proved that it 
regiospecifically methylates a variety of aromatic aryl acids.  Structural work and site-
directed mutagenesis has led to insight into specificity determinants.  Chapter 3 involves 
studies into the promiscuity of NcsB2, a CoA-ligase originally believed to attach the 
functionalized naphthoic acid to the enediyne core (50).  Studies of this enzyme have lead 
to significant changes to the proposed biosynthesis of NCS, which will be discussed in 
detail.  Also, we have identified a range of substrates that are activated by NcsB2.  This 
observed promiscuity suggests that this enzyme can be exploited to produce analogs of 
NCS by varying the naphthoic acid unit it activates and is subsequently attached to the 
enediyne core.   
Chapter 4 involves studies of the enzyme SgTAM, also known as SgcC4, an 
MIO-dependent tyrosine aminomutase responsible for producing  !-tyrosine, which is 
subsequently functionalized by downstream enzymes and incorporated into C-1027 (51).  
This class of enzymes performs a difficult chemical transformation via a mechanism that 
is still under debate.  Through site-directed mutagenesis and structural studies of SgTAM, 
we are closer to understanding how it affects the conversion of L-tyrosine into !-tyrosine.   
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Finally, Appendix A includes a discussion of and experimentals for the cloning of 
three ncsEs and attempts at isolating, purifying and crystallizing the enzymes for which 
they encode.  Appendix A also includes details of the synthesis of the benzoxazolinate 
moiety of C-1027.  Appendix B is a review of MIO chemistry based largely on recent 
structural characterization of MIO-containing enzymes (52). 
1.7 Future outlook 
 The development of new cancer treatments is a constant goal for pharmaceutical 
and research institutions.  We hope the knowledge gained from studies of enediyne 
biosynthetic enzymes will aid in the design and engineering of useful therapeutics.  
Accessing complex natural products via organic synthesis is a significant challenge in 
terms of time and efficiency.  Reactive enediynes are particularly difficult as synthesizing 
an array of unstable compounds is a challenge.  Production of enediynes using rationally 
altered enzymatic machinery may be a facile way of accomplishing this goal.  For 
example, we have synthesized a variety of analogs of the naphthoic acid moiety of NCS 
(see Chapter 3).  Production of NCS analogs may be as simple as feeding the free 
naphthoic acid analogs into S. carzinostaticus media (Figure 1.6).  With a combination of 
organic synthesis and molecular biology, accessing a variety of NCS analogs may only be 
limited by the specificity the NcsB2.  Furthermore, rational engineering of enzymes 
upstream of those responsible for their convergent assembly may also be away to produce 
analogs.  In addition to the enzymes in the naphthoic acid pathway of NCS, with proper 
engineering of the !-tyrosine producing SgTAM, we may be able produce other  !-amino 
acids, which may be incorporated to for C-1027 analogs.  The possibilities are limited to 
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our knowledge of enzyme chemistry and further research will support the field of drug 
development.  
 
Figure 1.6: Production of NCS analogs using organic synthesis and molecular biology 
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Chapter 2  
Molecular Basis of Substrate Promiscuity for the SAM-Dependent O-
Methyltransferase NcsB1 Involved in the Biosynthesis of the Enediyne 
Antitumor Antibiotic Neocarzinostatin 
 
 
 
 
 
 
Adapted from an article published in Biochemistry 2009, 48, 9590-8 in collaboration with 
E.L. Guenther, Y. Luo, B. Shen, and S.D. Bruner 
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2.1 Introduction 
The recent cloning and sequencing of the NCS biosynthetic pathway from 
Streptomyces carzinostaticus revealed a convergent assembly with two polyketide 
synthases playing central roles in building the carbon framework (1-3).  The scaffold for 
the naphthoate moiety in NCS is constructed by an iterative type I polyketide synthase 
via a mechanism common to the biosynthesis of diverse aromatic products (4-6).  Four 
additional gene products decorate and couple the naphthoic acid to the enediyne core 
(Scheme 2.1).  The activation and attachment steps will be introduced here but will be 
further elaborated in Chapter 3. 
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core with O-methyltransfer reaction catalyzed by NcsB1 boxed 
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The product of NcsB (2.2) is first hydroxylated at the C-7 position by a 
cytochrome P450 hydroxylase (NcsB3) to produce 2.3. The resulting hydroxyl group is 
methylated by NcsB1, producing the methyl ether 2.4 present in the natural product. This 
functionalized naphthoic acid is activated via adenylation, converted to the aryl-CoA 2.5 
by the CoA-ligase NcsB2, and is finally attached to the enediyne core by NcsB4 (a 
putative acyltransferase) to produce the natural product (2.1). The assignment of the 
naphthoic acid biosynthetic pathway is based on bioinformatic analysis (1) and 
biochemical characterization of NcsB2 as a CoA-ligase (7) and NcsB1 as an S-
adenosylmethionine (SAM)-dependent O-methyltransferase (O-MTase) (8).  NcsB1 was 
shown to catalyze the third step in the biosynthesis of the naphthoate moiety of the NCS 
chromophore (2.3 to 2.4).  Biochemical analysis also revealed relaxed substrate flexibility 
towards substituted naphthoic acids, and methylated 3-hydroxy-2-naphthoic acids with 
the reactive hydroxyl group located at either the 5 or 7 position on the ring.  NcsB1 also 
was demonstrated to methylate 1,4-dihydroxy-2-naphthoic acid (Figure 2.1, 2.6) at the 4-
hydroxyl group, which was surprising because of the large difference in the location of 
the reactive hydroxyl group from that on the natural substrate, necessitating a 
reorientation of the substrate in the active site.  This observation led to the prediction of a 
model by which naphthoic acids flexibly bind the active site, and that the 1,2-hydroxy  
Figure 2.1: 1,4-Dihydroxy-2-naphthoic acid, an alternate substrate 
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acid functionality was required for substrate binding and SAM-dependant methylation 
(8).  
There are ~160 classes of SAM-dependent MTases comprised of thousands of 
identified members. These functionally diverse enzymes methylate a wide range of 
substrates, including nucleic acids for regulation of gene expression, DNA repair or 
protection against restriction enzymes, proteins for repair or control of signal transduction 
pathways, hormones and neurotransmitters, and biosynthetic intermediates to produce 
secondary metabolites.  Structurally characterized MTases can be segregated into five 
general classes based on specific structural features (9).  Among the several examples of 
MTases that act on small molecules, catechol O-MTase isolated from rat liver was the 
first to be structurally characterized (10).  This structure exemplifies the basic SAM-
MTase core fold: a mixed !, " secondary structure with a "-sheet flanked on each side by 
three !-helices (11). A common feature of the active site of MTases is a glycine-rich 
region within the SAM binding pocket.  Despite low overall sequence homology amongst 
family members, structurally characterized SAM-MTases share this common fold and the 
biologically active unit typically exists as a homodimer. 
The role of NcsB1 was assigned in the enediyne neocarzinostatin biosynthetic 
pathway based on sequence homology to small molecule SAM dependent O-MTases 
including DnrK, an enzyme involved in the biosynthesis of the aromatic polyketide 
antibiotic daunorubicin from S. peucetius (44% sequence identity) (12).  The X-ray 
crystal structure of DnrK revealed a homodimer with each monomer exhibiting the 
conserved small molecule MTase fold (13).  RdmB from rhodomycin biosynthesis in S. 
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purpurascens is also homologous to NcsB1, sharing 44% sequence identity and 58% 
similarity, but interestingly is a hydroxylase, not an O-MTase (14, 15).  RdmB was used 
as a model for molecular replacement in solving the crystal structure of DnrK.  In 
addition to DnrK, other bacterial small molecule O-MTases structures have recently been 
determined, including examples requiring a cation for catalysis.  Cation-dependent O-
MTases include CmcI from cephamycin biosynthesis (16), LiOMT from the pathogenic 
bacterium Leptospira interrogans (17), and BcOMT2 from Bacillus cereus (18).  A 
limited number of cation-independent bacterial O-MTase structures have been 
structurally characterized and include DnrK and RebM from rebeccamycin biosynthesis 
(19).  
We sought to determine the structural basis for NcsB1 activity in a variety of 
cocomplexes with SAM or S-adenosyl-L-homocysteine (SAH) with or without 5-methyl-
2-hydroxy naphthoic acid (2.2), product (2.4), or 1,4-dihydroxy-2-naphthoic acid (2.6), 
an alternate substrate. The structures reveal that NcsB1 shares an overall architecture 
common to the large MTase family. The active site binding pocket is able to 
accommodate the natural substrate and structurally diverse analogs, allowing efficient 
methylation with distinct regiospecificity.  The specificity determinants of the naphthoate 
binding pocket were probed using site-directed mutagenesis and alternate substrates.  
Based on the results, we identified residues that affect the substrate specificity of the 
enzyme and tested NcsB1 for O-methyltransferase activity with alternate substrates.   
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2.2 Crystallization and x-ray structure determination 
 The 34.5 kDa/332 residue NcsB1 was cocrystallized with various combinations of 
SAH, SAM, deshydroxy-substrate analog 2.2 and the methylated product 2.4. The analog 
2.2 was used in crystallization experiments due to the oxidative instability of the substrate 
(2.3) over extended time periods. Two crystal forms were generated depending on the 
bound small molecules. When cocrystallized with a substrate analog/product and SAH or 
SAM, the cocomplex crystallized in the P65 space group.  In the absence of naphthoic 
acid, distinct crystals belonging to the C2221 space group formed.  The ternary complex 
of NcsB1/SAM/2.2 was the initial structure solved using molecular replacement with a 
polyalanine dimer model of DnrK (44% identity) as the search model.  This structure was 
then used as a search model for the alternate cocomplexes. Solution of the NscB1/SAH 
complex (C2221 space group) by molecular replacement was not straightforward, 
suggesting an alternate overall structure.  The final structural model was obtained by 
performing rotation and translation searches separately on the N- and C-terminal 
domains.  While a 0.6 Å RMSDC! was observed amongst the P65 structures, the 
NcsB1/SAH structure differed significantly from the others by an RMSDC! of 1.8 Å.  In 
addition, the two subunits of the NcsB1/SAH structure were quite distinct, with an 
RMSDC! of 2.8 Å between the homodimer chains.   
2.3 Overview of the structures 
The resulting dimer models of NcsB1 display a high degree of structural 
similarity with DnrK (RMSDC! = 1.8 Å).  In the initial NcsB1/SAM/2.2 structure, and 
others in the P65 space group, the two monomeric subunits exhibit a high degree of 
 27 
symmetry.  Each subunit of the NcsB1 dimer is made up of three domains totaling 
nineteen !-helices and eight "-sheets (Figure 2.2).  The N-terminal domain is largely !-
helical, with just two "-strands ("1 and "2), and constitutes most of the residues involved 
in the homodimer interface (~5300 Å2 total surface).  Of note, !5 (residues 52-65) has 
significant interactions with !18 (residues 284-292) from the C-terminal domain of the 
paired dimer.  The dimer interface is made up of primarily hydrophobic residues, and a 
dimeric biological unit was supported by size-exclusion chromatography (Figure 2.3).  A 
middle domain acts as a hinge-like region between the two larger terminal domains and is 
made up of !-helices 9-11.  The C-terminal domain exhibits a Rossman-like fold ("3-9 
flanked by !12-19), which is conserved in structural homologs and makes up the 
majority of the SAM binding site (19).  Based on structural alignment using the DALI 
server, NcsB1 shares the highest structural similarity with SAM-dependent enzymes that 
act on small molecules (Table 2.1, Figure 2.4) (20).  Homologs include DnrK (an O-
MTase) and RdmB (a hydroxylase), isoflavone-O-MTase from alfalfa (21), a putative O-
MTase from Nostoc punctiforme, a phenazine-specific N-MTase from Pseudomonas 
aeruginosa (22) and caffeic acid 3-O-MTase from alfalfa (23).  Among the structures, an 
indicative glycine-rich region of the SAM binding pocket is conserved. These six 
structural homologs demonstrate the ability of the conserved scaffold to catalyze a variety 
of transformations. 
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Figure 2.2: Cartoon representations of NcsB1. (A) Dimer of NcsB1 with the active site region 
indicated.  Chain A is colored light blue and chain B yellow. Ligands are depicted in stick format 
with SAH in red and naphthoic acid (NA, 4) in cyan.  B) Close up view of monomer with 
secondary structural elements and hinge regions labeled.   
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Table 2.1: Dali Structural Homolog Search (20) 
Positiona PDBb Zc 
RMSDCa 
(Å) 
# eq. 
res. 
# res. 
%ID of 
eq. res. 
Description 
1 (13) 1TW3 39.2 1.8 324 340 44 DnrK, Streptomyces peucetius 
5 (14) 1XDS 37.5 1.7 316 336 45 RdmB, Streptomyces purpurascens 
10 (21) 1FPX 29.6 3.8 309 345 23 IOMT, alfalfa 
12 2R3S 29.1 3.6 314 330 18 NPOMT, Nostoc punctiforme 
13 (22) 2IP2 28.7 4.8 317 330 26 PhzM, Pseudomonas aeruginosa 
16 (23) 1KYW 27.0 4.3 313 361 25 COMT, alfalfa 
a Position in listing of structural homologs.  Gaps indicate additional structures(s) of identical proteins.  
Reference in parentheses. 
b Protein Data Bank code     
c Strength of structural similarity    
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Figure 2.3: Size-exclusion chromatography calibration for estimating biological active unit of 
NcsB1 (!). Kav for NcsB1 = 0.491; Calculated size = 84.3 kDa, ~2 monomers. Actual size = 69.0 
kDA. 
 
 30 
 
Figure 2.4: Sequence alignment of NcsB1 structural homologs as determined by DALI structural 
alignment server.  Abbreviations used with accession codes from the RCSB Protein Data Bank in 
parentheses:  DnrK, S. peucetius O-MTase (Q06528); RdmB, S. purpurascens hydroxylase 
(Q54527); IOMT, alfalfa O-MTase (O24529); NPOMT, N. punctiforme putative O-MTase 
(ZP_00112478); PhzM, P. aeruginosa N-MTase (Q9HWH2); COMT, alfalfa O-MTase (P28002). 
Completely conserved residues are yellow, highly conserved residues are blue, and conserved 
residues are green.  Catalytic residues are indicated by an asterisk and conserved glycine region 
is boxed.  
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In the NcsB1/SAH cocomplex structure, the C-terminal domain of chain B is 
rotated by ~20o compared to NcsB1/SAH/2.2, displacing !13 by 6.8 Å and "8/"9 by 9.4 
Å (Figure 2.5). This movement 
results in a more open 
conformation of the active site, 
possibly functioning to allow the 
entrance of substrate. A similar 
domain displacement was seen in 
the DnrK ternary complex where 
two crystals with different space 
groups were also observed (13).  
Both DnrK crystals were bound 
to SAH and product, but the B-
factors were higher in one of the two subunits, suggesting lower occupancy of the 
ligands.  One of the crystal structures exhibited a significant difference between the two 
monomers, with an RMSDC! of 1.3 Å.  Likewise, the RdmB structures exhibit a domain 
movement upon substrate binding, though in this cocomplex structure, both domains 
were displaced (14). The NcsB1/SAH cocomplex described here exhibits a larger 
difference, likely due to complete lack of substrate analog or product in the crystallization 
conditions.  In addition, SAH bound in the open subunit (chain B) has higher relative B-
factors.  Several regions in chain B showed weak or no electron density, possibly 
indicating areas of flexibility on which the domain can twist.  These hinge regions 
Figure 2.5: Overlay of NcsB1/SAH/4 monomer (light 
blue) and NcsB1/SAH monomer (red). 
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include part of !11 (residues 150-159), the loop region between "7 and !18 (residues 
274-282) and the loop between !18 and !19 (residues 297-301) (Figure 2.2). 
2.4 SAM/SAH binding pocket 
 The SAM/SAH binding pocket is located at the C-terminus of the "-strands 
comprising part of the Rossman-like fold.  Electron density for SAM or SAH is clearly 
defined in all four cocomplex structures and the SAM binding interactions are largely 
conserved among small molecule MTases.  The adenine ring is involved in a hydrogen-
bonding interaction with Ser227, a # interaction with Phe228 and the binding pocket is 
lined with additional aromatic and/or hydrophobic residues, including Trp133, Trp248, 
Phe229 and Leu201 (Figure 2.6).  The ribosyl moiety is anchored by two hydrogen bonds 
between Asp200 and Ser143 and the homocysteine portion of SAM forms hydrogen 
bonding interactions with the sidechains of Asp175, Ser242, His153 and the backbone 
carbonyl of Gly177.  The LDXGXGXG motif indicative of SAM-utilizing proteins is 
found in NcsB1 as VDVGGGSG and is located between "3 and !14.  We previously 
reported that NcsB1 alkylates the substrate 2.3 with a variety of SAM analogs, including 
S-ethyl and S-n-propyl, to the corresponding 7-alkyl ether with reasonable efficiency (8).  
The nearest side chain to the methyl-group on SAM is the sterically small Ala243 (3.5 Å 
distance).  Based on the large size and flexibility of the substrate binding pocket, it is not 
surprising that NcsB1 could accommodate larger SAM analogs.    
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2.5 Naphthoic acid binding pocket  
 The naphthoic acid binding site is located at the juncture of helices from all three 
subdomains, including !7, !10, !11, !16, and !18, and the pocket is lined primarily 
with hydrophobic/aromatic residues (Figure 2.6).  Three methionine sidechain thioethers 
(Met150, 286 and 290) are present on either side of the naphthoate ring forming van der 
Waals interactions with the substrate.  The carboxylate and 2-hydroxyl group of the 
substrate interacts with Arg11 directly and with Asp157 through an ordered water.  This 
interaction represents the only hydrogen bonds between the enzyme and substrate and 
appears to anchor the naphthoic acid into the active site adjacent to the bound SAM.  In 
order to probe the importance of Arg11 in enzyme activity, site-directed mutagenesis was 
used to alter this site and the activity was evaluated.  This residue was mutated to Ala and 
Lys to assess the requirement of this hydrogen-bonding interaction for binding naphthoic 
Figure 2.6: Active site of NcsB1/SAM/2.2. (A) Substrate and SAM binding pocket. SAH is 
shown in green and naphthoic acid 2.2 in cyan; residues in the substrate and SAM binding 
pockets are shown in grey with pertinent hydrogen-bonds indicated. (B) Close up of active site 
in NcsB1/SAM/2 structure with 7-hydroxy group modeled onto 2.2, with the likely catalytic 
residues shown in grey.  SAM is shown in green and the naphthoic acid 2.3 in orange. 
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acids. Unexpectedly, the Arg11Ala mutant still effectively methylated naphthoic acid 2.3 
(Table 2.2), although the results showed a doubling of KM that was countered by a similar 
increase in kcat. The Arg11Lys mutant had 110% of the catalytic efficiency as compared 
to the WT.  This mutant likewise showed an increased rate of turnover.  This observation 
suggests that the specific hydrogen bond from Arg11 is not entirely crucial for substrate 
turnover and can be compensated for by a similar interaction with Lys or by increased 
overall catalytic turnover.  In addition, a simple benzoic acid lacking a hydroxyl group 
adjacent to the aryl acid (3-hydroxybenzoic acid, 2.9, Table 2.5) was methylated by 
NcsB1, although at a significantly decreased rate, further suggesting that the 1,2-hydroxy 
acid motif is not absolutely required for enzyme-catalyzed chemistry. 
Table 2.2: Kinetics of NcsB1 and mutant constructs 
Protein/substrate KM (µM) kcat (min
-1) 
kcat/KM 
(rel to WT/NA) 
WT/2.3 (8) 206 ± 49 0.69 ± 0.05 1 
Tyr293Ile/2.3   649 ± 9 0.76 ± 0.04 0.35 
Arg11Trp/2.3 400 ± 68 0.60 ± 0.03 0.45 
Arg11Ala/2.3 419 ± 61 1.24 ± 0.06 0.88 
Arg11Lys/2.3 319 ± 40 1.18 ± 0.05 1.10 
 
2.6 NcsB1 residues involved in methyltransferase chemistry 
Roles for residues in the active site relevant for catalysis could include activation 
of the phenol for nucleophilic attack via acid/base chemistry.  Histidine residues 
specifically have been implicated to play this role in RebM, a carbohydrate O-MTase in 
rebeccamycin biosynthesis, where mutation of two histidine residues in the substrate 
binding pocket to alanines led to a complete loss of activity, while single mutations 
showed a marked decrease in activity (19).  In NcsB1, three residues are in close 
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proximity to the substrate phenol; the diad of His246 and Asp247 side chains and the 
backbone carbonyl of Ala243 may function to aid in activation and/or proton shuttling 
(Figure 2.6B).   
2.7 Binding of 1,4-dihydroxy-2-naphthoic acid in active site of NcsB1 
 Previous exploration of substrate specificity of NcsB1 suggested a large degree of 
flexibility for naphthoate binding (8).  A model was proposed that involved anchoring of 
the substrate by the 1,2-hydroxy acid motif and subsequent methylation of exposed 
phenols in proximity to 
bound SAM (Figure 2.7).  
In order to probe this 
hypothesis, the structure of 
NcsB1 bound to 1,4-
dihydroxy-2-naphthoic 
acid (DHN, 2.6) was 
determined.   Methylation 
of this substrate would 
necessitate binding in a conformation distinct from the natural substrate while 
maintaining the interaction with the enzyme through the 1,2-hydroxy acid. In the 
cocrystal structure, the proximity and orientation of 2.6 to SAH and important hydrogen 
bonding partners were readily apparent, despite low resolution (Figure 2.8A).  The 
substrate is bound in an appropriate position for regioselective methylation by SAM with 
an alternate orientation of the bound naphthoic acid.  The methyl group on SAM is ~2.1 
Figure 2.7: Substrate binding scheme for NcsB1 
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Å away from the 5-hydroxyl group of 2.6 and the carboxylate is hydrogen bonded to 
Arg11 via an ordered water (Figure 2.8B). 
2.8 Probing the determinants of the substrate specificity for NcsB1 
 The biosynthetic gene cluster for the related enediyne C-1027 contains a gene 
(sgcD4) with high homology to ncsB1 (56% identity, 67% similarity), and the enzyme is 
proposed to methylate a benzoxazolinate (2.7, Figure 2.9) (24, 25).  Alignment of their 
Figure 2.9: NcsB1 and SgcD4 substrates and model substrate.  Arrow indicates point of 
methylation. 
OH
N
H
O
SgcD4 substrate
benzoxazolinate (2.7)
O
CH3
HO
CO2H CO2H
OH
CO2H
HO
NcsB1 substrate
naphthoic acid (2.3)
2,5-dihydroxybenzoic acid 
(2.8)
OH
Figure 2.8: Binding of alternate substrate, DHN (6). (A) Electron density map of 
NcsB1/SAH/2.6 active site, generated without 2.6.  2Fo – Fc map (blue, 1.5 !) and Fo – Fc map 
(green, 3 !)   (B) Overlay of 2.2 and 2.6 in NcsB1 active site.  Naphthoic acid 2.6 is hydrogen-
bonded to Arg11 via a water and the 4-hydroxyl group is in sufficiently close proximity to SAM 
(from NcsB1/SAM/2.2 structure) for methyl transfer to occur. 
 
 37 
corresponding amino acid sequences shows many residues pertinent to substrate and 
cofactor binding in common (Figure 2.10).  Of nine residues in NcsB1 identified to play a 
role in substrate binding, four have identical counterparts in SgcD4 (Trp96, Phe146, 
Met286, and Met290), two are similar (Met150NcsB1 is a Leu in SgcD4 and Phe294NcsB1 is 
a Tyr) and two residues are distinct (Arg11NcsB1 is a Trp and Tyr293NcsB1 is an Ile).   
Figure 2.10: NcsB1/SgcD4 sequence alignment with key residues boxed.  Naphthoic acid binding 
pocket, solid line; SAM binding pocket, dashed line; Catalytic residues, dotted line. 
In order to probe the substrate specificity determinants of NcsB1, two rational 
mutations were made on the residues in the active site that differed significantly between 
NcsB1 and SgcD4: Tyr293Ile and Arg11Trp.  These two additional mutant constructs 
were assayed against the natural substrate (2.3) (Table 2.2).  Both mutants methylated 
2.3, though they showed significant increases in KM compared to the wild-type enzyme.  
!"#$%&&&'()'*+,,-.)/+,/,0/,12(,3+3,,1/+3,0-.,,)-+1,,4.,5,,),-,05/0+/&67
58"09&&&(/)040)*,,4/:5(,!/)12(,3+3,,1/+.,0-.1,),-1,)4.,4,,,3-445/0+/&;<
&&&&&&&&&=>&=&?&&&&>&==>=>?>>>>>>>>>>>>=>>>>=>>&=>>?>>>?>>??>&=>>>>>
!"#$%&&&/+-/3,3)/@1+0)A)3B)/14@)4A/+00-,,)*+*:/0(!5,3)+)0/)@34/,-5.+&%%7
58"09&&&/+B/13+)//0+0)/)+B1/12/)+2/C40-2,)3+,:@0(4)',)+)4/5@30//-53+&%%D
&&&&&&&&>>=>??&>>=&>>>&>&>&>>&=>?&>&=>>?>>&>&>=>>=?&?>>>=>?>>=>&>>=>
!"#$%&&&1)A2,B23+B)15@:40/)5023/5,5@01/(5--/4/0B1).,,*B0:,,/)-3303))&%E7
58"09&&&1)*,,@2/+B)+2@:40/,402++,45@!+//)A03,1+,2,33,)@0:,51)-3.0/))&%ED
&&&&&&&&>>=?>=>=>>>&?>>>>>??>>&&=&>>=&>=?=?=&&&&??=?>&=>>>=&>>>=>=>>
!"#$%&&&)5))//5,//1,-40/5)13/0/A)2,5,,-++@/01)/5)+,A333)5@@02/2,),))&FG7
58"09&&&)0)5//1,//1,C25/+)13/0/24,3A+,*45@,35)/00+,!,3,)5@@0,/2,),),&FGD
&&&&&&&&>?>?>>=>>>>>&&?>&>>>>>>&&???&>=?&>&&=>>??>>=?>?>>>>>?>>>>>>?
!"#$%&&&B3/5,3/-0:00/5,3,./++C,4,,)5))33/3.4,3,)04-,)'1)(0/+(/1B@))*&FDE
58"09&&&B3/5/3/-0:004,53,./++C,4,,)A1)53@3.451)5,)0,2-1)(0/+(/C.B),*&FDD
&&&&&&&&>>>>&>>>>>>>&==>>>>>>>>>>>>?&>&>=>>>=???&&?>&&>>>>>>>>&&=>?>
!"#$%&&&4+5/,4/)4/,,A,)/,3+,,-2.5B35.34(1,/&GGF
58"09&&&4++344@44/,)+,)/+33,3-2,)25,..A(5,3&GG9
&&&&&&&&>>&=&>=&>>>?=>>>&>&>?>>&?&&=>==>=>=
!"#$%$&'()"('*)+',*',-)#&(./%))))))012)+',*',-)#&(./%))))))3"%"45%'()6/7'*8/7
 38 
A larger decrease in catalytic efficiency was seen with the Tyr293Ile mutant, which had a 
KM approximately three times higher than wild-type.  The KM was doubled for the 
Arg11Trp.  The ability of Arg11 mutants, especially the Trp and Ala mutants, to 
methylate naphthoic acid suggests that the aromatic binding pocket of NcsB1 is 
substantially more crucial to binding substrate than the hydrogen bond from Arg11.  The 
reduced aromatic character of the Tyr293Ile mutant supports this theory.   
We next tested a simple substrate analog of the benzoxazolinate, 2,5-
dihydroxybenzoic acid (2.8).  In this model compound, methylation occurs at the 5-
position (2.10), although with significantly lower efficiency than with the natural 
substrate.  2.8 was then assayed against the panel of mutants in Table 2.2, and indeed 
alternate specificity was observed as compared to wild-type NcsB1 (Table 2.3).  For 
example, although the relative measured activities were low, contrary to the wild-type 
enzyme, the Arg11Trp mutant has higher relative activity toward 2,5-dihydroxybenzoic 
acid while the Arg11Lys mutant was less efficient. These results implicate Arg11 in 
substrate discrimination for these related methyltransferases.   
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Protein/substrate Km (µM) kcat (min
-1) 
kcat/Km (rel 
to WT/NA) 
kcat/Km (rel 
to WT/BA) 
WT/2.8 280 ± 30 0.0043 ± 0.0001 0.005 1 
WT/2.9 137 ± 22 0.00064 ± 0.00002 0.001 0.3 
Tyr293Ile/2.8   558 ± 113 0.0033 ± 0.0003 0.002 0.4 
Arg11Trp/2.8 183 ± 27 0.0071 ± 0.0003 0.012 2.6 
Arg11Ala/2.8 216 ± 17 0.0022 ± 0.0005 0.003 0.7 
Arg11Lys/2.8 348 ± 41 0.0040 ± 0.0002 0.003 0.7 
 
NcsB1 was also demonstrated to methylate 2,4,5-trihydroxybenzoic acid.  The 
mass of both a single methylated and a double methylated product was found via LC-MS.  
The ability of NcsB1 to not only methylate 2.8 and 2.9, but also 2,4,5-trihydroxybenzoic 
acid shows that it is a relatively flexible O-methyltransferase and has the ability to 
transfer more than one methyl group onto a substrate. 
2.9 Conclusion 
In summary, we have solved the crystal structures of NcsB1 in two conformations 
with SAH/SAM bound, with and without a substrate analog or product.  These structures 
revealed a large displacement of the C-terminal domain when not bound to substrate, a 
movement that likely opens up the active site for naphthoate binding.  Additionally, the 
ternary complex structure of 1,4-dihydroxy naphthoic acid and SAH bound to NcsB1 was 
solved and showed a rotation of this alternate substrate in the binding pocket, allowing 
OHO
OH
R
2.8, R=OH
2.9, R=H
OHO
OCH3
R
2.10, R=OH
2.11, R=H
NcsB1
SAM SAH
Table 2.3: Kinetics of benzoic acids with NcsB1 and mutant constructs 
 
 40 
for methylation of the hydroxyl group at the 4 position.  These results led us to probe 
substrate binding using active site mutants, demonstrating altered substrate specificity 
and revealing the importance of key residues in substrate binding. 
2.10 Experimentals 
Protein expression and purification 
NcsB1 was overproduced as an N-terminal His6-tagged fusion protein using the 
expression plasmid pBS5039 in E. coli BL21(DE3) cells as reported previously (8). Cells 
were grown in 1 L Luria-Bertani media at 37 oC, 150 RPM to an OD600 = 0.5-0.8.  
Overexpression was induced with 50  µM isopropyl !-D-thiogalactopyranoside at 18 oC 
for 16 hr.  Cells were collected by centrifugation (20 min, 2000 g), resuspended in 25 mL 
of 20 mM Tris-HCl pH 7.5 and 500 mM NaCl, and flash frozen at -78 oC.  Cell pellets 
were thawed and lysed by two passes through a French Press cell disruptor at 1000 psi.  
The lysate was then clarified by centrifugation (20 min, 10,000 g) and the protein was 
purified batchwise using Ni-NTA resin (QIAGEN, Valencia, CA).  NcsB1 used in 
biochemical assays was dialyzed into 20 mM Tris-HCl pH 7.5, 50 mM NaCl, and 1 mM 
!-mercaptoethanol, then concentrated using an Amicon Ultra-4 concentrator (10 kDa 
MW cutoff, GE Healthcare) and frozen with 40% supplemented glycerol at -25 oC.  For 
crystallography, the Ni-NTA purified protein was dialyzed into 20 mM Tris-HCl pH 7.5, 
100 mM NaCl, 2 mM CaCl2, 1 mM !-mercaptoethanol) and concentrated to ~ 1 mL.  The 
His6-tag was cleaved by incubation with the protease Factor Xa for 36 h at 4 
oC 
(monitored by SDS-PAGE).  The protein solution was then diluted to 5 mL and purified 
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on a HiTrap-Q ion exchange column (0-1 M NaCl gradient in 50 mM Tris-HCl pH 7.5 
and 1 mM !-mercaptoethanol) followed by a Superdex 200 gel filtration column (20 mM 
Tris-HCl pH 7.5, 100 mM NaCl, 1 mM !-mercaptoethanol, 10% glycerol).  The purified 
protein was concentrated to ~10 mg/mL for crystallography (a total yield of 4 mg/L of 
cells).  Protein concentration was determined using UV absorption at 280 nm and the 
Bradford assay (26). 
Site-directed mutagenesis of ncsB1  
The Quikchange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was 
used to generate mutant constructs of NcsB1 using the following DNA oligonucleotide 
primers (IDT DNA, Coralville, IA) (mutant codon is underlined): Arg11Ala For: 5’ - 
GGC TGC ACA CAT CGG ATT GGC GGC GCT GGC CGA TCT GGC GAC – 3’ and 
Rev: 5’ - GTC GCC AGA TCG GCC AGC GCC GCC AAT CCG ATG TGT GCA GCC 
– 3’; Arg11Trp For: 5’ - GGC TGC ACA CAT CGG ATT GTG GGC GCT GGC CGA 
TCT GGC GAC – 3’ and Rev: 5’ - GTC GCC AGA TCG GCC AGC GCC CAC AAT 
CCG ATG TGT GCA GCC – 3’; Arg11Lys For: 5’ - GGC TGC ACA CAT CGG ATT 
GAA GGC GCT GGC CGA TCT GGC GAC – 3’ and Rev: 5’ - GTC GCC AGA TCG 
GCC AGC GCC TTC AAT CCG ATG TGT GCA GCC – 3’; Tyr293Ile For: 5’ - GCG 
CAT GCT CAC CAT CTT CGG AGG CAA GGA ACG C – 3’ and Rev: 5’ - GCG TTC 
CTT GCC TCC GAA GAT GGT GAG CAT GCG C – 3’.  The Quikchange protocol was 
followed as described with the addition of DMSO to the reaction to a final concentration 
of 5%.  Mutations were confirmed by sequencing (Genewiz, S. Plainfield, NJ) and 
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mutant constructs were transformed into E. coli BL21(DE3) cells, over-expressed and 
purified as described above. 
Crystallization and X-ray data collection 
Purified NcsB1 was crystallized with a substituted naphthoic acid and/or 
SAM/SAH by the hanging drop vapor diffusion method at 20 oC with ~4 M sodium 
formate (7 M stock solution from Hampton Research, see Table 2.4 for crystallization 
conditions).   
Table 2.4: Crystallization Conditions for NcsB1 
  SAH SAM and 2.2 SAH and 2.4 SAH and 2.6 
NcsB1 (mg/mL) 2 2 2 2 
cofactor (mM) 2 2 2 2 
NA (mM) 0 2 2 1 
!ME (mM) 1 1 1 10 
Sodium Formate (M) 3.70 3.60 3.66 3.90 
 
Stock solutions of the small molecules for cocrystallization were in 20 mM Tris-
HCl pH 7.5, 100 mM NaCl, 1 mM !-mercaptoethanol, 10% glycerol.  Naphthoic acids 
were synthesized as described previously (7, 27) and in chapter 3 or purchased from 
Aldrich. Typically, NcsB1 crystals appeared within a day and reached full size within one 
week.  Mature crystals were transferred to a cryoprotectant solution (4.0 M sodium 
formate, 15% glycerol) and soaked briefly before flash freezing in liquid nitrogen.  X-ray 
diffraction data was collected on the X25 beamline at the National Synchrotron Light 
Source at Brookhaven National Laboratories with an ADSC Q315 CCD X-ray detector.  
Diffraction intensities were indexed, integrated and scaled using HKL2000 (28) as 
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summarized in Table 2.5.  The crystals belonged to the space group P65 except for the 
NcsB1-SAH cocomplex, which belonged to the C2221 space group. 
Table 2.5: Data collection and refinement statistics 
 SAH SAM and 2.2 SAH and 2.4 SAH and 2.6 
Space group C2221 P65 P65 P65 
Unit cell parameters (Å) 
a=91.3,b=161.6, 
c=98.9 
a=b=109.1, 
c=206.9 
a=b=108.4, 
c=210.3 
a=b=108.0, 
c=211.9 
Data collection 
Resolution (Å) 
25-2.08 
(2.15-2.08) 
50-2.6 
(2.69-2.60) 
30-2.69 
(2.79-2.69) 
50.0-3.0  
(3.1-3.0) 
Wavelength (Å) 1 1 1 1 
No. of reflections 
(measured/unique) 
345090/44038 967889/42568 658394/38115 35878/27798 
% Completeness* 99.6 (99.6) 99.8 (100.0) 98.5 (100.0) 99.8 (100.0) 
Rmerge* 0.052 (0.349) 0.077 (0.441) 0.094 (0.49) 0.076 (0.523) 
I/!* 32.2 (4.4) 49.6 (6.4) 24.0 (7.0) 29.3 (4.5) 
Redundancy* 7.8 (7.4) 22.7 (22.9) 17.3 (17.8) 12.6 (12.8) 
Refinement 
No. of reflections 
(total/test) 
41442/2071 41357/2064 37165/3704 26923/2698 
Rwork 0.240 0.206 0.212 0.217 
Rtest 0.272 0.227 0.247 0.245 
No. amino acids (chains 
A/B) 
325/303 325/325 328/328 328/328 
No. atoms     
Protein (chains A/B) 2379/2193 2379/2379 2406/2406 2406/2406 
Ligands    
(cofactor/substrate/ 
glycerol) 
52/-/6 54/30/12 52/34/12 50/30/12 
Water Molecules 305 249 163 95 
Mean B (protein/SAM/ 
NA/water) 
46.0/36.0/ 
-/50.1 
53.0/42.3/ 
51.6/55.6 
71.4/59.6/ 
81.4/74.3 
69.9/59.9/ 
57.2/65.4 
RMSD from ideal 
geometry 
    
RMSD bonds (Å) 0.006 0.006 0.006 0.0013 
RMSD angles (o) 1.2 1.3 1.2 1.7 
Ramachandran plot by 
PROCHECK (%) 
    
Core region 90.6 93.2 91.7 88.8 
Allowed region 9.0 6.2 7.9 10.4 
Generously allowed 0.2 0.5 0.2 0.7 
Disallowed 0.2 0.0 0.2 0.0 
PDB code 3I53 3I5U 3I58 3I64 
*overall (highest resolution shell)     
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Structure determination 
An initial solution for the NcsB1/SAM/2.2 ternary complex was obtained using 
the molecular replacement program PHASER (29), part of the CCP4 suite (30). A 
polyalanine dimer model of DnrK from Streptomyces peucetius (PDB ID code 1TW2) 
truncated to residues 15-350 was used as the search model.  Manual building of the 
NcsB1 model was performed using the program COOT (31) and the structure was refined 
using CNS (32, 33).  This solution was used to solve phases in subsequent datasets in the 
P65 space group using molecular replacement.  For the NcsB1-SAH cocomplex (C2221 
space group), a partial solution (chain A and the N-terminus of chain B) was found using 
PHASER. The remaining C-terminus of chain B was placed into the model using the 
program MOLREP (34). All final structures were subjected to multiple rounds of 
building and refinement until the R-values converged.  Non-crystallographic restraints 
were used for all P65 space group structures until final stages of refinement.  Ligands 
were fit into the electron density maps and the PRODRG server (35) was used for 
generating topology and parameter files; SAM and SAH coordinates were obtained from 
the HICup server (36) and were subsequently altered to fit electron density. The program 
PyMOL (Delano Scientific, San Carlos, CA) was used to generate graphic images.  
RMSD values were calculated via structural comparison using TopMatch (37, 38). 
The NcsB1/SAH structure (C2221 space group) was solved at a resolution of 2.08 
Å and refined to an Rwork and Rfree of 24.0 and 27.2% (Table 2.5).  The asymmetric unit 
consisted of two monomers. For chain A, there was sufficient electron density to build in 
residues 5-330 and the bound SAH molecule.  For chain B, the final model consisted of 
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residues 9-150, 159-274, 282-297 and 302-330, as insufficient electron density was 
available to build the remaining 29 residues.  Electron density for the SAH molecule was 
well defined, albeit with higher B factors for the SAH molecule in chain B (Figure 
2.10A).  In addition, the dimer contained one glycerol molecule.  The NcsB1 cocomplex 
with SAM and the substrate analog (2.2) was solved at a resolution of 2.60 Å with Rwork 
and Rfree of 20.6 and 22.7%, respectively.  For both chains, N-terminal residues 1-4 could 
not be built, nor could residues 279-281, though sufficient electron density was available 
for both SAM and 2.2 to be built into each active site (Figure 2.10B).  NcsB1 with SAH 
and product (2.4) diffracted to 2.69 Å and was refined to an Rwork and Rfree of 21.2 and 
24.7%, respectively.  All residues of both chains could be built in as well as SAH, the 
product in the active site, and four glycerol molecules (Figure 2.10C).   
 
 
Figure 2.11: 2Fo – Fc maps contoured to 1.5 ! and Fo – Fc map contoured to 3.0 !.  Maps 
generated without ligands modeled into active site (A) NcsB1/SAH. (B) NcsB1/SAM/2.2. (C) 
NcsB1/SAH/2.4.    
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The final structure was a cocomplex of NcsB1 with SAH and an alternate 
substrate, 1,4-dihydroxy-naphthoic acid (2.6).  The crystal diffracted to 3.0 Å, likely a 
result of reduced crystal quality, as 10 mM !-mercaptoethanol was required for crystal 
growth because of problematic oxidation of the substrate. The final structure refined to an 
Rwork and Rfree of 21.7 and 24.5% and included residues 4-332, SAH and 2.6 in the final 
model.    
Size-exclusion chromatography calibration 
 Size-exclusion chromatography was used to determine the biologically active 
entity of NcsB1 using BSA, catalase, and ferritin as standards.  A standard solution was 
made up with 10 mg of BSA, 13.5 mg of catalase, and 1.4 mg of ferritin and was diluted 
up to final volume of 2 mL with gel filtration buffer (see section on protein purification). 
About 1 mL of the standard solution was injected onto the gel filtration column and was 
run at 1 mL/min for 1.5 column volumes.  Observed elution times were used to calculate 
the Kav and plotted against the log of molecular weight (Figure 2.11).  The calculated size 
of NcsB1 in solution was 84.3 kDa, which is roughly equal to two monomers. 
Kinetics of NcsB1 mutants  
To determine the kinetic parameters of all mutant constructs with the natural 
substrate, the previously reported biochemical assay was used with minor modifications 
(8). Reactions were run at 25 oC and contained 10 µM enzyme, 2.5 mM SAM, 100 mM 
phosphate buffer at pH 6.5 and varying concentrations of 2.3 ranging from 50 µM to 2.5 
mM for a total volume of 50  µL (see Chapter 3 for synthesis of 2.3).  Reactions were 
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quenched with trifluoroacetic acid to a final concentration of 16% after 15 minutes, 
except for WT and Arg11Ala, which were quenched at 10 min.  Samples were 
centrifuged at 14,000 g for 2 minutes and the supernatant was analyzed by HPLC at 340 
nm (eluent A: water with 0.1% trifluoroacetic acid; eluent B: acetonitrile; gradient: 0-12 
min at 10-60% B, 12-17 min at 0% B at a flow rate of 1 mL/min on a VYDAC C18 
Protein and Peptide column, 4.6 x 250 mm).  To obtain kinetic parameters, initial rates 
were plotted against substrate concentration and were fitted to the Michaelis-Menten 
equation using KaleidaGraph (Synergy Software, Reading, PA).   
Determination of substrate specificity of NcsB1 for benzoic acids 
To measure the ability of NcsB1 to methylate hydroxybenzoic acids 2.8 and 2.9, 
the previously reported biochemical assay was used with minor modifications (8). 
Benzoic acid substrates were purchased from Aldrich and used without purification.  A 
100 µL reaction containing 100 mM sodium phosphate pH 6.0, 2.5 mM SAM, and 2.5 
mM benzoic acid was initiated with 100  µM NcsB1 at 25 oC.  A 50 µL aliquot was 
quenched with trifluoroacetic acid to a final concentration of 16%  (Aldrich) at 1.5 and 24 
hr.  Samples were centrifuged at 14,000 g for 2 min and the supernatant was analyzed by 
HPLC (see method above).  UV detection was varied based on the UVmax of the substrate: 
2.8 was observed at 320 nm, 2.9 was observed at 287 nm.  The product(s) of the 
enzymatic reactions of NcsB1 with the various benzoic acid substrates were analyzed on 
an Agilent 6210 time-of-flight LC/MS in negative mode.  Enzymatic reactions were set 
up as above.  The reactions were quenched after 18 h at 25 oC with trifluoroacetic acid 
and were submitted for LC-MS analysis (eluent A: water with 0.1% formic acid; eluent 
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B: acetonitrile with 0.1% formic acid; gradient: 0-12 min at 10-60% B, 12-15 min at 60% 
B, 15-17 min at 60-10% B, 17-20 min at 10% B at a flow rate of 0.2 mL/min).  Products 
of the enzymatic reactions were isolated from a large-scale reaction, purified by HPLC 
and subjected to 1H NMR and NOE analysis. 
 
2,5-dihydroxybenzoic acid (2.8) to 2-hydroxy-5-methoxybenzoic acid (2.10) LC-MS 
(ESI-): found m/z 153.1 and 167.1, respectively ([M-H]- for both). 1H NMR (500MHz, 
CD3OD) !: 7.36 (1H, d, J=5Hz, C6-H), 7.10 (1H, dd, J=10, 5Hz, C4-H), 6.87 (1H, d, 
J=10Hz, C3-H), 3.78 (3H, s, C5-OCH3). NOE (500MHz, CD3OD): correlations between 
Hs at ! 7.36/3.78 and 7.10/3.78. 
 
3-hydroxybenzoic acid (2.9) to 3-methoxybenzoic acid (2.11) LC-MS (ESI-): found m/z 
137.1 and 151.1, respectively  ([M-H]- for both). 
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2,4,5-trihydroxy benzoic acid to single methylated product LC-MS (307 nm, ESI-): 
found m/z 169.1 and 183.1, respectively  ([M-H]- for both) (trace amounts of 2-hydroxy-
4,5-dimethoxy benzoic acid, found m/z 197.1, [M-H]- for overnight reaction). 
Determination of kinetic parameters of NcsB1 with benzoic acids 
 To determine the kinetic parameters of NcsB1 with 2.8 and 2.9 and mutant 
constructs with 2.8, 50 µL reaction mixtures containing 2.5 mM SAM, 100 mM 
phosphate buffer at pH 6.5 and varying concentrations of benzoic acid ranging from 50 
µM to 2.0 mM were set up.  Reactions were initiated by the addition of 100 mM enzyme, 
and run at 25 oC.  Reactions were quenched with trifluoroacetic to a final concentration of 
16% at a specified time to determine the initial rate.  Reaction times were as follows: 2.8 
with WT, Arg11Ala, and Arg11Lys for 90 min, 2.8 with Tyr293Ile and 2.9 with WT for 
120 min, 2.8 with Ala11Trp for 60 min.  Reactions were analyzed by UV detection as 
described above.  To obtain kinetic parameters, initial rates were plotted against substrate 
concentration and were fitted to the Michaelis-Menten equation using KaleidaGraph 
(Synergy Software, Reading, PA).   
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Chapter 3  
Characterization of NcsB2 as a Promiscuous Naphthoic Acid/Coenzyme 
A Ligase Integral to the Biosynthesis of the Enediyne Antitumor 
Antibiotic Neocarzinostatin 
 
 
 
 
 
Adapted in part from an article published in J. Am. Chem. Soc. 2007, 129, 7728-9 in 
collaboration with J. Zhang, M.A. Griffin, K. Nonaka, S.G. Van Lanen, B. Shen, and 
S.D. Bruner, and including experimental work done by E.L. Guenther and E.J. Feris. 
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3.1 Introduction  
When the NCS (3.1) biosynthetic gene cluster from Streptomyces carzinostaticus 
ATCC15944 was first sequenced, a convergent pathway featuring an NcsB2-catalyzed 
direct coupling between naphthoyl-S-NcsB and an enediyne core intermediate was 
proposed (Scheme 3.1) (1).  This prediction was consistent with the sequence-based 
annotation of NcsB2 as a CoA-ligase, which would need to act in the reverse direction on 
a naphthoyl-S-NcsB tethered intermediate to perform the predicted coupling.  Contrary to 
this hypothesis, when NcsB, a polyketide synthase (PKS), was overexpressed in 
heterologous hosts, accumulation of free 2-hydroxy-5-methyl-1-naphthoic acid was 
observed (2).  This finding would argue against the involvement of a tethered 
intermediate in NCS biosynthesis as originally proposed. 
 
A reverse CoA-ligase would act on the enzyme-tethered aryl-thioester (3.2) with a 
donor hydroxyl group coming from, in this case, the enediyne core (Figure 3.1).  NcsB2 
is homologous to a number of biochemically and structurally characterized adenylate- 
and CoA-ligases.  While there is little literature precedence for reverse CoA-ligase 
Scheme 3.1: Original proposed biosynthesis 
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activity, there is substantial bioinformatic support for NcsB2 playing a role in activation 
of the free naphthoic acid based on homology to characterized enzymes.  DhbE is one 
such homolog (42% identity and 62% similarity).  It is a standalone adenylation (A) 
domain involved in the biosynthesis of the catecholic siderophore bacillibactin (3, 4).  
DhbE activates 2,3-dihydroxybenzoic acid via adenylation and subsequently attaches it to 
holo-DhbB (an isochorismate lyase and aryl-carrier protein) via a phosphopantetheinyl 
arm (Scheme 3.2).  Subsequent transformations with the NRPS DhbF produce the natural 
product.  It seems likely that NcsB2 would act in a similar manner to DhbE, though 
NcsB2 might instead transfer the functionalized naphthoic acid either directly onto the 
enediyne core or onto CoA.  For the latter activity to occur, an additional enzyme-
catalyzed step would be required to complete the biosynthesis of NCS.  
Figure 3.1: Reactions catalyzed by a CoA-ligase and a hypothetical reverse CoA-ligase. A CoA-
ligase acts by first adenylating an aryl acid and then transfers it to the thiol of CoA to form a 
thioester.  A reverse CoA-ligase would transfer an enzyme tethered aryl group to a donor 
hydroxyl group.  In the case of NcsB2, R = enediyne core. 
ATP
Ar
O
OH Ar
O
AMP
PPi CoA AMP
Ar
O
SCoA
CoA-Ligase
Ar
O
S-Enz Ar
O
OR
S-EnzR-OH
Reverse CoA-Ligase
 56 
 
  In this chapter, the in vitro characterization of NcsB2, including studies into its 
promiscuity as an adenylation domain and its activity following activation of naphthoic 
acid are discussed.  A revised biosynthetic pathway of 2-hydroxy-7-methoxy-5-methyl 
naphthoic acid is presented featuring its incorporation into NCS with free naphthoic acids 
as intermediates.  The results of these studies present an outstanding opportunity to 
produce novel analogs of NCS by engineering NCS biosynthesis. 
3.2 Initial studies 
It was first confirmed that NcsB2 is essential for NCS biosynthesis by inactivation 
and complementation of the resultant !ncsB2 mutants in vivo (5).  Replacing ncsB2 with 
a mutant copy yielded an S. carzinostaticus SB5006 mutant strain that completely lost its 
ability to produce NCS.  Production was partially restored to SB5006 by overexpressing a 
functional copy of ncsB2 in trans, alleviating any concern over potential polar effects 
Scheme 3.2: Biosynthesis of bacillibactin 
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from ncsB2 inactivation on the expression of downstream genes in SB5006.  While these 
initial studies made it clear that NcsB2 is required for NCS biosynthesis, the actual role 
of NcsB2 had not yet been established.  Whether NcsB2 acted on free naphthoic acid or 
on an enzyme tethered naphthoyl substrate would have considerable implications for the 
overall biosynthetic scheme. In order to fully understand NcsB2 activity, we needed to 
first synthesize the predicted free naphthoic acid substrate (3.3), which was done using a 
rapid synthesis developed by Ji et al (Scheme 3.3) (6).  If NcsB2 could adenylate free 
naphthoic acids, the earlier prediction of its activity would likely be incorrect, 
necessitating revision of NCS biosynthesis. 
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Scheme 3.3: Synthesis of 2-hydroxy-7-methoxy-5-methyl naphthoic acid 
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3.3 Characterization of NcsB2 as a CoA ligase 
In order to determine the role of NcsB2 in NCS biosynthesis, we cloned the ncsb2 
gene from S. carzinostaticus genomic DNA, over-expressed NcsB2 in E. coli, purified it 
to homogeneity, and characterized it for naphthoyl-CoA ligase activity in vitro.  CoA 
ligases have two activities: (1) ATP-dependent activation of carboxylic acids as acyl-
AMP esters and (2) formation of acyl-CoAs by coupling the activated acyl group with the 
thiol nucleophile of CoA.  We examined the first half of the enzymatic activity of NcsB2 
by the ATP-[32P]pyrophosphate exchange assay, which has been widely used in the 
characterization of adenylating enzymes (Scheme 3.4) (7).  This assay relies on the 
incorporation of labeled pyrophosphate into unlabeled ATP, which occurs due to the 
reversibility of the adenylation reaction.  The reactions are quenched with acid and 
incubated on charcoal, for which ATP has a strong affinity.  The charcoal is filtered and 
washed and is submitted for scintillation counting.  The amount of radioactivity counted 
corresponds to the reaction rate.  Efficient exchange of ATP was readily observed, 
indicative of the formation of naphthoyl-AMP ester 3.4 (Scheme 3.5).  The reaction 
occurs with a kcat of 38 min
-1 ± 2 and KM of 0.6 µM ± 0.2, values which are comparable to 
those for other characterized adenylation enzymes such as DhbE (kcat of 167 min
-1 and KM 
of 7.6 µM) (3).  At this point, we knew that NcsB2 acted by adenylating a free naphthoic 
acid substrate, making it very unlikely that NcsB2 also acted as a reverse CoA-ligase on 
Scheme 3.4: ATP-pyrophosphate exchange assay 
Adenylating Enzyme
ATP
Ar
O
OH Ar
O
AMP
PPi32PPi 32PPi
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enzyme-tethered naphthoyl intermediates.  Still, based on homology, we knew that 
NcsB2 might also catalyze a second step after adenylation.  We verified the second half 
of the CoA ligase reaction of NcsB2 by directly monitoring the formation of 3.5 from 3.3 
in the presence of ATP and CoA using HPLC.  As shown in Scheme 3.5, 3.3 was 
converted to 3.5 via 3.4, which was confirmed by LC-MS.  CoA was the only nucleophile 
among a range of potential coupling partners tested that efficiently supported this 
conversion, including those that were considered analogs to the enediyne core, such as 
cyclopentanol.     
Scheme 3.5: Revised biosynthetic pathway of naphthoic acid and NCS 
Enediyne core
Deoxy aminosugar
NCS (3.1)
H3C SCoA
O SCoA
O
O O
+
R
CH3
OHO
OH
NcsB2
 ATP             PPi            
 CoA-SH       AMP
NcsB NcsB4
H3CO
CH3
RO
OH
R = AMP, 3.4
R = CoA,  3.5
x5
R = H, 3.6
R = OH, 3.7
R = OCH3, 3.3
NcsB3
NcsB1
 60 
3.4 Revision of biosynthetic pathway 
The characterization of NcsB2 as a naphthoyl-CoA ligase prompted us to revise 
this portion of the biosynthetic pathway, which includes the production of free naphthoic 
acid (3.3) and its subsequent incorporation into NCS.  The functional assignments of 
NcsB as the naphthoic acid synthase, NcsB3 as the hydroxylase, and NcsB1 as the O-
methyltransferase, all acting on naphthoyl-S-NcsB tethered intermediates, are consistent 
with the current finding of NcsB2 as a CoA ligase (1).  However, we now prefer a 
scheme where NcsB produces the free naphthoic acid intermediate (2) for hydroxylation 
by NcsB3, followed by O-methylation by NcsB1 ((8) and as discussed in Chapter 2) to 
produce 3.3 (Scheme 3.5).  The new proposal would require an additional enzyme to 
catalyze the coupling of 3.5 to the enediyne core.  Re-examination of the NCS 
biosynthetic gene cluster indeed led to the identification of an additional open reading 
frame, orf27, immediately downstream of ncsB3, whose function was not assigned 
previously (1).  We now renamed orf27 as ncsB4.  NcsB4 shows high sequence similarity 
to known esterases and acyltransferases, serving as a candidate to catalyze the coupling 
between 3.5 and the enediyne core to afford NCS. 
3.5 Substrate specificity of NcsB2 
Next, we directly compared the kinetic parameters of 3.3 as a substrate for NcsB2 
with those of 3.6 and 3.7, two alternative substrates for NcsB2 depending on the timing 
of the CoA-ester formation step in 3.5 biosynthesis.  These alternate substrates and others 
were synthesized using the same synthetic scheme as that of the natural substrate, but the 
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functional groups on the benzaldehyde to be coupled to the phosphonate intermediate 
were varied (with the experimental assistance from M. Griffin).  Both 3.6 and 3.7 can be 
activated by NcsB2 in the presence of ATP but with kcat/Km values ~2 fold lower than 3.3 
(Table 3.1).  Taken together, these results are consistent with the assignment of 3.3 as the 
preferred substrate of NcsB2 and support the timing of the individual steps as proposed 
for 3.5 biosynthesis (Scheme 3.5).  
 
Table 3.1: Naphthoic acid substrate scope of the NcsB2 CoA ligase 
 
Naphthoic 
acid 
Km (µM) kcat (min
-1) Rel. kcat/Km 
3.3 0.59 ± 0.2 38 ± 2.0 1 
3.6 0.25 ± 0.1 8.1 ± 0.6 0.47 
3.7 3.1 ± 0.1 93 ± 0.6 0.50 
3.8 2.3 ± 0.7 7.1 ± 0.8 4.8 x 10-2 
3.9 > 500 - - 
3.10 1.1 ± 0.4 25 ± 2.4 0.35 
3.11 3.4 ± 0.9 2.8 ± 0.2 1.3 x 10-2 
3.12 18 ± 9 6.7 ± 1.4 5.8 x 10-3 
 
 
The fact that NcsB2 activated all three naphthoic acid biosynthetic intermediates 
inspired us to further probe its substrate specificity.  Since NcsB2 acts on free naphthoic 
acids, as opposed to an enzyme-tethered substrate, we thought that perhaps it could 
activate a larger variety of naphthoic acids, which could be subsequently incorporated 
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into NCS to produce analogs.  A variety of 1-naphthoic acid analogs with different 
substitutions at the 2-, 5-, or 7-position (3.8–3.12) were either prepared or were 
purchased.  Each of the analogs was subjected to the ATP-[32P]pyrophosphate exchange 
assay to examine if they would serve as substrates for NcsB2.  Remarkably, substitutions 
at all three positions were well tolerated with their observed kcat and KM values ranging 
within 30-fold of the natural substrate (Table 3.1).  Even unfunctionalized naphthoic 
acids (3.11 and 3.12) were adenylated, albeit at a significantly lower catalytic efficiency.  
Substrate 3.11 has a Km value within the range of the other alternate substrates, while that 
of 3.12 is much higher.  This result suggests that the hydroxyl group adjacent to the acid 
is an important feature for substrate recognition by the NcsB2. The one exception to the 
rather relaxed substrate specificity of NcsB2 was 3.9, which showed essentially no 
detectable activity, presumably due to the strong electron-withdrawing effect of the nitro 
group. We also tested 2-hydroxybenzoic acid, benzoic acid, and the benzoxazolinate 
moiety from C-1027 (see Appendix A for synthesis details) as potential substrates for 
NcsB2 but no measurable activity was detected, suggesting the naphthalene ring as the 
minimal substrate recognition element for NcsB2.   
3.6 Crystallization attempts 
 In addition to characterizing NcsB2 biochemically, we also sought to solve its X-
ray crystal structure, as we hoped to gain insight into specificity determinants.  Thus far 
there have been 47 structures solved of adenylate forming enzymes (9).  Some examples 
include DhbE (46% identical, 62% similar, PDB code 1MDB (4)), firefly luciferase (25% 
identical, 41% similar, PDB code 1BA38 (10)) and 4-chlorobenzoyl-CoA ligase (25% 
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identical, 42% similar, PDB code 1T5D (11)).  For the most part, sequence homology is 
low, typically around 20% identical.  Nevertheless, the structures of DhbE, firefly 
luciferase, and of the phenylalanine activating module of the Gramicidin S NRPS (12) all 
share a common fold despite low sequence homology (4). 
 Initial attempts to crystallize NcsB2 included screening using Hampton Crystal 
Screens at 4 and 20 oC.  Unfortunately, no reproducible crystal hits were found; therefore 
addition of glycerol, ATP, AMP, and MgCl2 in a variety of combinations and different 
temperatures was tried.  Again, there were no reproducible hits, so the next step was to 
attempt to trap the enzyme in one conformation in hopes that this would encourage 
crystal formation.   
Often, addition of a ligand, inhibitor, or stable analog of a catalytic intermediate 
will help crystallization by maintaining the enzyme in one conformation (13), and for an 
enzyme such as NcsB2 which binds to multiple substrates (naphthoic acid, ATP, CoA), a 
fair amount of movement may occur during one catalytic cycle.  A variety of local and 
overall changes in conformation have been observed for adenylate ligase homologs (4, 9, 
14).  The first intermediate analog explored was a naphthoyl sulfamoyl adenosine.  
Sulfamoyl adenosines are analogous to the adenosine monophosphate intermediate 
produced by adenylation domains and tRNA synthetases but are non-hydrolyzable under 
biological conditions.  This type of compound has been shown to inhibit amino and aryl 
acid adenylation enzymes (15, 16).  To synthesize these inhibitors, adenosine is acetonide 
protected and is coupled to the sulfamoyl group by reacting with sulfamoyl chloride.  
Next, the amino or aryl acid is either coupled to the protected sulfamoyl adenosine using 
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standard peptide coupling reagents or is first activated with N-hydroxysuccinimide for 
subsequent coupling.  TFA deprotection affords the aryl or amino sulfamoyl adenosine 
inhibitor in four linear steps.  The first stable analog made was 1-naphthoyl sulfamoyl 
adenosine (Figure 3.2, 3.13) and it was incubated with NcsB2.  Unfortunately, this 
inhibitor did not encourage crystal growth.  Next, the natural substrate, 3.3, was coupled 
to sulfamoyl adenosine, producing 3.14 (synthesized and characterized by E. Feris).  
Once again, X-ray quality crystals were not obtained.  The synthesis of a third stable 
intermediate analog, naphthoyl amino-CoA 3.15, is currently being developed by E. 
Guenther, using a chemoenzymatic synthesis of amino CoA as described previously by 
Y. Liu (17), to provide a stable analog of the naphthoyl CoA thioester. 
Figure 3.2:  Stable intermediate analogs for cocrystallization with NcsB2 
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3.7 Truncated constructs of NcsB2 
In addition to conformational changes being problematic to crystal formation, 
floppy ends or loops can also be detrimental to reaching this goal.  Therefore, truncated 
constructs of NcsB2 were prepared based on sequence alignment with SgcD5 and DhbE 
to remove what might be disordered regions on the N- and C-termini (Figure 3.3).  
SgcD5 shares little sequence homology with NcsB2 but it is proposed to be a CoA-
synthetase for the benzoxazolinate moiety on C-1027 (18), acting in a similar manner to 
NcsB2.  Based on homology, NcsB2 has eight amino acids on the N-terminus and four on 
the C-terminus that might not contribute to the fold.  We hoped that truncating NcsB2 
would lower the amount of disorder in the protein, aiding in crystallization.  Overall, 
NcsB2 is 19 amino acids longer than DhbE, much of which is in the middle of the 
enzyme.  Grown under the same conditions as the original NcsB2 construct, over-
expression and purification resulted in less than half of the typical amount of NcsB2 and 
attempts at improving protein yield by varying length and temperature of expression were 
both unsuccessful.  Neither of the truncated constructs aided crystal growth and were 
fraught with over-expression problems.   
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Figure 3.3: Sequence alignment of NcsB2 with sequence homology DhbE (1MD9_A) and SgcD5 
(AAL06665), a putative benzoxazolinate CoA synthetase from C-1027 biosynthesis. 
DhbE       --------MLKGFTPWPDELAETYRKNGCWAGETFGDLLRDRAAKYGDRIAITCGNTHWS 52 
NcsB2      MHETAAAPAPAGFVPWPDDVAARYTAAGHWEGRSLGTHLAEAARKVPEAVCLVDGPVRMS 60 
SgcD5      --------MRDGRRPGPGGTGPLDPD----ADSEFWSAYGQVSDAFYRGELTAADRERWE 48 
                      *  * *.  .          .  :     : :         . .  : . 
 
DhbE       YRELDTRADRLAAG--FQKLGIQQKDRVVVQLPNIKEFFEVIFALFRLGALPVFALPSHR 110 
NcsB2      YSELMARADGAAVR--MRGLGIRPADRVVVQLPNCWEHVVVTMACLRLGALPIWALPQYR 118 
SgcD5      GERLTAVLRHVTRRSPFYRRHLAGVDVEAVTPANLADLPFTTKDDLRREMHDVLSGPLHE 108 
              * :     :    :    :   *  .*  .*  :   .    :*     : : * :. 
 
DhbE       SSEITYFCEFAEAAAYIIPDAYSGFDYRSLARQVQSKLPTLKNIIVAG-----------E 159 
NcsB2      HRELSGVVTHARASALVVPDVYREFDHQALAHEVAEAQPTVRHVLVAGSDVRPDSVDLRA 178 
SgcD5      AR---IYYETTGTTGAATPCPRGEKDIATSNIAVRESWRRMLEARFGG---------RMP 156 
                     : ::.   *      *  :    * .    : .  ..*             
 
DhbE       AEEFLPLEDLHTEPVKLP--EVKSSDVAFLQLSGGSTGLSKLIPRTHDDYIYSLKRSVEV 217 
NcsB2      LCEPLDADEAARVAAELDRSAPRGEEVAMLKLSGGTTGLPKLVARTHNDLSYMIKRAAQV 238 
SgcD5      VVGLMGPSELYAFGDVFTAVAAELGACHVKIWPES----PRVGFRKALRLIEELEVEVVV 212 
               :  .:       :     .     .   . .    .::  *.       ::  . * 
 
DhbE       CWLDHSTVYLAALPMAHNYPLSSPGVLGVLYAGGRVVLSPSPSPEIAFPLIEREKVTITA 277 
NcsB2      CGFGRDTVYLAVLPLGHGFPNTGPGVLGTLLAGGRVVISGSPAPEAAFALMERERVTATS 298 
SgcD5      CAP-ALCLSLAKAALHYGYDLARLPVKLFLTLG--EICTPQFADNVATLWP-------QA 262 
           *      : **  .: :.:  :   *   *  *   : : . : : *            : 
 
DhbE       LVPPLAMVWMDAASSR-RDDLSSLQVLQVGGAKFSAEAARRVKAVFGCTLQQVFGMAEGL 336 
NcsB2      VVPAIVMRWLQYRDERPGADLGSLELMQVGASRLEPEVARQVGPKLGCRLQQVFGMAEGL 358 
SgcD5      VVRPTLYGSQEALCIATGADTGALHLAQP--NYLTELVEPDTGAVVG-------DTGEGE 313 
           :* .      :        * .:*.: *     :   .   . . .*       . .**  
 
DhbE       VNYTRLDD-PEEIIVNTQGKPMSPYDEVRVWDDHDRDVKPGETGHLLTRGPYTIRGYYKA 395 
NcsB2      LCLTRLDD-PDDVVHYTQGRPISPDDEIRVVDPEGRTVGVGEPGALLTRGPYTPRGYYDS 417 
SgcD5      LVLTMLVDGIKPLIRYRTG------DLVRILPAGPGEPLPGPRIQVIGR--VADRIPLGD 365 
           :  * * *  . ::    *      * :*:          *    :: *   : *      
 
DhbE       EEHNAASFTEDGFYRTGDIVRLTRDGYIVVEGRAKDQINRGGEKVAAEEVENHLLAHPAV 455 
NcsB2      PSANARAFTPDGWYRTGDLVRRTPDGNLIVVGREKDLINRGGEKINAEEVEGFAVQVDGV 477 
SgcD5      VTLQPAELEAAILDGVGGCL-----GYQVVIDRQDDGSD--AVTVRMDLLAGAEGERQGI 418 
              :.  :       .*. :     *  :* .* .*  :  . .:  : : .      .: 
 
DhbE       HDAAMVSMPDQFLGERSCVFIIPRD-EAPKAAELKAFLRERGLAAYKIPDRVEFVESFPQ 514 
NcsB2      LQAAAVGLPDSELGERICLFVVLADGTRVELADVRKVMENAETASFKLPERLITLPSLPT 537 
SgcD5      GEAVAARLRER----------TGAHAGIVVDTDLDPVTHTGSFVSWKA-ARVVDNRSGPD 467 
            :*. . : :              .      :::  . .    .::*   *:    * *  
 
DhbE       TGVGKVSKKALREAISEKLLAGFKK 539 
NcsB2      TPMGKIDKKALRAAAGRMSET---- 558 
SgcD5      RAVLTARQVAHRYAITT-------- 484 
             : .  : * * *            
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3.8 Conclusion 
The characterization of NcsB2 as a CoA ligase with promiscuous substrate 
specificity is exciting because it presents an outstanding opportunity to produce novel 
analogs of NCS by engineering NCS biosynthesis.  Analogous to adenylation domains 
found in nonribosomal peptide biosynthesis, NcsB2 could be viewed as the “gate-keeper” 
that selects and activates naphthoic acids to be incorporated into NCS, assuming that the 
ensuing NcsB4 acyltransferase also possesses relaxed substrate specificity.  Generation of 
novel enediynes has found success as exemplified by the production of C-1027 and 
calicheamicin analogs (19, 20), the availability of which has already unveiled new insight 
into the mode of action and drug discovery for the enediynes (21).  This work now sets 
the stage to explore these possibilities within the NCS scaffold, one of two enediyne 
natural products currently used as anticancer drugs (22, 23). 
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3.9 Experimentals 
General  
DNA oligonucleotide primers were obtained from Integrated DNA Technology 
(Coralville, IA).  Restriction enzymes and bovine serum albumin (BSA) were purchased 
from New England Biolabs (Ipswich, MA).  Thrombin was purchased from Sigma-
Aldrich (St. Louis, MO).  DNA purification kits and Ni-NTA resin were from Qiagen 
(Valencia, CA).  Tetrasodium [32P] pyrophosphate was purchased from Perkin Elmer Life 
Science (Boston, MA).  DNA sequencing was performed by Genewiz (New Brunswick, 
New Jersey).  Columns for protein purification were from GE Healthcare.  Competent E. 
coli cells were purchased from Invitrogen (Carlsbad, CA) and Fisher Scientific 
(Pittsburgh, PA).  Liquid scintillation counting was performed on a Beckman Coulter LS 
6500 Multi-purpose Scintillation Counter.  Chemicals and reagents were purchased from 
Sigma-Aldrich (St. Louis, MO) or VWR (West Chester, PA).  Chemical reactions, unless 
otherwise noted, were run in solvents that were dried using stills by Glass Contour (Santa 
Monica, CA).  Deuterated solvents were purchased from Cambridge Isotopes (Andover, 
MA).  Silica gel used for all flash chromatography purifications was purchased from 
VWR, EMD brand Geduran.  Mass Spectrometry (MS) was performed on a Waters LCT 
Classic.  1H NMR spectra were recorded on a Varian 500, 400 or 300 MHz spectrometer.  
Proton chemical shifts are reported in ppm (!) relative to internal tetramethylsilane 
(TMS, ! 0.0 ppm).  Data are reported as follows: chemical shift (multiplicity [singlet (s), 
doublet (d), triplet (t), quartet (q), and multiplet (m)], coupling constants [Hz], 
integration).  13C NMR spectra were recorded on a Varian 500 (126 MHz) or 400 (100 
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MHz) spectrometer with complete proton decoupling.  Carbon chemical shifts are 
reported in ppm (!) relative to the CDCl3 or CD3OD as the external standard (! 77.26 
ppm or 49.00 ppm, respectively). 
Cloning of ncsB2 from genomic DNA.   
A 2.4 kb fragment of the genomic DNA containing the ncsB2 gene was amplified 
from S. carzinostaticus ATCC 15944 by PCR using the oligonucleotide primers 5’-GAA 
CTT GTC CGG CGA GTC GAG ATC-3’ (forward) and 5’-CTG AGG TTC GTT CTC 
ACC GC-3’ (reverse) with the following PCR program: 94.0 oC for 5 min, then 30 cycles 
of 94.0 oC for 1 min, 59.1 oC for 1 min, and 72.0 oC for 5 min, followed by 72.0 oC for 10 
min.  The ncsB2 gene was then amplified from the fragment using the primers 5’-GGC 
CAT ATG CAC GAG ACA GCA GCA GC-3’ (forward, the NdeI site is shown in bold) 
and 5’-GGC GGA TCC TCA GGT TTC GGA CAT C-3’ (reverse, the BamHI site is 
shown in bold) with the following PCR program: 92.0 oC for 2 min, then 30 cycles of 
92.0 oC for 1 min, 65.1 oC for 1 min, and 72.0 oC for 2 min, followed by 72.0 oC for 10 
min.  The ncsB2 gene was ligated into the pET28a vector as a 1.7 kb an NdeI-BamHI 
fragment and transformed into competent cells.  The resulting plasmid contained ncsB2 
as an N-terminal His6-tagged fusion protein and was confirmed by double digest and 
sequencing. 
 Overproduction and purification of NcsB2  
Plasmid pBS5035 was transformed into BL21(DE3)pLysS chemically competent 
cells.  Cells were spread onto an LB agar plate containing 30 µg/mL of both 
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chloramphenicol and kanamycin; the plate was incubated at 37 oC for 16 h.  One colony 
was then used to inoculate a 1L flask of LB with the same antibiotics.  The cells were 
grown at 37 oC (125 RPM) until OD600 reached 0.55-0.80.  Expression was induced at 25 
oC with 100 µM IPTG and cells continued growth for 6 h.  Cells were collected by 
centrifugation (20 min, 2000 g), resuspended in 25 mL of buffer containing 20 mM Tris-
HCl and 500 mM NaCl, pH 7.5 and frozen at -78 oC.  To obtain protein for assays, the 
cell pellet was thawed and lysed by two passes through a French Press cell disruptor at 
1000 PSI.  The lysed cells were then centrifuged (20 min, 10,000g) to remove cell debris 
and the protein was purified batchwise using Ni-NTA resin.  The purified protein was 
dialyzed into low salt buffer (50 mM NaCl, 20 mM Tris-HCl, 1 mM !-mercaptoethanol, 
pH 7.5) diluted to 10 µM and stored at -78 oC in 20% glycerol for use in assays.   
For crystallography, the Ni-NTA purified protein was dialyzed into low salt 
buffer and concentrated to less than 1 mL.  The His6-tag was cleaved by incubation with 
10 U thrombin for 2-3 h at 4 oC in thrombin cleavage buffer (20 mM Tris-HCl pH 7.5, 
100 mM NaCl, 2 mM CaCl2).  The cleavage was stopped by adding 30 µL 100 mM 
PMSF in methanol and incubated on ice for 10 min.  The protein solution was then 
diluted, repurified on Ni-NTA resin, dialyzed into low salt buffer, purified on a HiTrap-Q 
ion exchange column (0-1 M NaCl gradient in 50 mM Tris-HCl pH 7.5 and 1 mM !-
mercaptoethanol) and on a Superdex 200 gel filtration column (20 mM Tris-HCl pH 7.5, 
100 mM NaCl, 1 mM !-mercaptoethanol).  The purified protein was concentrated to 10 
mg/mL for crystallography (a total yield of 1.5 mg/L of cells or 7.3 mg/L of cells without 
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cleavage of His6-tag).  Protein concentration was determined using UV absorption at 280 
nm. 
Identification of ncsB4 as a candidate encoding an acyltransferase to catalyzes coupling 
between 2-hydroxy-7-methoxy-5-methyl-1-naphthoyl CoA and the enediyne core  
The ncsB4 gene (previously known as ncs orf27) is adjacent to and downstream 
of ncsB3, the gene product of which is the P450 monooxygenase predicted to be involved 
in the maturation of the naphthoic acid moiety.  NcsB4 has sequence similarity to 
proteins found in COG0596, which are predicted hydrolases or acyltransferases of the 
!/" hydrolase superfamily.  The closest functionally characterized homolog is EstC from 
Lactobacillus casei (22% identity/33% similarity; accession no. AAM90952).  This 
family of enzymes mediates both the synthesis and hydrolysis of esters, with EstC 
displaying specificity towards fatty acid-phenyl esters.   
Truncations of NcsB2 
 New primers were used to produce truncated constructs of NcsB2 with the same 
restriction sites as for the wild-type construct.  N-terminal truncation primers were: 5’-
GGC CAT ATG CCC GCA GGA TTC GTC CCC-3’ (forward) and 5’-GGC GGA TCC 
TCA GGT TTC GGA CAT C-3’ (reverse).  C-terminal truncation primers were: 5’-GGC 
CAT ATG CAC GAG ACA GCA GCA GC-3’ (forward) and 5’-CAT GGA TCC TCA 
ACC GGC GGC AGC AC-3’ (reverse).  PCR cycling program for the N-terminal 
truncation was 92.0 oC for 5 min, then 30 cycles of 92.0 oC for 1 min, 64.6 oC for 1 min 
(annealing), and 72.0 oC for 2 min (extension), followed by 72.0 oC for 10 min.  For the 
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C-terminal truncation, the successful annealing temperature was 64.9 oC.  Truncated 
protein constructs were purified using same purification steps as for native construct, 
yielding uncleaved N-terminal truncated and C-terminal truncated protein at 3.8 mg/L 
and 2.5 mg/L, respectively.  Protein was screened for crystal formation using Hampton 
Crystal Screens with cleaved and uncleaved protein (cleavage resulted in a very low yield 
of pure protein).  Screening resulted in no reproducible crystal hits.     
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ATP-[32P]pyrophosphate exchange assay 
ATP-(32P)PPi exchange by NcsB2 was monitored for the natural substrate (3.3) 
and analogs (3.4-3.12).  KM and kcat typically were determined from seven different 
substrate concentrations for each naphthoic acid with a constant ATP concentration.  The 
assay mixture contained 10 mM MgCl2, 5 mM DTT, 5 mM ATP, 0.2 mg/mL BSA, 250 
nM NcsB2, 1 mM tetrasodium pyrophosphate decahydrate (containing enough 
tetrasodium [32P]pyrophosphate to detect activity), 75 mM Tris-HCl,  pH 8.0 and a range 
of substrate concentrations from 0.05 µM to 50 µM in a total volume of 0.1 mL.  
Reactions were initiated with the addition of 10 µL of a substrate stock.  After incubation 
at 24 oC for 3 minutes, the reaction was quenched with 0.4 mL of a mixture containing 
3.5% perchloric acid, 1.6% (w/v in water) activated charcoal and 100 mM tetrasodium 
pyrophosphate.  The suspension was centrifuged, the supernatant removed, and the 
charcoal was washed one time with 1 mL of wash solution containing 3.5% perchloric 
acid and 100 mM tetrasodium pyrophosphate.  The charcoal was transferred into 3 mL of 
Ecolite(+) scintillation fluid using a total volume of 0.6 mL water and submitted for 
scintillation counting.  Specific activity was determined by counting 3 µL of the reaction 
mixture in 3 mL of scintillation fluid.  Significant substrate/product inhibition as well as 
protein instability caused large errors in the kinetics data, which was partially rectified by 
the addition of BSA.   
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Coenzyme A arylation assay 
The ability of NcsB2 to couple the activated natural substrate (3.4) to CoA was 
assayed with similar conditions used by Linne et al.3 An assay mixture containing 1 µM 
NcsB2, 4 mM ATP, 1 mM CoA, 0.2 mg/mL BSA, 0.5 mM naphthoate substrate (3.3) in 
assay buffer (50 mM HEPES-NaOH, 100 mM NaCl, 1 mM ethylendiaminetetraacetic 
acid, 10 mM MgCl2, pH 7.5) was incubated at 37 
oC for 1.5 h.  The assay was quenched 
by the addition of TFA to a final concentration of 20%.  After incubation on ice for 5 
min, the mixture was centrifuged for 2 min at 13,000 rpm and the supernatant was 
transferred to HPLC-vials.  A control without CoA was run as well.  The assay products 
were separated on a VYDAC C18 column (250 mm, ID=4.6 mm) at a flow rate of 1 
mL/min using the following conditions (buffer A: 2 mM triethylamine/water; buffer B: 2 
mM triethylamine/80% acetonitrile/20% water): 5% buffer B (5 min), linear gradient to 
30% buffer B (over 20 min), linear gradient to 95% buffer B (over 4 min) followed by 
100% B for 2 min.  The products were identified via UV detection at 320 nm.  LC-MS 
was subsequently performed using ESI in negative mode.  MS (ESI-): m/z calculated for 
(C34H45N7O19P3S)
- 980.2, found 979.8.  Other nucleophiles were tested for activity, 
including !-mercaptoethanol, cyclopropanol and 2-indanol and showed no turnover.   
Synthesis of substrates and analogs 
All substrates were synthesized following the convergent procedure by Myers (6).  
Compounds made in our lab that were previously synthesized all matched published 
spectra.  The following procedures are for the synthesis of three analogs (3.6, 3.7, and 
3.8) tested not previously reported.   
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Methyl substituted (Z)-olefin.  To a stirring solution of phosphonate (330 mg, 0.886 
mmol, 1.4 eq) in THF (5 mL), DBU (188 µL, 1.26 mmol, 2 eq) was added dropwise via 
syringe at 23 oC.  The yellow solution was stirred for 20 min at 23 oC.  A solution of o-
tolualdehyde (73.0 µL, 0.629 mmol, 1 eq) in THF (5 mL) was added dropwise to the 
stirring reaction mixture at 0 oC over 1 min.  The reaction was stirred overnight at 4 oC 
and then was allowed to warm up to room temperature and stirred for another 4 h.  The 
reaction was quenched with saturated aqueous ammonium chloride solution (20 mL) and 
the THF was removed in vacuo.  The aqueous mixture was extracted with ethyl acetate (3 
x 20 mL), the extracts were combined and washed with brine (2 x 20 mL) and the organic 
layer was dried over anhydrous sodium sulfate.  The solution was filtered and 
concentrated.  The crude mixture was purified by flash column chromatography (9:1 
hexanes-ethyl acetate to 4:1) giving the product as a yellow oil in a 5:1 mixture with the 
(E)-olefin (by 1H NMR, data annotated for (Z)-olefin) (185 mg, 99 % yield). 1H NMR 
(500 MHz, CDCl3) !: 7.20-7.13 (m, 4H), 7.01 (d, J = 12.5 Hz, 1H), 6.04 (d, J = 12.0 Hz, 
1H), 5.25 (s, 1 H), 2.26 (s, 3H), 1.44 (s, 6H).  13C NMR (125 MHz, CDCl3) !: 163.9, 
161.9, 140.4, 136.2, 135.6, 129.7, 128.7, 128.4, 125.3, 122.7, 106.3, 96.1, 25.4, 24.9, 
20.1.  HRMS (ESI+): m/z calculated for (C15H16O3Na)
+ 267.0997, found 267.0985   
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Trifluoroethyl 2-hydroxy-5-methyl-1-naphthoic acid ester.  Trifluoroethanol (452 µL, 
6.29 mmol, 10 eq) was dissolved in THF (5 mL), sodium hydride (60% dispersion in 
mineral oil, 90.5 mg, 3.77 mmol, 6 eq) was added to the solution.  The reaction mixture 
was allowed to stir for 20 min at 23 oC, resulting in a clear, orange solution.  A solution 
of the (Z)-olefin (12) (154 mg, 0.629 mmol, 1 eq) in THF (5 mL) was added dropwise to 
the reaction mixture, which was then allowed to stir at 23 oC for 50 min.  The reaction 
was concentrated in vacuo to dryness and the resulting residue containing trifluoroethyl 
ester was taken up in acetic acid (3 mL).  Manganese (III) acetate trihydrate (337 mg, 
1.26 mmol, 2 eq) was added and the solution was stirred at 23 oC for 20 h.  The reaction 
was quenched with water (30 mL) and extracted with ethyl acetate (3 x 25 mL).  The 
organic extracts were combined and washed with saturated sodium bicarbonate solution 
(2 x 40 mL) and the organic layer was dried over anhydrous sodium sulfate.  The solution 
was filtered and concentrated.  The residue was purified by flash column chromatography 
(2:1 hexanes-ethyl acetate) giving cyclized product (92.5 mg, 52% yield).  1H NMR (500 
MHz, CDCl3) !: 11.59 (s, 1H), 8.53 (d, J=9.0 Hz, 1 H), 8.20 (d, J=9.0 Hz, 1 H), 7.48 
(dd, J = 9.0, 7 Hz, 1H), 7.25 (d, J = 6.5 Hz, 1H), 7.213 (d, J = 9.0 Hz, 1H), 4.87 (q, J = 
8.5 Hz, 2H), 2.69 (s, 3H).   13C NMR (125 MHz, CDCl3) !: 170.6, 164.3, 135.3, 133.7, 
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131.9, 128.7, 127.7, 125.4, 123.4, 121.4, 118.6 (m), 104.1, 61.0 (m), 19.9. HRMS (ESI-): 
m/z calculated for (C14H10O3F3)
- 283.0582, found 283.0580  
 
 
 
 
 
2-Hydroxy-5-methyl-1-naphthoic acid (3.6).  To a stirring solution of naphthoic ester 
(92.5 mg, 0.0325 mmol, 1 eq) in 6 mL 2:1 THF-water, lithium hydroxide monohydrate 
(273 mg, 6.51 mmol, 20 eq) was added.  The solution was stirred at 40 oC for 22 h.  The 
THF was removed in vacuo and the pH of the resulting slurry was adjusted with 1 M HCl 
until a pH of 2 was reached.  The mixture was extracted with ethyl acetate (3 x 15 mL).  
The organic layer was washed with brine (2 x 10 mL), dried with sodium sulfate and then 
concentrated.  The resulting residue was purified via flash column chromatography (1:2 
hexanes-ethyl acetate with 1% acetic acid), yielding the naphthoic acid (3.6) (65.7 mg, 
99% yield). 1H NMR (400 MHz, CDCl3) !: 12.1 (s, 1H), 8.78 (d, J = 8.8  Hz, 1H), 8.22 
(d, J = 9.2 Hz, 1H), 7.50 (dd, J = 7.2, 8.8 Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 
9.6 Hz, 1H), 2.70 (s, 3H). 13C NMR (100 MHz, CDCl3) !: 175.6, 165.2, 135.4, 134.1, 
132.7, 128.8, 127.9, 125.5, 124.1, 119.1, 104.1, 20.2. HRMS (ESI-): m/z calculated for 
(C12H9O3)
- 201.0552, found 201.0558 
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Methoxy substituted (Z)-olefin. To a stirring solution of phosphonate (500 mg, 1.34 
mmol, 1.4 eq) in THF (5 mL), DBU (284 µL, 1.91 mmol, 2 eq) was added dropwise via 
syringe at 23 oC.  The yellow solution was stirred for 20 min at 23 oC.  A solution of 4-
methoxy benzaldehyde (116 µL, 0.954 mmol, 1 eq) in THF (5 mL) was added dropwise 
to the stirring orange solution at 0 oC over 1 min.  The reaction was stirred overnight at 4 
oC.  The reaction was quenched with saturated aqueous ammonium chloride solution (20 
mL) and the THF was removed in vacuo.  The aqueous mixture was extracted with ethyl 
acetate (3 x 30 mL) and the extracts were combined, washed with brine (2 x 20 mL), and 
dried over anhydrous sodium sulfate.  The solution was filtered and concentrated.  The 
crude mixture was purified by flash column chromatography (1:1 hexanes-ethyl acetate) 
giving product in a 1:1.5 inseparable mixture with the (E)-olefin (by 1H NMR) (248 mg, 
99 % yield). 1H NMR (500 MHz, CDCl3) !: 7.33 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 9 Hz, 
2H), 6.82 (d, J = 12.5 Hz, 1H), 5.83 (d, J = 12.5 Hz, 1H), 5.37 (s, 1H), 3.83 (s, 3H), 1.62 
(s, 6H).   13C NMR (125 MHz, CDCl3) !: 164.5, 162.5, 160.5, 131.5, 129.8, 128.1, 
120.0, 113.8, 96.1, 55.8, 25.6.  HRMS (ESI+): m/z calculated for (C15H16O4Na)
+ 
283.0946, found 283.0950  
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Trifluoroethyl 2-hydroxy-7-methoxy-1-naphthoic acid ester.  Trifluoroethanol (277 
µL, 3.85 mmol, 10 eq) was dissolved in THF (5 mL), and sodium hydride (60% 
dispersion in mineral oil, 55.4 mg, 2.31 mmol, 6 eq) was added.  The solution was stirred 
for 20 min at 23 oC, turning clear and orange.  A solution of the (Z)-olefin (mixture with 
(E)-olefin) (100 mg, 0.384 mmol, 1 eq) in THF (5 mL) was added dropwise to the 
reaction and stirred at 23 oC for 50 min.  The reaction was concentrated in vacuo and the 
resulting residue containing trifluoroethyl ester was taken up in acetic acid (3 mL).  
Manganese (III) acetate trihydrate (337 mg, 1.26 mmol, 2 eq) was added and the solution 
was stirred at 23 oC for 20 h.  The reaction was quenched with water (30 mL) and 
extracted with ethyl acetate (3 x 25 mL).  The organic extracts were combined and 
washed with saturated sodium bicarbonate solution (2 x 40 mL) and the organic layer was 
dried over anhydrous sodium sulfate.  The solution was filtered, concentrated, and the 
brown residue was purified by flash column chromatography (gradient 3:1 to 1:1 
hexanes-ethyl acetate) giving product (82.0 mg, 71 % yield).  1H NMR (500 MHz, 
CDCl3) !: 8.12 (d, J = 2.5 Hz, 1H), 7.86 (d, J = 9 Hz, 1H), 7.65 (d, J = 9 Hz, 1H), 7.04 
(dd, J = 2.5, 9.0 Hz, 1H) 7.02 (d, J = 9.0 Hz, 1H), 4.87 (q, J = 8.5 Hz, 2H), 3.92 (s, 3H).  
13C NMR (125 MHz, CDCl3) !: 171.1, 166.3, 160.8, 138.2, 133.6, 131.0, 124.1, 116.5, 
O
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116.4, 105.2, 101.5, 61.8 (m), 55.4.  HRMS (ESI-): m/z calculated for (C14H10O4F3)
- 
299.0531, found 299.539.  
 
 
 
 
2-Hydroxy-7-methoxy-1-naphthoic acid (3.8).  To a stirring solution of naphthoic ester 
(82.0 mg, 0.273 mmol, 1 eq) in 6 mL 2:1 THF-water, lithium hydroxide monohydrate 
(229 mg, 5.46 mmol, 20 eq) was added.  The solution was stirred at 40 oC for 22 h.  The 
THF was removed in vacuo and the pH of the resulting slurry was adjusted with 1 M HCl 
until a pH of 2 was reached.  The mixture was extracted with ethyl acetate (3 x 15 mL).  
The organic layer was washed with brine (2 x 10 mL), dried with sodium sulfate and then 
concentrated.  The resulting residue was purified via flash column chromatography (2:1 
hexanes-ethyl acetate with 1% acetic acid), yielding the naphthoic acid (3.8) (39.9 mg, 61 
% yield).  1H NMR (400 MHz, CDCl3) !:  12.01 (s, 1H), 8.34 (s, 1H), 7.88 (d, J = 9.2 
Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.04 (t, J = 9.2 Hz , 1H), 3.97 (s, 3H).  13C NMR (125 
MHz, CDCl3) !:175.9, 166.7, 160.5, 138.1, 134.1, 130.8, 127.3, 124.0, 116.7, 115.3, 
106.4, 55.6.  HRMS (ESI-): m/z calculated for (C12H9O4)- 217.0501, found 217.0494.  
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2,7-Dihydroxy-5-methyl-1-naphthoic ester.  Dissolved naphthoic ester (24.8 mg, 
0.0832 mmol, 1 eq) in 3 mL dichloromethane and cooled to -10 oC while stirring under 
nitrogen.  A 1 M solution of boron tribromide in dichloromethane (83.2 µL, 0.0832 
mmol, 1 eq) was added dropwise, turning the reaction from clear to yellow.  The reaction 
was allowed to stir at 23 oC for 20 h.  The reaction was quenched with 5 mL of methanol 
and then concentrated to dryness.  Dissolved residue in methanol (2 x 5 mL) and 
concentrated to dryness with each addition.  The brown residue was purified by flash 
column chromatography (2:1 hexanes-ether with 1% acetic acid) yielding the 
demethylated product (17.4 mg, 90% yield).  1H NMR (400 MHz, CDCl3) !: 11.70 (s, 
1H), 8.09 (d, J = 9.6 Hz, 1H), 7.92 (s, 1H), 7.04 (d, J = 9.2 Hz, 1H), 6.88 (s, 1H), 4.98 (s, 
1H), 4.87 (q, J = 8.4 Hz, 2H), 2.64 (s, 3H).  13C NMR (100 MHz, CD3OD) !: 170.5, 
161.3, 158.5, 138.3, 135.5, 132.5, 126.3, 123.7, 117.8, 117.6, 115.9, 115.6, 106.7, 62.0 
(m), 20.9.  HRMS (ESI-): m/z calculated for (C14H10O4F3)
- 299.0531, found 299.0538.  
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2,7-Dihydroxy-5-methyl-1-naphthoic acid (3.7).  To a stirring solution of naphthoic 
ester (17.4 mg, 0.075 mmol, 1 eq) in 4 mL 1:1 THF-water, lithium hydroxide 
monohydrate (0.063 g, 1.45 mmol, 20 eq) was added.  The yellow solution was heated to 
40 oC with stirring overnight.  The THF was removed in vacuo and the pH of the 
resulting slurry was adjusted with 1 M HCl to pH 2.  The mixture was extracted with 
dichloromethane (3 x 10 mL).  The organic layer was washed with brine (1 x 30 mL), 
dried with sodium sulfate and then concentrated.  The resulting residue was purified via 
flash column chromatography (1:1 hexanes-ether with 1% acetic acid), resulting in the 
naphthoic acid (3.7) (4.4 mg, 99% yield). 1H NMR (400 MHz, CD3OD) !: 8.15 (d, J = 
2.4 Hz, 1H), 8.04 (d, J = 9.2 Hz, 1H), 6.92 (d, J = 9.2 Hz, 1H), 6.80 (d, J = 0.8 Hz, 1H), 
2.59 (s, 3H).   13C NMR (100 MHz, CD3OD) !: 165.0, 162.8, 158.2, 137.9, 136.6, 132.5, 
123.8, 117.1, 116.2, 108.2, 106.7, 20.2.  HRMS (ESI-): m/z calculated for (C12H9O4)
- 
217.0501, found 217.0506. 
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Naphthoyl-NHS.  To a round bottom flask equipped with a stir bar, 3.12 (251 mg, 1.46 
mmol, 1 eq) and N-hydroxysuccinimide (169 mg, 1.46 mmol, 1 eq) in 5 mL THF, N,N’-
dicyclohexylcarbodiimide (300.9 mg, 1.458 mmol, 1 eq) was added.  The clear solution 
was allowed stirred at room temperature until a fine white precipitate formed (30 min).  
The crude slurry was filtered through a pad of celite and concentrated under reduced 
pressure.  The residue was resuspended in ethyl acetate and filtered again through celite.    
The resulting crude product was concentrated under reduced pressure and purified via 
flash column chromatography (3:1 hexanes-ethyl acetate to 1:1 then to 100% ethyl 
acetate), resulting in activated 1-naphthoyl-N-hydroxysuccinimide ester (390 mg, 99% 
yield). 1H NMR (400 MHz, CDCl3) !: 8.79 (d, J = 8.4 Hz, 1H), 8.44 (d, J = 8.4 Hz, 1H), 
8.13 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.65 (m, 1H) 7.56 (m, 3H), 2.93 (s, 
4H).    
 
Acetonide protected naphthoyl sulfamoyl adenosine.  Acetonide protected sulfamoyl 
adenosine (128 mg, 0.332 mmol, 1 eq, synthesized by published literature procedure 
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(24)) was dissolved in 3 mL dry DMF.  1,8-Diazabicyclo[5.4.0]undec-7-ene (121  µL, 
0.797 mmol, 2.4 eq) was added to clear solution.  Upon addition of activated naphthoic 
acid (134 mg, 0.498 mmol, 1.5 eq), solution turned from clear to yellow.  The reaction 
was stirred under nitrogen at room temperature.  After 24 h, the crude reaction was 
concentrated to dryness with slight heating.  The crude residue was purified via flash 
column chromatography (9:1 chloroform-methanol with 1% triethylamine (TEA)) 
resulting in a TEA salt (115 mg, 0.212 mmol, 53.8% yield).  A second column was 
required to obtain pure product.  1H NMR (400 MHz, CD3OD) !:  8.54 (m, 2H), 8.18 (s, 
1H), 7.79 (m, 2H), 7.77 (d, J = 7.2 Hz, 1H), 7.65 (m, 3H), 6.27 (d, J = 3.2 Hz, 1H), 5.42 
(dd, J = 6.0, 3.2 Hz, 1H), 5.26 (dd, J = 6.0, 2.4 Hz, 1H), 4.62 (t, J = 2.4 Hz, 1H), 4.41 (d, 
J = 4.0 Hz, 2H), 1.62 (s, 3 H), 1.25 (s, 3H). HRMS (ESI+): m/z calculated for 
(C24H24NaN6O7S)
+ 563.1319, found 563.1505. 
 
Naphthoyl sulfamoyl adenosine (3.13).   Starting material (111 mg, 0.173 mmol, 1 eq) 
was dissolved in 4 mL 1:1 H2O-TFA.  Stirred orange slurry at room temperature for 2 h.  
Quenched with small amount of methanol, evaporated solvent in vacuo.  Purified by flash 
column chromatography (4:1 dichloromethane-methanol to 3:1), yielding 3.13 in 99% 
yield. 1H NMR (400 MHz, CD3OD) !:  8.41 (s, 1H) 8.40 (d, 1H), 8.12 (s, 1H), 7.79 (m, 
3H), 7.37 (m, 3H) 6.06 (d, J = 5.2 Hz, 1H), 4.68 (t, J = 5.2 Hz, 1H), 4.51 (m, 3H), 4.36 
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(d, 1H).   13C NMR (100 MHz, CD3OD) !: 175.8, 163.0, 156.9, 153.4, 150.7, 141.3, 
137.0, 135.2, 131.7, 129.3, 128.2, 127.7, 127.0, 125.8, 120.3, 116.8, 89.9, 84.3, 75.9, 
72.3, 70.4.  HRMS (ESI+): m/z calculated for (C21H20N6NaO7S)
 523.1012, found 
523.1031. 
Crystallization attempts 
NcsB2 was screened for crystallization using cleaved and uncleaved protein with 
Hampton Crystal Screens (Hampton Research, Aliso Viejo, CA) as well as Wizard 
Crystal Screens I and II (Emerald Biosystems, Bainbridge Island, WA) at 4 and 20 oC.  
Next, cleaved NcsB2 was screened for crystallization with 1.6 mM 3.3, with and without 
5 mM ATP, 2 mM MgCl2 at 4 and 20 
oC.  Truncated constructs of NcsB2 were screened 
with the Hampton Crystal Screens without substrate at 4 and 20 oC.         
NcsB2 was also screened with both sulfamoyl adenosine inhibitors (3.13 and 
3.14).  A 10 mM stock solution of inhibitor was made up in water.  NcsB2 (10 mg/mL) 
was incubated on ice for 1 h with 1.61 mM naphthoyl sulfamoyl adenosine.  Two 
Hampton Crystal Screens were set up at 4 oC and 20 oC.  No crystal hits resulted. 
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Tryosine Aminomutase SgTAM 
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4.1 Introduction 
C-1027 (4.1) is an enediyne antitumor-antibiotic that contains a functionalized !-
tyrosine moiety, (S)-3-chloro-4,5-dihydroxy-!-phenylalanine (1, 2).  This component of 
C-1027 is biosynthesized and attached to the enediyne core via six enzymatic 
transformations (Scheme 4.1) (3).  SgTAM, originally named SgcC4, is the first of these 
enzymes to act, catalyzing a 2,3-amino shift on L-"-tyrosine (4.2) to form (S)-!-tyrosine 
(4.3) (4-6).  Next, SgcC1 activates 4.3 as an (S)-!-tyrosyl adenylate (4.4) and is 
subsequently loaded onto the phosphopanthetheinyl arm of the peptidyl carrier protein 
(S-PCP) SgcC2, forming 4.5 (7, 8).  The conjugated !-amino acid is then chlorinated and 
hydroxylated to generate 4.7 by SgcC3 and SgcC, respectively (7, 9, 10).  Finally, the 
condensation enzyme SgcC5 attaches the functionalized (S)-!-tyrosine to the enediyne 
core of C-1027 (11). 
Scheme 4.1: Biosynthesis of !-tyrosine moiety and attachment to enediyne core of C-1027 
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 SgTAM is a tyrosine aminomutase (TAM) that contains the unique prosthetic 
group 4-methylideneimidazole-5-one (MIO, Scheme 4.2) (4, 5), which is formed by the 
self-condensation of a conserved Ala-Ser-Gly motif within the enzyme.  MIO-containing 
enzymes are known to catalyze two types of transformations involving aromatic amino 
acids, including conversion of histidine, phenylalanine, and tyrosine to their 
corresponding deaminated, unsaturated products, urocanate, cinnamate, and p-
hydroxycinnamate (HCA), respectively (Scheme 4.3) (12-14).  Enzymes that catalyze 
these transformations are called ammonia lyases.  Lyases accomplish this elimination via 
electrophilic catalysis involving the MIO, prosthetic group.  A recently discovered 
transformation catalyzed by MIO-containing enzymes is a 1,2-amino shift.  Examples are 
known where tyrosine and phenylalanine are converted to their corresponding !-amino 
acids involving an additional step to lyase activity, which involves the readdition of 
ammonia into an  ",!-unsaturated intermediate (4, 15-17).  SgTAM belongs to the 
aminomutase class of MIO-dependent enzymes and preferentially converts L-tyrosine to 
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Scheme 4.2: Post-translational formation of MIO prosthetic group from Ala-Ser-Gly motif 
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(S)-!-tyrosine.  This recent discovery reignited interest in the unusual chemistry of MIO-
containing enzymes.  The mechanism by which SgTAM and other MIO-containing 
enzymes catalyzes the conversion of L-amino acids to their lyase or mutase products is 
intensely debated (18, 19).  For a comprehensive review of MIO chemistry, see Appendix 
2. 
There are two very different proposed mechanisms by which lyases and mutases 
act, though both mechanisms involve electrophilic catalysis driven by the MIO.  The first 
mechanism to be proposed is the amino-MIO adduct mechanism (Figure 4.1A), which 
was uncontested for 35 years (18).  This mechanism involves the electrophilic addition of 
the  "-amino group on the substrate into the exo-methylene carbon of the MIO.  Then, 
deprotonation at the !-position occurs, followed by formation of a carbanion intermediate 
and elimination via an E1-cB mechanism.  It is likely that binding of the MIO to the 
amine on the substrate puts it in proper alignment for antiperplanar elimination to occur, 
facilitating elimination of the leaving group.  One issue with this mechanism is the high 
pKa of the benzylic proton; formation of the MIO adduct alone only lowers the pKa of 
this proton by about 4 units, from a value of ~40 (20).  Because of this issue, the 
CO2
-
H3N
CO2
-
Ar Ar
CO2
-
Ar
NH3
NH3 NH3
Lyase
Mutase
Scheme 4.3: Reactions catalyzed by MIO-dependent enzymes with L-tyrosine, L-phenylalanine, 
and L-histidine.  Ar = aromatic ring. 
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amino-MIO adduct mechanism fell out of favor for some time upon the suggestion of a 
new mechanism by Rétey and coworkers—a Friedel-Craft type mechanism (Figure 4.1B) 
(19).  This mechanism involves electrophilic activation of the substrate’s aromatic side 
chain, resulting in aromatization of the MIO and in a carbocation intermediate.  This 
carbocation contributes to a lowering in pKa of the !-proton.  Reformation of the MIO 
leads to ammonia elimination from the substrate.  For mutases, free ammonia adds back 
into the unsaturated substrate via a 1,4-addition. 
 
There are a few issues associated with a Friedel-Craft type mechanism, the first 
being the prediction of the carbocation intermediate.  Based on the structures of a variety 
of MIO-containing enzymes, the active site is located at the positive end of a number of 
 "-helices (20), a situation that would very much disfavor a positively charged 
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Figure 4.1:  Two proposed mechanisms for MIO-containing enzymes with L-tyrosine as the 
substrate.  Either hydroxycinnamate is produced or an additional step may occur for mutase 
activity involving the further addition of ammonia to produce (S)-!-tyrosine. 
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intermediate.  On the other hand, the positive nature of the active site could play a role in 
lowering the pKa of the !-proton for the amino-MIO adduct mechanism by stabilizing 
the incipient carbanion on the  "-carbon.  Additionally, it has been demonstrated that the 
lyase (as well as mutase) reaction is reversible; feeding lyases exogenous ammonia and 
the corresponding olefin results in formation of the  "-amino acid (21, 22).  The reverse 
of the Friedel-Craft mechanism is not chemically reasonable, which adds additional doubt 
to the likelihood of this mechanism.  Rétey originally postulated that a tyrosine ammonia 
lyase (TAL) could not exist because the p-hydroxyl group would make the formation of 
the carbocation intermediate very unlikely (23).  This hypothesis has been subsequently 
disproven as a number of TALs and TAMs are now known.  Therefore, based on current 
structural information as well as past biochemical studies, we favor the earlier of the two 
mechanisms: the amino-MIO adduct mechanism.     
The mechanism of MIO-dependent lyases has been thoroughly studied and the 
discovery of MIO aminomutases has revealed even more insight into their chemistry (4).  
Specifically, it has been demonstrated that SgTAM not only produces !-tyrosine, but also 
it produces hydroxycinnamate (HCA), the concentration of which increases over time to 
eventually make up 100% of total substrate/product ratio (Figure 4.2) (5).  The overall 
time course for the reaction with L-tyrosine revealed that !-tyrosine concentration never 
exceeds 60% and is quickly outpaced by HCA production, which is produced from both 
!-tyrosine and L-tyrosine (Figure 4.2).  Either mechanism would support HCA as an 
intermediate in the catalytic pathway of MIO aminomutases, and an increasing 
production of it over time suggests that it and ammonia diffuse out of the active site and 
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are unlikely to rebind.  Interestingly, it has been shown that addition of high 
concentrations of ammonium chloride (10 mM) and HCA (10 mM) to SgTAM results in 
the production of 13 µM !-tyrosine after 24 h (5).  Additionally, SgTAM can use L-3-
chlorotyrosine as an amino source for the reverse reaction.  When SgTAM was incubated 
with 10 mM of L-3-chlorotyrosine and 10 mM HCA, 27 µM !-tyrosine was produced 
after 24 h.  These observations suggest that ammonia remains bound in the active site 
longer than the unsaturated acid, perhaps due to a covalent bond with the MIO.  Since L-
3-chlorotyrosine is not the preferred substrate of SgTAM, following deamination its 
unsaturated product leaves the active site, the ammonia molecule remains bound and 
HCA diffuses in.  This differing rate 
of diffusion has been observed 
previously (18) and lends further 
support for the amino-MIO adduct 
mechanism. Over time and under 
standard reaction conditions, the 
concentration of free ammonia is 
too low to promote further !-
tyrosine formation and all tyrosine is 
converted to HCA. 
The fact that mutases also have lyase activity begs the question: What differences 
in these enzymes are responsible for different reaction pathways?  A mutase needs to 
catalyze the additional step of a 1,4-addition of ammonia into the ",!-unsaturated acid to 
Figure 4.2: Time course of SgTAM-catalyzed 
conversion of L-tyrosine (!) to !-tyrosine (!) and HCA 
("). 
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form a !-amino acid.  The fact that the reverse reaction of lyases is also observed 
complicates the issue of differing between lyases and mutases, as one would expect a 
significantly higher dissociation constant for ",!-unsaturated products with lyases that 
would disallow further reaction with unsaturated acids (though it is significant that a 
much higher concentration of ammonia is required to observe this activity).  Furthermore, 
if the reverse reaction can be observed in lyases, why can’t these enzymes form the 
corresponding !-amino acid?  These questions need to be answered to truly differentiate 
the chemistry of lyases and mutates. 
We have previously solved the first structure of an MIO aminomutase (SgTAM) 
(Figures 4.3) and have determined pertinent active site residues (Figure 4.4) (6).  With L-
tyrosine modeled into the active site, key hydrogen bonding interactions are apparent 
between the substrate carboxylate and Arg311 as well as between the substrate phenol 
and His93 and Tyr415.  Tyr308 and Asn438 are in close proximity to the MIO.  Tyr63, 
positioned directly above the "-protons, is believed to be the enzymatic base and is 
rigidly conserved among MIO-containing enzymes.  The biologically active unit is a 
tetramer and the observed asymmetric unit is a dimer.  Residues within the active site 
originate from three monomers, though the majority is on the same chain from which the 
MIO originates.  We compared the structure SgTAM to that of a TAL and active site 
residues are well conserved that, except for Tyr415.  Additionally, residues Glu71 and 
Tyr303 close the tunnel to the active site of SgTAM, while the tunnel of the TAL is open.  
These residues that block the opening to the active site are believed to sequester ammonia 
and/or L-tyrosine in the active site so that the complete transformation to !-tyrosine can 
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occur, instead of immediately releasing HCA.  We have probed Tyr63 to prove its 
function as the enzymatic base via biochemical (24) and structural studies.  This chapter 
will include discussions into insights gained through these studies mentioned above as 
well as additional with mutant constructs of SgTAM (a full list can be found in the 
Experimentals section). 
Figure 4.3: Cartoon representations of SgTAM X-ray structure.  (Top) Monomer is made up 
primarily of  !-helices with one "-sheet.  Two additional "-sheets form at the dimer interface.  
(Bottom) Two tetramers, the biologically active unit, are shown down two axes of symmetry.  
Each monomer is indicated by a different color. 
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4.2 Activity assays of mutants 
 All of the mutant constructs produced 
were tested for activity using a previously 
published procedure (4).  As will be discussed 
in the following sections, no turnover was 
observed for any mutant constructs involving 
changes in the immediate active site (Figure 
4.4).  A variety of binding studies were 
conducted to gain further information into the 
effect of these mutations on substrate binding.  
Mutant constructs that did show turnover include residues located with in the tunnel 
leading up to the active side.  These constructs were further probed via time course assays 
(as in Figure 4.2). 
4.3 Selectivity switch, His93 
 Residue His93 was proposed to be the selectivity switch for SgTAM, based on 
similar studies with lyases.  When mutated to phenylalanine, it was predicted that it 
would favor L-phenylalanine as a substrate and produce !-phenylalanine, converting 
SgTAM into a phenylalanine aminomutase (PAM).  This assumption was based on prior 
research done on RsTAL, a tyrosine ammonia lyase from R. sphaeroides, which was 
shown to change substrate specificity from L-tyrosine to L-phenylalanine with mutation 
of His89 of this enzyme to Phe (for sequence alignment, see Figure 4.5) (25, 26).  
Unfortunately, in the His93Phe mutant construct of SgTAM this change in specificity did 
Figure 4.4: View of SgTAM active site.  L-
Tyrosine is modeled in (cyan) and bound 
to MIO (red) with active site residues 
(gray). 
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not occur; in fact, no activity for either substrate was detected even after 24 h of 
incubation with enzyme.  The lack of activity may be explained by improper folding or 
by simply poor binding of both L-tyrosine and L-phenylalanine.  Furthermore, wild-type 
mutase activity is quite slow (5) in comparison to RsTAL lyase activity (25).  RsTAL has 
a kcat of 27.7 s
-1 and a kcat/KM of 1.1x10
5 M-1s-1, while SgTAM has a kcat of 0.010 s
-1 and a 
kcat/KM of 360 M
-1s-1.  Lyase activity for SgTAM is substantially slower as well; HCA is a 
side-product of the mutase reaction, with a kcat of 1.2x10
-3 s-1 and kcat/KM of 50 M
-1s-1.  
Mutase activity of SgTAM is 108 times less efficient than RsTAL lyase activity and 
perturbations to the active site could easily extinguish activity overall.  Additionally, it 
was predicted based on UV-Vis spectroscopy that SgTAM only has about 18% of 
possible MIO formed.  Minor changes in the active site might perturb the structure 
enough to eliminate nearly all MIO formation.  Finally, wild-type SgTAM shows very 
little activity towards L-phenylalanine after 24 h (27), while RsTAL does.  Perhaps it is 
the combination of a sluggish enzyme and other factors that make conversion of this 
TAM into a PAM difficult. 
4.4 A potential MIO modulator, Tyr308 
Tyr308 appears to play a crucial role either in mediating the formation of the MIO 
or by maintaining the MIO in a non-aromatic, active state.  As shown in Figure 4.4, 
Tyr308 is in close proximity to the MIO, and the hydroxyl group of the residue appears to 
form a hydrogen bond with the NH of the MIO and with the side chain of Gln442.  
Previously, the function of this residue was probed in the histidine ammonia lyase (HAL) 
PpHAL via mutagenesis and biochemical and structural analysis (28).  Tyr280 (the same 
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residue based on alignment with SgTAM) was mutated to Phe (Figure 4.5).  The structure 
of this mutant construct was compared to that of a high-resolution structure of the wild-
type HAL; both structures were solved with free cysteine bound in the active site.  In the 
wild-type structure (the MIO is formed at residues 142-144), the nitrogen from the Gly 
residue of the MIO (144-N) appeared to be in its pyramidal sp3 hybridized state.  
Contrarily, the Tyr280Phe mutant X-ray structure revealed a planar sp2 hybridized 144-N, 
suggesting that the MIO existed in its intermediate aromatic state.  The effect of this 
mutation seemed to be due to the lack of hydrogen bonding of Tyr280 to Glu414 
(analogous to Gln442 in SgTAM), which caused a displacement of the Glu414 side chain.  
This hydrogen bond may present enough negative charge at the nitrogen from the Ser 
residue of the MIO (143-N) to cause sp3 hybridization of 144-N in an unliganded state.  
Without this hydrogen bond, the MIO may not be able to remain in its active, catalytic 
state.  Mutation of Tyr308 to Phe in SgTAM led to a loss of catalytic activity, as expected 
(the Tyr280Phe mutant of PpHAL had less than 1% activity compared to wild-type (28) 
and the Tyr300Phe mutant of RsTAL had no activity (29)).  This mutant was further 
investigated in binding studies, which will be discussed in section 4.8. 
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Figure 4.5: Sequence alignment of representative MIO-dependent ammonia lyases and 
aminomutases.  The secondary structure of SgTAM is indicated above the sequence and inner 
and outer loop regions are indicated by green lines below sequence.  MIO forming residues are 
indicated by green box.  Aligned sequences include SgTAM (S. globistorus tyrosine 
aminomutase), PaPAM (P. agglomerans phenylalanine aminomutase), PpHAL (P. putida 
histidine ammonia lyase), and RsTAL (R. sphaeroides tyrosine ammonia lyase). 
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4.5 A possible mutase/lyase switch, Tyr415 
 An overlay of the active sites of RsTAL 
and SgTAM shows very similar active sites 
where the major difference is at residue Tyr415, 
where a valine is located in RsTAL (Figure 4.6) 
(6, 26).  Since RsTAL is a lyase, it was expected 
that the Tyr415Val mutant construct of SgTAM 
would lack mutase activity and would produce 
only HCA.  Unfortunately, this mutation did not 
convert SgTAM into a lyase; no mutase or lyase 
activity was observed even after 24 h.  Prior to any folding studies, we postulated that this 
change in polarity of the active site was affecting binding of L-tyrosine, perhaps to the 
point where it would prefer L-phenylalanine.  This change in substrate specificity was 
also not detected, perhaps because additional mutations were required.   
The double mutant of Tyr415Phe and His93Phe was made and tested for activity 
against the alternate substrate.  Again, no activity toward L-phenylalanine was observed.  
It seems very likely that the single mutation in the active site is leading to problems in 
folding or tetramer assembly as attempts to crystallize the His93Phe mutant construct 
failed.  In our experiments, mutants typically crystallized similarly to wild-type enzyme, 
with and without ligand (see Glu71Ala and Tyr63Phe mutants).  Further biochemical 
studies of the Tyr415Val and His93Phe mutant constructs might give insight into why no 
lyase or mutase activity is observed. 
Figure 4.6: Overlay of active sites of 
SgTAM (dark gray) and RsTAL (light 
gray, pdb #2O6Y). 
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4.6 The predicted enzymatic base, Tyr63 
Tyr63 was predicted to be the enzymatic base of SgTAM; it likely exists in the 
phenolate form and is situated directly above the !-carbon of substrate L-tyrosine (Figure 
4.4) (24).  Tyrosine is absolutely conserved at this position among all sequence homologs 
(Figure 4.5).  The deprotonated form of tyrosine would be favored, as the active site is 
located at the positive end of seven !-helices, which would stabilize the negative charge.  
Additionally, the phenolate hydrogen-bonds to the backbone of Gly70, lowering the pKa 
of the sidechain.  If our assumption is correct, mutation of the tyrosine residue to a 
phenylalanine would remove the phenolate base, rendering the enzyme inactive.  As 
expected, the Tyr63Phe mutant showed no turnover of substrate.  Mutation of RsTAL 
Tyr60 to Phe also resulted in a complete loss of activity (29). 
To further prove that Tyr63 is the enzymatic base and that mutation results in the 
loss of this base and is not a result of perturbation of the active site, we solved the 
cocrystal structure of the Tyr63Phe mutant construct with L-tyrosine (Figure 4.7).  The 
Figure 4.7: Tyr63Phe mutant structure.  A) Active site of mutant with L-tyrosine bound to the MIO.  
B) Representation of major interactions in the active site. C) Electron density maps of active site.  
The 2Fo"Fc map is controured to 1.5  # and the Fo"Fc to map 3.0 #.  Maps were generated without 
L-tyrosine modeled into active site. 
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crystal diffracted to a resolution of 2.3 Å and the Fo-Fc map of the structure minus L-
tyrosine in the active site showed density for the majority of the ligand bound to the MIO.  
Electron density corresponding to the substrate’s phenyl ring is partially visible and the 
phenol has significant density, appearing to be hydrogen bonded to residues His93 and 
Tyr415, as seen in the  !,!-difluoro-"-tyrosine cocrystal structure (24).  Though density 
for the !-carbon of L-tyrosine is weak, the MIO is most certainly bound to a ligand, as 
density extends from the exo-cyclic methylidene carbon of the MIO.  Electron density for 
this bond is apparent in both the Fo#Fc and 2Fo#Fc maps.  The weak density may be 
attributed either to substoichiometric binding of the ligand or ligand in multiple 
conformations in the active site.  If it were the case that less than a quarter of the active 
sites have MIO in its active form and the rest are either not fully formed or in their 
inactive, aromatic state, then it would make sense for fewer active sites to be occupied by 
ligand or for ligand to be in an alternate positions.  It may also be random as to which 
active site in a tetramer has bound L-tyrosine, which would result in electron density for 
ligand in both active sites in the asymmetric unit.   
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4.7 Tunnel mutants 
Two main differences exist between TAL and TAM; SgTAM has a tyrosine 
residue in the active site where RsTAL has a valine and the tunnel to the active site of 
SgTAM is closed and much smaller compared to that of RsTAL.  Since the initial attempt 
failed to convert SgTAM into an ammonia lyase by making the Tyr415Val mutation, 
mutations to the tunnel leading to the active site were made.  The open active site of 
RsTAL exposes the MIO to outside solvent.  It was postulated that an exposed active site 
decreases the ability of the enzyme to maintain HCA and ammonia in the active site; 
creating a more accessible active site in SgTAM might preclude mutase activity.  Glu71 
and Tyr303 in the tunnel of SgTAM are hydrogen bonded to each other and may act to 
block the MIO from direct contact with solvent (Figure 4.8).  We mutated these residues 
to sterically less bulky amino acids and analyzed their activity over time.  The tunnel 
Figure 4.8: Surface views of MIO.  The MIO of SgTAM is not solvent accessible due to a 
hydrogen bond between Tyr303 and Glu71 (left).  The MIO of RsTAL is solvent 
accessible due to a less sterically crowded tunnel (right). 
 115 
mutant constructs included Glu71Ala, Tyr303Ala, and the double mutant of the two.  
Despite a decrease in activity, all three showed lyase activity while still producing some 
amount of !-tyrosine (Figure 4.9).  Glu71Ala had the biggest decrease in activity of the 
two single mutants; the percent of HCA and !-tyrosine both never surpassed 15% even 
after 24 hrs, with !-tyrosine forming in excess of HCA the entire time.  The effect of the 
Tyr303Ala mutation was limited as a similar time curve was observed to the wild-type 
enzyme (Figure 4.2), though wild-type converted as much as 60% of tyrosine to !-
tyrosine, while the mutant peaked just under 40%.  The double mutant resulted in roughly 
the same time course as the single Glu71Ala mutant.  
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Figure 4.9: Time courses catalyzed converstion of L-tyrosine (!) to  !-tyrosine (!) and HCA 
(") by tunnel mutants. 
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To further investigate the Glu71Ala mutant, we solved its structure to a resolution 
of 2.3 Å.  Figure 4.10A shows a cutaway view of the wild-type SgTAM active site, 
including the closed tunnel.  When Glu71 is mutated to an alanine, the tunnel is open and 
the active site is solvent exposed (Figure 4.10B).  It was expected that opening this tunnel 
so that it more resembled the tunnel from RsTAL (Figure 4.10C) would result in the 
increased rate of release of ammonia or HCA before the ammonia could add back into 
HCA to form !-tyrosine.  This activity was not observed for the Glu71Ala mutant or for 
the double mutant.  It appears that SgTAM still acts as a mutase, but its overall rate of 
turnover is decreased, perhaps as a result of improper formation of the active unit.  The 
biological unit is composed of four monomers, three of which contribute residues to the 
active site; residues 71 and 303 within one tunnel are from two different monomers.  
Problems with the interface of the monomers may be to blame for the lowered activity. 
 
 
A B C 
Glu71Ala 
     \ 
Glu71 
     \ 
Figure 4.10: Cutaway views of active site and tunnel comparing solvent accessibility to MIO 
(probe sphere radius of 1.4 Å).  A) Wild-type SgTAM with a closed tunnel.  B) Glu71Ala mutant 
of SgTAM with an open tunnel.  C) RsTAL with an open tunnel and large active site. 
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4.8 Binding assays of inactive enzymes 
 In an effort to further characterize the inactive mutant constructs of SgTAM, we 
set out to study the binding of L-tyrosine and, in some cases, L-phenylalanine.  By doing 
so, we hoped to determine which mutant constructs were inactive due to lack of pertinent 
catalytic resides and which were simply unable to bind substrate. 
4.7.1 Fluorescent quenching 
Fluorescent quenching was the first technique attempted but was quickly 
abandoned, despite a small amount of observed quenching. A low signal-to-noise ratio 
was observed, caused by the complete lack of tryptophan residues in SgTAM.  The error 
associated with each measurement was simply too large to be considered accurate and the 
values were within the error range of the blanks (despite previous success with RsTAL 
(29)).   
4.7.2 Equilibrium dialysis 
We next attempted to determine the binding constant of SgTAM mutants for L-
tyrosine using equilibrium dialysis.  We initially focused on the Tyr63Phe mutant 
construct as we knew binding was occurring because electron density for L-tyrosine was 
present in the active site of the crystal structure.  It was apparent that binding was 
occurring with the Tyr63Phe mutant construct, though values obtained from multiple 
experiments were imprecise and the error was significant.  No specific binding was 
observed for the His93Phe/Tyr415Val double mutant, though aberrant binding of tyrosine 
was seen (that is, an excessive amount of radioactivity was measured on the protein side 
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of the dialyzer, but did not correlate to tyrosine concentration).  Despite the minor 
success with the Tyr63Phe mutant, this technique was abandoned due to the inaccuracy 
of binding constants among experiments, likely a result of the difficult loading of the 
dialyzers. Air bubbles at the membrane of the dialyzers more often than not obscured 
dialysis across the membrane.   
4.7.3 Isothermal Titration Calorimetry 
Finally, we tried isothermal titration calorimetry (ITC), as it is a highly sensitive 
biophysical technique commonly used to study the binding of small molecules to 
macromolecules.  It was hoped that its sensitivity would allow us to measure the minute 
differences in binding that we expected to observe among the various inactive mutants 
(and one tunnel mutant), which the other techniques did not allow.  A number of 
protein/ligand combinations were tested, all of which showed no binding except for 
Tyr63Phe and Glu71Ala to L-tyrosine (Figure 4.10).   Pairs that were tested and showed 
A B C 
Figure 4.11: ITC curves of SgTAM mutants with L-tyrosine. A)Tyr63Phe mutant, B)Tyr308Phe 
mutant, C) Tyr415Val mutant. 
 120 
no binding include Tyr415Phe/L-tyrosine, Tyr415Phe/L-Phenylalanine, His93Phe + 
Tyr415Phe/L-Phenylalanine, and Tyr308/Phe/L-tyrosine.  The latter experiment showed 
binding but the change in enthalpy was very small and constant for the entire run.  It 
appears that all mutations made to the active site of SgTAM have a significant effect on 
ligand binding and, for the most part, extinguish activity for this reason.   
In the case of the Tyr63Phe mutant, it is not surprising that binding does occur, as 
this residue acts as the enzymatic base and does not interact with the substrate phenol and 
it is hypothesized that the mutation does not affect folding or tetramer assembly as we 
were able to grow crystals and solve the structure.  These observations further support the 
role of the residue in catalysis.  Nevertheless, a binding constant was difficult to calculate 
for this mutant because the full sigmoidal titration curve could not be obtained.  
Typically, the first few additions of titrant (a solution of ligand) result in roughly the 
same enthalpy change, while subsequent aliquots result in a decreasing change in 
enthalpy.  In the case of this mutant, after the initial titration the decrease in enthalpy was 
immediate.  Attempts to obtain the anticipated curve were not successful.  These attempts 
include lowering the amount of ligand being titrated in or raising the concentration of the 
protein in solution.  It appears as though all active sites are not available to bind ligand, 
which would result in a smaller enthalpy change per aliquot added.  This result may be 
caused by incomplete MIO formation.  Also, active sites with formed, active MIO may 
covalently bind L-tyrosine particularly strongly, which would result in smaller changes in 
enthalpy upon further addition of ligand.  ITC is best used for protein/ligand pairs with 
dissociation constants (Kd) greater than 1 µM, a minimum that can be lowered with more 
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favorable binding conditions, specifically those that affect a large enthalpic change.  The 
calculated Kd from the partial curve obtained for Tyr63Phe/L-tyrosine was 6.85  µM ± 
0.74 (while the apparent binding constant, Km, was originally measured to be 28 µM (5)).  
Whether or not this value can be considered accurate is debatable, as the appropriate ITC 
curve was not obtained.  It is possible that the dissociation constant is actually lower.  
The combination of a less than 1:1 binding stoichiometry and a low Kd makes quantifying 
binding difficult.  Nevertheless, we have confirmed that all mutations in the active site, 
aside from Tyr63Phe, impede ligand binding.  Tyr308Phe shows an enthalpy change 
upon ligand titration, but a typical sigmoidal curve did not appear.  Perhaps this result is 
due to the state of the MIO; as discussed above, mutations to this residue cause the MIO 
to exist primarily in its aromatic state.  Clearly ligand binding is partially due to binding 
to MIO, hence the lack of the typical sigmoidal titration curve.  The Glu71Ala mutant 
construct still turns over the substrate and hence shows ligand binding, as expected. 
4.9 Folding as determined by circular dichroism   
 The lack of binding of ligands to the His93Phe+Tyr415Phe double mutant (as 
well as the single mutants of the two) may be a result of improper folding.  In order to 
test this hypothesis, a simple CD experiment was set up to compare the folding of the 
double mutant to the Tyr63Phe mutant (Figure 4.12).  It appears that there is a difference 
in folding between the two mutant constructs, as seen by the significant reduction in  !-
helical character of the protein (signified by large dip between 210 and 330 nm).  
Addition of salt to the double mutant seems to improve folding slightly but the difference 
between the two mutant constructs is still significant.  Furthermore, the increased !-
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helical character of the Tyr63Phe mutant compared to the double mutant supports the fact 
that the latter mutant is well folded, maintains normal ligand binding and has no catalytic 
ability due to lack of the enzymatic base.   
4.10 Conclusion 
 From these observations, it is quite clear that SgTAM is sensitive to perturbations 
to the active site.  Futhermore, from studies on the Tyr63Phe mutant, which maintains 
substrate binding, we can conclude that an enzymatic base is required for catalysis and 
conversion to  !-tyrosine cannot occur without deprotonation of the !-carbon first.  
Simple proximity to MIO and correct geometric arrangement of L-tyrosine is not enough 
for catalysis. These observations suggest that the active site of SgTAM is incredibly 
sensitive to mutations.  It is possible that certain changes in active site residues affect 
Figure 4.12: Circular dichroism spectra of Tyr63Phe and His93Phe/Tyr415Val mutants with and 
without salt. 
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either the formation of MIO, maintenance of the MIO in its active, non-aromatic state, or 
the makeup of the active site due to incorrect folding.  To determine which of these 
problems are responsible for the lack of activity of the majority of mutants, we would 
need further biochemical experiments, including more in depth folding experiments, 
dynamic light scattering to determine size, and UV experiments to measure the 
absorbance of the MIO to verify its state.   
4.11 Experimentals 
General 
PfuUltra, DpnI and other reagents for site-directed mutagenesis were ordered 
from Stratagene (La Jolla, CA).  Oligonucleotide primers were ordered from IDT DNA 
(Coralville, IA). T4 DNA ligase and restriction enzymes were orderd from New England 
Biolabs (Ipswich, MA).  Kits for uses for DNA purification were purchased from 
QIAGEN (Valencia, CA).  DNA sequencing was done by Genewiz (S. Plainfield, NJ).  
Thrombin, IPTG, LB media, antibiotics and other reagents were from Sigma-Aldrich (St. 
Louis, MO) or VWR (West Chester).  NovaBlues and BL21 (DE3) were from VWR.  
HiTrap-Q column and HiLoad 16/60 SuperDex 200 gel filtration column were from GE 
Healthcare (Pittsburgh, PA).   
DNA manipulation   
Mutant constructs of SgTAM from Streptomyces globisporus (Locus AY048670) 
were produced from the plasmid expression construct pBS1022 (in pET-28a in NdeI-
HindIII sites) using a modified version of the Quikchange site-directed mutagenesis 
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protocol as described previously (5). Mutants were produced using their corresponding 
primer pairs as shown in Table 2.1. 
Table 2.1: Oligionucleotide primers used for producing mutant constructs of SgTAM with mutant 
codon underlined. 
Mutation Forward Primer Reverse Primer 
Y63F 5’-cagaacatccccatcttcggggtgaccaccggg-3’ 5’-cccggtggtcaccccgaagatggggatgttctg-3’ 
E71A 5’-ccgggtacggcgcgatgatctacatgc-3’ 5’-gcatgtagatcatcgcgccgtacccgg-3’ 
E71A, DM 5’-ccgggtacggcgctatgatctacatgc-3’ 5’-gcatgtagatcatagcgccgtacccgg-3’ 
H93F 5’-ccaatctcgtccgtagcttcagcgcgggagtcggtcc-3’ 5’-ggaccgactcccgcgctgaagctacggacgagattgg-3’ 
Y303A 5’-gcgctcggagatcgccctgcagaaggcc-3’ 5’-ggccttctgcagggcgatctccgagcgc-3’ 
Y308F 5’-cctgcagaaggccttctcgctgcgggcc-3’ 5’-ggcccgcagcgagaaggccttctgcagg-3’ 
Y415V 5’-cgccggcgcccaggtcccggccaccgc-3’ 5’-gcggtggccgggacctgggcgccggcg-3’ 
 
The Tyr303Ala mutant was produced using the procedure from the Quikchange 
handbook.  Modifications to the published protocol for the remaining mutants were as 
follows: the Tyr63Phe and Tyr308Phe mutants were produced using 1x reaction buffer, 
100 ng plasmid, 500 ng forward and reverse primer, 200 µM dNTPs, 5% DMSO, and 2.5 
U PfuUltra, with the following thermal cycler parameters: 95 oC for 5 min; 35x (95 oC for 
30 sec, 62 oC for 45 sec, 72 oC for 10 min); 72 oC for 10 min; 4 oC.  The remaining 
mutants had slightly altered procedures: Tyr415Val had an extenstion time of 8 min, 
Glu71Ala and Tyr93Phe were cycled 20x to lower the chance of random annealing and 
had an extension time of 10 min.  To produce the Glu71Ala/Tyr303Ala double mutant, 
new primers were used with the Tyr303Ala mutant (E71A, DM) because the original 
could not again successfully produce the mutation despite repeated attempts.  The 
reaction was cycled 20x with an extension time of 10 min, producing the double mutant.  
Following mutagenesis, 2 µL of DpnI was added to the reaction mixture and incubated 
for 2 h at 37 oC.   The QIAquick PCR purification kit was used to removed enzyme and 
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purify plasmid DNA, which was eluted with 30 µL H2O.  To close nicks resulting from 
mutagenesis, a ligation was performed overnight with 1 µL T4 DNA ligase, 1x T4 DNA 
ligase reaction buffer at 16 oC.  Typically, 1 µL of the ligation mixture was transformed 
into NovaBlues, which were grown in 5 mL LB broth overnight supplemented with 
kanamycin.  Plasmid was isolated using the QIAprep Spin MiniPrep Kit and mutations 
were confirmed by sequencing. 
To produce the Tyr93Phe/Tyr415Val mutant, the Tyr93Phe and Tyr415Val 
plasmids were digested with NdeI and SacI.  The digests were run on an 1% agarose gel 
and the smaller fragment from Tyr93Phe containing the 93 mutation and the larger 
fragment from Tyr415Val containing the 415 mutation were excised from the gel.  The 
DNA was purified using the QIAquick Gel Extraction Kit.  The two pieces were ligated 
together with T4 DNA ligase and transformed as above. 
Enzyme production and purification   
Mutant SgTAM constructs were transformed into BL21(DE3) E. coli cells.  One 
colony was used to inoculate 5 mL of LB media and was grown for 16 h at 37 oC. The 
overnight culture was subsequently used to inoculate 1 L of LB media, which was grown 
to O.D. = 0.6 with shaking (37 oC at 150 RPM).  Overexpression was induced by addition 
of 50 µM IPTG and the culture was incubated overnight at 18 oC.  Cells were collected 
by centrifugation (20 min, 2000 g), resuspended in 25 mL of lysis buffer containing 20 
mM Tris, pH 7.5 and 500 mM NaCl, and frozen (-78 oC.)   The cell pellet was thawed 
and lysed by two passes through a French Press at 1000 PSI.  The lysed cells were then 
centrifuged (20 min, 10,000 g) to remove cell debris and the protein was purified batch-
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wise using Ni-NTA resin.  For use in activity and binding assays, the purified protein was 
dialyzed into a low salt buffer (50 mM CHES pH 9.0, 50 mM KCl) and was either used 
immediately or stored at -78 oC in 20% glycerol to be used for assays within one week.  
Protein for crystallography was dialyzed into low salt buffer (20 mM Tris pH 7.5, 100 
mM NaCl), concentrated to less than 1 mL, and the His6-tag was cleaved using 5 U of 
thrombin in cleavage buffer (20 mM Tris pH 7.5, 100 mM NaCl, 2 mM CaCl2) for 2 days 
at 4 oC.  The protein solution was then diluted to 5 mL and purified on a HiTrap-Q ion 
exchange column (0-1 M NaCl gradient in 50 mM Tris-HCl pH 7.5 and 1 mM !-
mercaptoethanol) followed by a Superdex 200 gel filtration column (20 mM Tris-HCl pH 
7.5, 100 mM NaCl).  The purified protein was concentrated to ~10 mg/mL for 
crystallography (a total yield of 4 mg/L of cells).    
Biochemical assay of SgTAM mutant constructs 
 The activity of SgTAM mutants was measured using an HPLC based assay (5).  
Reactions were performed at 25 oC with 100 µM L-tyrosine, 50 mM CHES, 50 mM KCl, 
pH 9.0 and 0.5 mg/mL enzyme in a total volume of 1.5 mL.  All mutant constructs were 
monitored for activity with time points at 1 h and 18 h.  For Glu71Ala and Tyr303Ala 
mutants, a time course assay was run by quenching 50 µL aliquots of reaction mixture by 
addition to a tube containing 2 µL 0.5 M HCl.  Time points were taken at 10 min, 30 min, 
then every half hour for 8 h, and then every hour until 12 h.  Additional time points were 
taken after 24 h.  Each aliquot was centrifuged for 1 min at 14,000 g to remove enzyme.  
The supernantant was subjected to o-phthaldialdehyde (OPA) derivation by increasing 
the pH to 10 with 2 µL 1M NaOH followed by mixing with 50 µL of fresh, degassed 
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OPA reagent (4 mg OPA, 4.25 mL 100 mM sodium borate buffer pH 10.7, 50 µL ethanol 
and 11 µL  !-mercaptoethanol) for 30 sec, and then quenched with 1 µL glacial acetic 
acid.  Derivatized samples were subjected to HPLC analysis on a VYDAC C18 Protein 
and Peptide column (eluent A: 5 mM sodium acetate pH 5.7 in with 5% THF; eluent B: 5 
mM sodium acetate pH 5.7, 45:45:10 methanol/acetonitrile/water; gradient: 0-38 min at 
10-50% B, 38-40 min at 50%, 40-52 min at 50-10% B, 52-57 min at 10% B at a flow rate 
of 1 mL/min).     
 Mutant constructs Tyr93Phe, Tyr415Val, and the double mutant of the two were 
tested for activity with L-phenylalanine under similar assay and analysis conditions. 
Fluorescence quenching 
 The binding of p-hydroxycinnamic acid (HCA) to the Tyr63Phe mutant was 
monitored using a Jas.Co FP-6300 Spectrofluorimeter equipped with stirring.  In a 
cuvette, 900  µL of 50 mM CHES pH 9.0, 50 mM KCl and 1.5 µM protein was 
equilibrated to 25 oC by stirring for 3 minutes.  A number of excitation/emission values 
were tested and the largest signal was observed for an excitation range between 220 nm 
and 300 nm, producing the highest emission signal at 345 nm.  A 5 mM solution of HCA 
was titrated in 2 µL aliquots over time, to a concentration of 0.15 mM HCA (no more 
than 3% of total volume was exceeded with the HCA solution).  The same experiment 
was used to measure HCA binding with the His93Phe mutant and His93Phe/Tyr415Val 
double mutant.   
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Equilibrium dialysis  
 DISPO equilibrium dialyzers (Harvard Apparatus, Holliston, MA) were used to 
run small-scale dialyses of L-tyrosine and SgTAM mutant constructs to measure the 
binding constant.  One side of the dialyzer contained 50 µl of 0.5 mg/mL protein, 50 mM 
CHES pH 9.0 and 1  µM 3H-tyr.  The other side contained 50 µL of various 
concentrations of L-tyrosine, ranging from 0 to 100 µM.  The dialyzers were shaken at 25 
oC for 16 h and three 3 µL aliquots of solution were removed from each side of the 
dialyzer and were added to 5 mL aliquots of scintillation fluid in 20 mL vials and 
subjected to scintillation counting.  
Isothermal titration calorimetry 
 A VP-ITC (MicroCal Inc.) at the Biophysical Instrumentation Facility at MIT was 
used for all measurements.  The basic experiment was set up with a 1.4 mL of protein at a 
concentration of 30-60 µM in the cell.  Ligand was titrated in, typically in 10 µL aliquots 
at a concentration of 100-300 µM.  All experiments were run at 25 oC, with a DP of 15 
µcal/sec.  Concentrations of protein and ligand were varied to optimize the curve 
obtained.  Protein/ligand pairs tested include Tyr63Phe with L-tyrosine, Tyr415Val with 
L-tyrosine and L-phenylalanine, His93Phe+Tyr415Val/L-phenylalanine, Gln71Ala/L-
tyrosine and Tyr308Phe/L-tyrosine.  Data was interpreted using the program provided by 
MicroCal.   
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Circular dichroism 
 Protein was prepared as for assays and concentrated to 0.5 mM.  All runs 
contained 10 mM phosphate pH 9.0 buffer and sometimes contained 10 mM KCl.  A 
cuvette blank was run at 190-300 nm, with a 2 sec average time, for 1 scan at a 1 nm step.  
A buffer blank was run at 178-300 nm, 0.5 sec average time, for 3 scans and a 1 nm step 
(with and without KCl).  Protein solutions were made with a final concentration of 
protein at 5 µM with buffer, with and without KCl, and were run with the same 
parameters as the buffer blank.   
Crystallization and X-ray data collection 
SgTAM mutant constructs Glu71Ala and Tyr63Phe (both 58 kDA, 539 amino 
acids) were crystallized as described previously with some minor modifications (6). The 
Glu71Ala mutant was crystallized in 100 mM trimethylamine N-oxide (TMAO), 4.6 M 
sodium formate, at 4 oC. The Tyr63Phe mutant crystallized in 95 mM TMAO, 4.6 M 
sodium formate with 2 mM L-tyrosine (incubated with protein for two days at 4 oC), at 20 
oC.  All stock solutions of crystallization conditions were homemade with reagents 
purchased from Aldrich.  Solutions were sterile filtered prior to use.  Crystals typically 
formed within two days and reached full size within a few weeks.  Data was collected at 
the National Synchrotron Light Source at Brookhaven National Laboratories on 
beamlines X12C and X25, respectively (Table 2.2).   
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Table 2.2: Data collection and refinement statistics 
  Tyr63Phe Glu71Ala 
Space group P21212 P21212 
Unit cell parameters (Å) a=92.7,b=145.9,c=74.8 a=92.6,b=145.9,c=74.9 
Data collection 
Resolution (Å) 50.0-2.20 (2.28-2.20) 50-2.20 (2.28-2.20) 
Wavelength (Å) 0.9793 1 
No. of reflections (measured/unique) 751714/52517 226063/50047 
% Completeness*  99.9 (100.0) 95.2 (87.1) 
Rsym* 0.087 (0.653) 0.086 (0.440) 
I/!" 30.0 (4.3) 11.0 (1.8) 
Redundancy* 14.3 (14.2) 4.6 (4.0) 
Refinement 
No. of reflections (total/test) 50153/5053 47693/4814 
Rwork 0.204 0.238 
Rtest  0.249 0.265 
No. amino acids (chains A/B) 529/529 529/529 
No. atoms   
Protein (chains A/B) 4012/4012 4010/4010 
Ligands (L-tyrosine) 26 - 
Water Molecules 216 468 
Mean B (protein/Tyr/water) (Å2) 42.9/30.8/37.8 39.3/-/38.3 
RMSD from ideal geometry   
RMSD bonds (Å) 0.008 0.005 
RMSD angles (o) 1.4 0.8 
Ramachandran plot by PROCHECK (%)   
Core region 89.8 87.0 
Allowed region 10.2 12.7 
Generously allowed  0.0 0.2 
Disallowed 0.0 0.0 
*overall (highest resolution shell)   
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A1. 1 Biosynthesis of the neocarzinostatin enediyne core 
 The carbon scaffold of the enediyne core is produced by the polyketide synthase 
(PKS) NcsE, which iteratively catalyzes seven Claisen condensations as well as 
ketoreductions and dehydrations to yield the enzyme bound hexadecahexaene product 
(Scheme A1.1) (1).  The thioesterase (TE) NcsE10 hydrolyzes the linear polyene, which 
is then decarboxylated and dehydrated (1).  Subsequent transformations, likely catalyzed 
by all or some of the remaining NcsEs, result in the an enediyne core intermediate (2).  
The activity of these enzymes has yet to be determined as many of the NcsEs are 
homologous only to proteins of unknown function.  We sought to elucidate the function 
of some of these unknown proteins using X-ray crystallography and comparing their 
structures to structures of enzymes of known function.   
Scheme A1.1: Biosynthesis of enediyne core of neocarzinostatin by the NcsEs 
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A1.2 Experimentals for NcsEs 
Cloning of ncsE2 and ncsE3 
 Both ncsE2 and ncsE3 were cloned from genomic DNA into pET-30b by T. 
Montavon.  A 2 bp frameshift required them to be recloned into pET-30a.  This was done 
by a sequential digest of the vector using BamHI and HindIII, purification on a 1% 
agarose gel, and excision of the DNA from the gel, which was purified using the 
QIAquick DNA purification kit (QIAGEN, Valencia, CA).  The DNA was ligated into 
the new plasmid using T4 DNA ligase (NEB, Ipswich, MA) and the mixture was 
transformed into TOP10 cells (Invitrogen, Carlsbad, CA).  Successful clones were 
confirmed by double digest using NcoI and HindII, resulting in the correct digest pattern 
(Figure A1.1), and by sequencing (GENEWIZ, S. Plainfield, NJ).   
Figure A1.1: Cloning of ncsE2 and ncsE3.  Double digest of inserts from pET-30b (left) and 
double digest of inserts in new expression vector, pET-30a (middle and left). 
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NcsE2 expression tests 
 The ncsE2-pET-30a plasmid was transformed into BL21(DE3) cells (Invitrogen) 
and one colony was used to inoculate 5 mL of LB broth (EMD) supplemented with 30 
µg/mL kanamycin (Aldrich, St. Louis, MO.).  The culture was shaken at 37 oC at 250 rpm 
to OD600 = 0.60 and 2 mL of culture was transferred to a new tube containing 100 µM 
IPTG (Aldrich).  Both tubes were shaken for 1 h at 37 oC.  Various amounts of each 
culture were run on an SDS-PAGE gel to confirm overexpression of induced culture 
(Figure A1.2).  A 1 L culture was 
grown at 37 oC and 150 rpm to OD600 = 
0.70 and overexpression was induced 
at 18 oC with 100 µM IPTG.  Cells 
were shaken at this temperature for 16 
h.  Following centrifugation at 2,000 g 
for 20 min, the cells were resuspended 
in 20 mL lysis buffer (20 mM Tris-HCl 
and 500 mM NaCl, pH 7.5), frozen to -
70 oC.  The cells were lysed and the protein was purified using same procedure for NcsB2 
(see section 3.9 Experimentals).  Gel showed a significant amount of overexpression of 
NcsE2 in inclusion bodies (Figure A1.3).  Overexpression at 16 oC did not have a positive 
effect on the solubilization of NcsE2 and, in fact, appeared to result in a decreased 
amount of expression (Figure A1.3).    
Figure A1.2: Small-scale over-expression test of 
NcsE2 showing induced (I) and uninduced (U) 
cultures. 
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We attempted to purify NcsE2 under denaturing conditions.  The pellet was 
resuspended in 15 mL buffer A (6 M Gu-HCl, 0.1M NaH2PO4, 0.01 M Tris-HCl pH 8.0).  
The slurry was stirred at 25 oC for 2 h.  To pellet insolubilized portion, the slurry was 
centrifuged at 10,000 g for 30 min at 4 oC.  Ni-NTA resin was washed with buffer A and 
was incubated with supernatant for 1 h at 25 oC.  The resin was spun down at 2,000 g for 
5 min.  The supernatant was poured and the resin was resuspended in buffer A and 
washed 4 x 10 mL with the same buffer.  In an attempt to renature the solubilized protein, 
a gradient maker was used to exchange buffer A for a non-denaturing buffer (20 mM 
Tris-HCl, 100 mM NaCl, 1 mM  !-mercaptoethanol, pH 7.5).  About 80 mL of each was 
placed in either side of the gradient maker, which went directly onto the column 
containing the Ni-NTA resin and protein.  Following gradient exchange, a 10 mL elution 
off of the Ni-NTA column was collected (elution buffer: 20 mM Tris pH 7.5, 500 mM 
NaCl, 250 mM imidazole, 1 mM  !-mercaptoethanol).  No protein was obtained.  
Figure A1.3: SDS-PAGE gels of lysed NcsE2 cell pellets subjected to Ni-NTA purification.  Gels 
are of NcsE2 over-expression at 18 
o
C (left) and at 16 
o
C (right).  Each gel shows aliquots taken 
from pellet (P), flow-through (FT), wash (W) and elutions 1-3 (E1-E3) during purification.   
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Finally, a freshly lysed pellet was resuspended in a 
denaturing buffer containing 4 M urea (Figure A1.4).  
Denatured protein was successfully obtained but renaturing 
by dialyzing into standard low salt buffer with Tween-20 
(at the critical micelle concentration, 0.005%) resulted in 
nearly all of the protein precipitating out of solution.  It 
seems unlikely that this protein could be purified under 
standard conditions, even with the help of refolding 
screens.  Because its activity is unknown, determining if 
proper refolding into its native conformation has occurred 
would be quite difficult.  At this point, we began to focus 
more on the isolation and purification of NcsE3. 
NcsE3 expression tests 
A 5 mL expression test was run as for NcsE2, but overexpression was not 
apparent (Figure A1.5).  Therefore, a large-scale 1 L prep was set up and overexpression 
was induced with 100 µM IPTG at 18 oC.  Using standard purification conditions, soluble 
protein was obtained in good yield (Figure A1.5).  NcsE3 is a 328 amino acid protein 
with a molecular weight of 35711.3 Da and a calculated pI of 9.19 (Ec = 59025 M
-1).  
With the His6-tag, it is 377 amino acids long with a molecular weight of 41012.0 and a pI 
of 7.88 (Ec = 59025 M
-1).  Even with the affinity tag, NcsE3 has a very high pI.  In 
general, soluble proteins have a pI below 7, and often around 5.  It is not surprising that 
upon dialysis into low salt buffer at a neutral pH (50 mM NaCl, 20 mM Tris-HCl, 1 mM 
Figure A1.4: SDS-PAGE gel 
of solubilized, denatured 
NcsE2.  Lanes are pellet 
prior to denaturing (P1), 
pellet following denaturing 
(P2), and supernatant after 
denaturing (S2). 
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!-mercaptoethanol, pH 7.5), protein began to precipitate out.  It became apparent that a 
high concentration of salt was needed to stabilize the protein in a soluble form.  A new 
protein preparation was run and the protein was purified under standard conditions and 
dialyzed into an ammonium sulfate buffer (1 mM NH4SO4, 50 mM NaH2PO4, 1 mM !-
mercaptoethanol, pH 7.0).  Some protein precipitated but most remained soluble.  
Dialysis studies to determine optimal salt concentration were run.  First, the purified 
protein was dialyzed for 2 h into 1 L of high salt buffer (500 mM NaCl, 20 mM Tris, 1 
mM !-mercaptoethanol, pH 7.5).  It was then transferred to 300 mM NaCl dialysis buffer 
for 2 h, then to 200 mM NaCl dialysis buffer for 2 h, followed by 100 mM for 16 h.  The 
bulk of protein precipitation occurred between 100 and 200 mM NaCl.  It seemed 
unlikely that standard purification methods could be used (i.e. ion-exchange on a Mono-
Q column).   
Therefore, following dialysis into the ammonium sulfate buffer, NcsE3 was 
subjected to further purification on a hydrophobic-interaction column (HIC) (phenyl 
sepharose column from GE Healthcare) using the following buffer system: A- 1 M 
NH4SO4, 50 mM NaH2PO4, 1 mM !-mercaptoethanol, pH 7.0; B- 50 mM NH4SO4, 50 
mM NaH2PO4, 1 mM !-mercaptoethanol, pH 7.0) at 2 mL a minute for 40 mL total, 0-
100 % B.   Very pure protein resulted (Figure A1.5). 
The HIC method was further improved by dialyzing into a higher pH buffer (50 
mM Tris-HCl, 1 mM NH4SO4, 1 mM !-mercaptoethanol, pH 8.8 with 10% glycerol).  
The HIC purification was run under pH 8.8, with a 30 mL 0-100% B gradient followed 
by a 10 mL wash at 100% B, which resulted in better elution of protein off the column.   
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NcsE2 was concentrated to under 20 mL and dialyzed into a 250 mM NaCl buffer, 
followed by concentration to 10 mg/mL.  Hampton crystal screens were set up at both 4 
and 20 oC at 10 mg/mL, but most resulted in a large amount of precipitated protein, 
which could not be lessened with addition of 0.1% Triton x-100.  Many false crystal hits 
resulted, as ammonium sulfate is known to form salt crystals in the presence of divalent 
cations, in this case in the presence of Ca2+ and Mg2+.  Attempts to remove ammonium 
sulfate were made by dialyzing into high-salt gel filtration buffer and by purifying on a 
size-exclusion column prior to screening using a Superdex 200 gel filtration column 
(buffer- 20 mM Tris-HCl, 1 M NaCl, 1 mM !-mercaptoethanol, 10% glycerol, pH 8.8).  
Typical protein yields from all of the above preps were about 5-6 mg protein per liter 
prep. 
A final attempt was made at improving the solubility of NcsE3 without using 
exceedingly high salt concentrations by dialyzing into another common detergent 
solution: 1.5 mM deoxycholic acid, 20 mM Tris-HCl, 50 mM NaCl, 1 mM !-
Figure A1.5:  SDS-PAGE gels of overexpression and purification of NcsE3.  A gel of the small-
scale over-expression test at 37 
o
C is shown (left) as well as a gel of lysis and Ni-NTA purification 
of large-scale over-expression (middle).  HIC purification results in very pure protein, as observed 
in gel (right).   
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mercaptoethanol, pH 7.5.  Nearly 100% of previously soluble protein precipitated out of 
solution.   
Finally, NcsE3 was purified using only Ni-NTA resin and size exclusion 
chromatography (buffer contained 250 mM NaCl, 20 mM Tris pH 7.5, 1 mM !-
mercaptoethanol).  Crystal screens were set up at 4 and 20 oC.  Crystal screens did not 
result in 100% crashed out protein but higher salt concentrations maintained solubility.  
Trays containing PEG 400 and sodium citrate were set up (30% PEG 400 and 0.2 M 
sodium citrate were identified as conditions that allowed good solubility) as well as 
conditions containing a variety of precipitants (MPD, PEG 1000 and 4000), all at pH 7.5.  
No crystal hits resulted.   
An NcsE3 solubility study with 100 mM metal solutions was run because a blast 
search reveled some remote homology to metal utilizing enzymes.  Metals included: 
nickel(II) sulfate, ferrous(II) sulfate, copper(II) sulfate, ferric(III) chloride, cobalt(II) 
chloride.  All solutions resulted in precipitated protein after 30 min at room temperature.   
Attempts to improve solubility of NcsE2 and NcsE3 during expression 
Maltose-binding protien (MBP) constructs of misfolded proteins have been shown 
to improve overall solubility.  Therefore, both ncsE2 and ncsE3 were cloned into the 
pMAL-C2X expression vector at the BamHI and HindIII site (Figure A1.6).   
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A small-scale over-expression test was run (as previously) and it was apparent 
that both pMAL constructs over-expressed (Figure A1.7).   
Also, because NcsE3 is significantly more soluble than NcsE2, which is 
expressed in inclusion bodies, and because NcsE3 and NcsE2 are 41% identical and 57% 
similar, we thought that perhaps the two enzymes are coexpressed in vivo.  Coexpression 
of the two constructs in E. coli might result in an overall soluble protein heterodimer.  
Therefore, ncsE2 and ncsE3 were cloned into the pQE expression vector, which contains 
no affinity tag and is ampicillin resistant (pET-30a is kanamycin resistant) (Figure A1.6).  
Cotransformation of the two plasmids and double selection using both antibiotics would 
result in colonies containing both expression plasmids.   
An initial small-scale overexpression test was run, which included not only 
coexpression of the His6-tagged constructs with the untagged pQE contructs, but also 
Figure A1.6: Cloning of NcsE2 and NcsE3 into various expression vectors.  (Left) Double digest 
of ncsE2 and ncsE3 and pQE and pMAL plasmids and (right) double digest of DNA extracted 
from colonies following transformation of ligation mixture into E coli.  The last five lanes show 
successful ligations. 
 144 
coexpression of the His6-tagged constructs with the pMAL constructs (Figure A1.8).  
There was a difference between the induced and uninduced cultures but it was unclear 
from this test if coexpression was advantageous to solubility.  Large-scale preps were set 
up with coexpression of the His6-tagged constructs and the pQE constructs.  
Unfortunately, not only did coexpression of the two proteins not increase the solubility of 
NcsE2, it appeared that the solubility (and perhaps overexpression) of NcsE3 suffered 
remarkably.     
Figure A1.8: SDS-PAGE gels of coexpression of plasmids.  Small scale (left), including pET-30a-
ncsE2 and pQE-60-ncsE3 (1), pET-30a-ncsE2 and pMAL-c2x-ncsE3 (2), pET-30a-ncsE3 and pQE-
60-ncsE2 (3), pET-30a-ncsE3 + pMAL-c2x-ncsE2 (4) induced (I) and uninduced (U).  Gel of large 
scale prep (right) shows that solubility is not improved by coexpression, which is apparent from a 
large amount of accumulated protein in pellet. 
 
Figure A1.7: Small scale overexpression test of pMAL constructs of NcsE2 and NcsE3 showing 
induced (I) and uninduced (U) cultures. 
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Cloning and overexpression of ncsE4 
 We next sought to clone ncsE4 from genomic DNA as it is also highly conserved 
among enediyne producers and many other organisms, yet has an unknown function.  
Prior to cloning, we analyzed it using the Dense Alignment Surface Method (DAS) (3) to 
predict any transmembrane domains that would lead to issues with soluble 
overexpression (Figure A1.9).  The first 25 or so amino acid residues appear to be 
embedded in a membrane and we predicted that truncating ncsE4 would give us soluble 
protein.  Therefore, we cloned both the entire gene and a truncated construct (lacking the 
first 25 amino acids).  The full NcsE4 construct would express as a 636 amino acid 
protein, with a molecular weight of 68852.2 Da, with a predicted pI of 4.71, and an Ec of 
Figure A1.9: DAS transmembrane segment prediction of NcsE4 with a loose cutoff (-----) and a 
strict cutoff (——). 
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100,505 M-1.  The truncated construct would be 611 amino acids in length, with a 
molecular weight of 66093.9 Da, a pI of 4.64 and an Ec of 95, 005 M
-1.    
Two sets of primers (from IDT DNA, Coralville, IA) were used to clone ncsE4 
from genomic DNA into the expression vector pET-28a.  The first set of primers was 
forward 5’-CCG TTG CCT CCC GGA ATG-3’ and reverse 5’-ACG GAG ATC GAG 
ATC GCG-3’ and were used to clone a 2100 bp piece of DNA from genomic DNA 
previously isolated from S. carzinostaticus.  Three dilutions of genomic DNA were made 
up by diluting the stock by 1/10, 1/100 and 1/1000 in water.  PCR solutions were 100 µl 
and contained 10% DMSO, 1x Deep Vent Polymerase buffer, 2 mM MgSO4, 20 mM 
dNTPS, 0.1 nmol of each primer, 1 µl of DNA dilution, 2 U of Deep Vent R Polymerase 
(all reagents were from NEB, Ipswich, MA) and water.  The time program used was as 
follows: 94 oC for 5 min, then 30 cycles of 94 oC for 1 min, 1 min at 51.4, 54.3 or 57.5 
oC, and 1 min at 72 oC, with a final extension time of 10 min at 72 oC.  Each genomic 
DNA was set up at each annealing temperature.  Following PCR, the reactions were run 
on a 1% agarose gel (Figure A1.10).  DNA from lane three of the 1/100 genomic DNA 
dilution was excised from the gel and purified using the QIAquick DNA purification kit 
(QIAGEN, Valencia, CA).   
Another PCR was set up with the same reagents as above but with nested primers 
containing the proper restriction sites for cloning.  Two different forward primers were 
used to clone either the entire gene of ncsE4 or the truncated construct of it.  The primers 
were forward (full length) 5’-GCA GCT AGC ACC ATG GCG AAG AAC-3’, forward 
(truncated) 5’-GAT GCT AGC TAC GTC GTT CGC CTC-3’ and reverse 5’-CGC CTC 
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GAG TCA CTT CTC CTT GAC CTG-3’.  The underlined codons represent restriction 
sites for NheI (forward) and XhoI (reverse).  The time program was the same as for the 
first set of primers but with a variety of different annealing times.  The successful 
annealing time for ncsE4 was 56.2 oC and for ncsE4t (truncated construct) was 60.2 oC.  
The DNA was purified as above and double digested using the two restriction enzymes 
per standard NEB protocol along with pET-28a.  Successful cloning of both constructs 
was confirmed by double digest and agarose gel electrophoresis (Figure A1.10).  
Plasmids were transformed into BL21(DE3). 
Figure A.10: Cloning of ncsE4 from genomic DNA. First round of PCR produced 2100 bp DNA 
fragment (left).  Each column is a different annealing temperature (1=51.4 
o
C, 2=54.3 
o
C, 3=57.5 
o
C) at three dilutions of genomic DNA.  Second round of PCR using nested primers for full length 
and truncated constructs, followed by purification, double digest and ligation into pET-28a, which 
were confirmed by 1% agarose gel (middle, ncsE4 and right, ncsE4t).  
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A small-scale expression test was run on both 
constructs of NcsE4 (Figure A1.11).  From this simple 
test, it was clear that the truncated construct (NcsE4t) 
overexpressed better than the full-length construct.  
Therefore, large-scale preps of NcsE4t were set up.  The 
first prep included growth of cells at 37 oC and induction 
of overexpression at 16 oC, which resulted in little to no 
soluble protein following purification on Ni-NTA resin 
(Figure A1.12).  Next, an attempt to improve the solubility 
of NcsE4t was made by growing cells at 15 oC and inducing overexpression at the same 
temperature after three days.  The cells were shaken for an additional 16 h.   No soluble 
protein resulted as all was present in inclusion bodies.  
Figure A1.11: Overexpression 
of full length (E4) and truncated 
(E4t) constructs of NcsE4. 
Figure A1.12: Large-scale overexpression of NcsE4t.  Growth at 37 
o
C with 16 
o
C induction (left) 
and growth and induction at 15 
o
C (right).  Both purified using Ni-NTA resin.  
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A1.3 Benzoxazolinate moiety 
 In an effort to study the convergent biosynthesis of C-1027, we sought to 
synthesize benzoxazolinate (A1.1) from C-1027.  The benzoxazolinate methyl-ester 
(A1.2) has previously been synthesized by Shibuya and coworkers (4).  We intended to 
use benzoxazolinate in studies with the predicted aryl-transferase SgcD6.  Unfortunately, 
overexpression of SgcD6 was never realized, as it is a transmembrane protein consisting 
of six transmembrane regions.  Whether or not the gene encoding for SgcD6 is directly 
involved in the biosynthesis of C-1027 is debatable.  Nevertheless, benzoxazolinate was 
synthesized using the published procedure as a guideline, with some minor modifications 
and additions.  Benzoxazolinate was tested as a potential substrate for NcsB2.  
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Figure A1.13: Synthesis of benzoxazolinate (A1.1) (1) Cu(NO3)2!H2O, Ac2O, 79%, (2) BCl3, 
CH2Cl2, -78 
o
C to 4 
o
C, 95%, (3) BnBr, NaH, reflux, 93%, (4) SnCl2!H2O (5 eq), EtOAc, 78 
o
C, 
61%, (5) DCC (4 eq), HOBt, DMAP, (5 mol %), Pyruvic acid, NMP, 66%, (6) H2, Pd/C (10 mol%), 
CH3OH, 89%, (7) MsCl (3 eq), Et3N (5 eq), DMAP (4 mol %), 58%, (8) LiOH, H2O/THF, 71%. 
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Experimentals for benzoxazolinate synthesis 
General.  Chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO) 
or VWR (West Chester, PA).  Solvents were dried using stills by Glass Contour (Santa 
Monica, CA).  Deuterated solvents were purchased from Cambridge Isotopes (Andover, 
MA).  Silica gel used for all flash chromatography purifications was purchased from 
VWR, EMD brand Geduran.  Mass Spectrometry (MS) was performed on a Micromass 
LCT TOF.  1H NMR spectra were recorded on a Varian 400 or 300 MHz spectrometer.  
Proton chemical shifts are reported in ppm (!) relative to internal tetramethylsilane 
(TMS, ! 0.0 ppm).  Data are reported as follows: chemical shift (multiplicity [singlet (s), 
doublet (d) or multiplet (m)], coupling constants [Hz], integration).   
 
Methyl 3,5-dimethoxy-2-nitrobenzoate (A1.4).  Methyl 3,5-dimethoxy benzoate (5.81 
g, 26.6 mmol) was added to a round-bottom flask containing 50 mL acetic anhydride.  
The clear solution was cooled to 0 oC in an ice bath.  Cupric nitrate (7.97 g, 33.0 mmol) 
was added to the solution over a 1 h.  The clear blue solution was slowly warmed to 25 
oC and stirred for 3 h.  The reaction mixture was poured over crushed ice to quench and 
was extracted with ethyl acetate (3 x 100 mL).  The organic layer was washed with a 
saturated bicarbonate solution (2 x 250 mL) and brine (2 x 10 mL), dried with 
magnesium sulfate, filtered using a Buchner funnel and then concentrated.  The resulting 
residue was purified via flash column chromatography (6 cm column, 1:1 hexanes-ethyl 
acetate), yielding the nitrated product (A1.4) (5.61 g, 78.6% yield). Rf = 0.61. 1H NMR 
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(400 MHz, CDCl3) !: 7.00 (d, J = 2.8 Hz, 1H), 6.71 (d, J = 2.8 Hz, 1H), 3.89 (s, 3H), 
3.88 (s, 6H).  
 
Methyl 3-hydroxy-5-methoxy-2-nitrobenzoate (A1.5).  A1.4 (5.61 g, 23.3 mmol) was 
dissolved in 300 mL dry DCM in a round-bottom flask.  The solution was cooled to -78 
oC and a 1 M solution of boron trichloride (47 mL, 46.6 mmol) was added dropwise.  The 
clear, orange solution was warmed to 0 oC and stirred overnight.  The brown solution was 
slowly quenched with 10 mL methanol, followed by 10 mL water and was concentrated.  
The brown residue was dissolved in 100 mL DCM and was washed with 1 M HCl (2 x 
100 mL) and with brine (1 x 100 mL).  The solution was dried with magnesium sulfate, 
filtered thru a silica plug, and concentrated under reduced pressure, yielding the 
monodemethylated product (A1.5) (4.97 g, 95% yield). 1H NMR (400 MHz, DMSO) !: 
11.39 (s, 1H), 6.84 (d, J = 2.4 Hz, 1H), 6.75 (d, J = 2.4 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 
3H).  
 
Methyl 3-(benzyloxy)-5-methoxy-2-nitrobenzoate (A1.6).  A1.5 (4.97 g, 22.0 mmol) 
was dissolved in 200 mL dry DMF in a round-bottom flask, which was cooled to 0 oC in 
an ice bath under an inert atmosphere.  Sodium hydride (0.97 g, 24.2 mmol) was added to 
solution and was stirred for 5 min.  Benzyl bromide (287 mL, 24.2 mmol) was added to 
the solution, which was slowly warmed to 25 oC and allowed to stir overnight.  The 
reaction was quenched first with a small amount of methanol, followed by 10 mL brine.  
The solution was extracted with DCM (4 x 150 mL), which was washed with brine (1 x 
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100 mL).  The solution was concentrated under reduced pressure with slight heating to 
remove the DMF.  Mineral oil was removed by mixing with hexanes followed by 
decanting.  The final product was recrystallized in ethyl acetate (15 mL).  Crystals were 
washed with hexanes to yield benzyl-protected product (A1.6) (6.46 g, 92.5% yield).  1H 
NMR (400 MHz, DMSO) !: 7.42 (m, 5H), 7.20 (d, J = 2.4 Hz, 1H), 7.00 (d, J = 2.4 Hz, 
1H), 5.33 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H). 
  
Methyl 2-amino-3-(benzyloxy)-5-methoxybenzoate (A1.7).  A1.6 (6.46 g, 20.4 mmol) 
was added to a round-bottom flask containing 100 mL ethyl acetate.  Tin (II) chloride 
(23.0, 0.102 mol) was added to the clear solution, which was refluxed at 78 oC overnight.  
The reaction was cooled to room temperature and poured over ice.  The pH was adjusted 
to 7 with saturated sodium bicarbonate solution.  The solution was concentrated under 
reduced pressure to remove the ethyl acetate.  To remove the tin, the aqueous solution 
was mixed with 100 mL DCM and the biphasic solution was filtered through a Buchner 
funnel.  The organic layer was separated from the aqueous layer, the latter of which was 
extracted with DCM (2 x 50 mL).  The organic extracts were combined, dried with 
magnesium sulfate, and concentrated under reduced pressure.  The resulting residue was 
purified via flash column chromatography (5 cm column, 3:1 hexanes-ethyl acetate), 
yielding the reduced product (A1.7) (3.59  g, 61.3% yield).  1H NMR (400 MHz, CDCl3) 
!: 7.40 (m, 5H), 6.94 (d, J = 2.8 Hz, 1H), 6.64 (d, J = 2.8 Hz, 1H), 5.77 (s, b, 1H), 5.07 
(s, 2H), 3.88 (s, 3H), 3.75 (s, 3H).  
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Pyruvyl aminobenzoate (A1.8).  A1.7 (1.92 g, 6.67 mmol) was added to a round-bottom 
flask containing N,N-dicyclohexylcarbodiimide (5.51 g, 26.7 mmol), HOBt (3.61 g, 26.7 
mmol) and DMAP (18 mg, 10 mol %).  30 mL NMP was added to flask, which was 
cooled to 0 oC.  Pyruvic acid (1.86 mL, 26.7) was added to stirring, orange slurry.  The 
solution was warmed to 25 oC and was stirred overnight.  The reaction mixture was 
diluted with 50 mL of ethyl acetate, washed with saturate sodium bicarbonate solution (2 
x 50 mL) and brine (1 x 50 mL).  The organic layer was filtered to remove the insoluble 
dicyclohexylurea and was concentrated under reduced pressure.  The crude product was 
purified via flash column chromatography (7:3 hexanes-ethyl acetate), to yield A1.8 (1.58 
g, 66.3% yield).  1H NMR (400 MHz, CDCl3) !: 9.24 (s, 1H), 7.40 (m, 5H), 6.94 (d, J = 
2.8 Hz, 1H), 6.64 (d, J = 2.8 Hz, 1H), 5.77 (s, b, 1H), 5.07 (s, 2H), 3.88 (s, 3H), 3.75 (s, 
3H).  
 
Hydroxy benzoxazolinate (A1.9).  A1.8 (1.56 g, 4.36 mmol) was dissolved in 30 mL 
methanol in a round-bottom flask.  Pd(OH)/C (0.067 g) was added to flask.  The flask 
was flushed with hydrogen three times and stirred under a hydrogen atomosphere 
overnight.  The slurry was filtered through a pad of celite and washed with ethyl acetate 
and toluene.  The solution was concentrated under reduced pressure, yielding A.19 (1.03 
g, 88.5%). 1H NMR (300 MHz, DMSO) !: 9.95 (s, 1H), 7.74 (s, 1H), 7.08 (d, J = 2.4 
Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 3.89 (s, 3H), 3.76 (s, 3H), 1.65 (s, 3H).  
  
 154 
Methyl benzoxazolinate (A1.2).  A1.9 (0.686 g, 2.57 mmol) was dissolved in 30 mL dry 
DCM in a 50 mL round-bottom flask.  Diisopropylethylamine (2.24 mL, 12.9 mmol) and 
DMAP (10 mg) were added to the yellow solution, which was stirred under an inert 
atmosphere in an ice bath.  Mesyl chloride (0.598 mL, 7.70 mmol) was added dropwise, 
turning the solution brown.  The solution was warmed to 25 oC and was stirred overnight.  
The reaction mixture was washed with saturate sodium bicarbonate solution (3 x 50 mL) 
and brine (1 x 50 mL).  The organic layer was dried using magnesium sulfate, filtered and 
concentrated under reduced pressure.  The crude product was purified via flash column 
chromatography (7:3 hexanes-ethyl acetate), to yield A1.2 (0.371 g, 58.0% yield).  1H 
NMR (400 MHz, CDCl3) !: 10.41 (s, 1H), 7.18 (d, J = 2.8 Hz, 1H), 6.79 (d, J = 2.8 Hz, 
1H), 5.64 (d, J = 2, 1H), 5.08 (d, J = 2, 1H), 3.94 (s, 3H), 3.80 (s, 3H).  
 
Benzoxazolinate (A1.1).  A1.2 (0.373 g, 1.50 mmol) was dissolved in 12 mL THF and 
12 mL 2 M sodium hydroxide solution in a 50 mL round-bottom flask.  The yellow 
solution was refluxed overnight.  The reaction mixture was concentrated under reduced 
pressure to remove the THF and was extracted with DCM (2 x 15 mL) to remove 
unreacted starting material.  The aqueous layer was acidified to pH less than 2 and was 
extracted with DCM (3 x 15 mL).  Insoluble material was filtered and saved.  The organic 
layer was dried using magnesium sulfate, filtered, concentrated under reduced pressure, 
and combined with insoluble material (which was confirmed to be product by NMR) 
yielding A1.1 (0.249 g, 70.5% yield).  1H NMR (400 MHz, D2O) !: 7.14 (d, J = 4.0 Hz, 
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1H), 6.78 (d, J = 4.0 Hz, 1H), 5.47 (d, J = 2.8 Hz, 1H), 5.15 (d, J = 2.8 Hz, 1H), 3.810 (s, 
3H).  LRMS (ESI-): m/z calculated for (C12H9O4)
- 234.04, found 234.07. 
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A2.1 Summary of recent advances 
The prosthetic group 4-methylideneimidazole-5-one (MIO) is the catalytic 
component of the ammonia lyase class of enzymes.  This family is responsible for the 
processing of amino acids in a variety of metabolic pathways through the elimination of 
ammonia to form unsaturated products.  Recently, new chemistry has been attributed to 
this family with the discovery of MIO-based aminomutases. The mechanism of 
electrophilic chemistry catalyzed by MIO-based enzymes has been investigated for 
several decades. Recent X-ray crystal structures of members of the family have provided 
novel insight into the molecular basis for catalysis and substrate recognition. In addition, 
the inclusion of aminomutases in natural product biosynthetic pathways has spurned 
recent advances toward rational engineering and chemoenzymatic applications.  
A2.2 Introduction 
Electrophilic catalysis by enzymes often requires small molecule cofactors or 
metal ions as the functional group repertoire of proteins is limited.  Flavins, pyridoxal 
phosphate, and chelated metals are representative of electrophilic cofactors employed in 
diverse, well-characterized enzymes. The ammonia lyase class of enzymes are unique 
members of this family, carrying out chemistry without a metal or common cofactor 
(Figure A2.1A) (1, 2, 3).  The family catalyzes the elimination of ammonia from L-amino 
acids to generate unsaturated products, functioning in a variety of biological pathways 
from amino acid catabolism to the generation of intermediates in the biosynthesis of 
secondary metabolites. In 2003, an enzyme with aminomutase activity, highly 
homologous to ammonia lyases, was described (4). This expanding sub-family is 
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responsible for the biosynthesis of !-amino acids in structurally diverse natural products 
(Figure A2.1C). In this review, we will discuss recent efforts toward elucidating the 
mechanism of these enzymes and summarize their use in chemoenzymatic applications. 
Figure A2.1: The chemistry of MIO-based enzymes. A) Summary of chemical reactions catalyzed 
by MIO-based ammonia lyases and aminomutases.  The currently known amino acid substrates 
for each class are listed. B) The structure of 4-methylideneimidazole-5-one (MIO) generated by 
the autocatalytic condensation of an Ala-Ser-Gly motif. C) Examples of natural products 
containing !-amino acid moieties (highlighted) derived from MIO catalysis. 
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A2.3 MIO-based ammonia lyases 
The chemical mechanism of ammonia lyases has been under investigation since 
the middle part of the last century (5). It was originally postulated that electrophilic 
catalysis was promoted through an active site dehydroalanine moiety (6).  Early 
biochemical investigations supported a mechanism where the !-amine of the substrate 
added into the dehydroalanine and the elimination of bound ammonia occurred through 
an E1-cB mechanism (Figure A2.2A) (7, 8).  In 1999, the first X-ray crystal structure of 
an ammonia lyase revealed that the active site moiety was not dehydroalanine, but was 
the novel prosthetic group 4-methylideneimidazole-5-one (MIO, Figure A2.1B) (9).  The 
MIO is derived from auto-catalytic condensation of an Ala-Ser-Gly motif and is 
structurally similar to the well-characterized green fluorescence protein (GFP) 
chromophore (10). The mechanistic conclusions proposed for dehydroalanine are largely 
transferable to MIO as both are non-aromatic electrophilic species.  The discovery of this 
novel chemical entity produced renewed interest in the study of this enzyme class and 
resulted in additional investigations into an alternate mechanism that proceeds via 
electrophilic activation (Friedel-Crafts-type) of the substrate aryl side chain (Figure 
A2.2B) (2, 11).  Among the data used to support this mechanism are isotope effects 
consistent with hydrogens on the aromatic ring being directly involved in the reaction 
pathway (12), the activity of alternate substrates with substitutions on the aromatic ring 
(11, 13) and designed small molecule model systems (14). 
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A2.4 MIO-based aminomutases 
In 2003, new chemistry for the MIO-based ammonia lyase family was described 
with the characterization of a novel class of aminomutases (4, 15).   !-Amino acids are 
typically prepared enzymatically from the corresponding L-amino acid via a 2,3-amine 
shift (16, 17).  Members of the enediyne antitumor/antibiotic class of natural products 
often contain a functionalized !-tyrosine moiety (see Figure A2.1C) (18).  Analysis of the 
biosynthetic gene cluster for the enediyne C-1027, produced by Streptomyces 
globisporus, did not reveal a gene homologous to previously characterized 2,3-
aminomutases. There was, however, a gene with high sequence homology to MIO-
dependent ammonia lyases and, indeed, the purified enzyme, SgTAM, was shown to 
convert L-tyrosine to (S)-!-tyrosine (4).  The enzyme exhibits biochemical characteristics 
consistent with an active site MIO and, after extended reaction times, the lyase product 
(4-hydroxycinnamate) predominates. SgTAM can catalyze the reverse reaction (!-amino 
Figure A2.2: Proposed chemical mechanisms for MIO utilizing enzymes.  Two mechanisms are 
illustrated with L-tyrosine as an example substrate.  In a lyase enzyme, the cinnamate product will 
be released while a mutase will catalyze the conjugate addition as illustrated. 
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acids to L-amino acids) as well as the addition of ammonia into cinnamates. These 
findings, along with the high sequence homology, suggests that the chemical mechanism 
of MIO-based aminomutases is similar to that of lyases and that the former may have 
evolved from the latter.  
In addition to the C-1027 enediyne, the biosynthetic pathway to the anticancer 
therapeutic paclitaxel, isolated from the yew tree, also utilizes an MIO-based 
aminomutase (19).  The first biosynthetic step to the paclitaxel-sidechain is the 
preparation of (R)-!-phenylalanine by an L-phenylalanine specific aminomutase. 
Characterization of this enzyme suggested an MIO-based mechanism similar to SgTAM 
except SgTAM generated the opposite stereochemistry.  Unlike SgTAM, there is no 
scrambling of the stereochemistry of !-amino acid products over extended reaction times. 
Recently, additional MIO-based aminomutases have been described from biosynthetic 
gene clusters including the enediyne maduropeptin (20), antibiotic andrimid (21, 22), and 
the chondramides (23). 
The chemical mechanism for aminomutases was originally suggested to be an 
extension of the Friedel-Crafts-type mechanism proposed for ammonia lyases, but with 
an additional step involving conjugative addition of ammonia to yield the !-amino acid 
(see Figure A2.2B) (4).  However, with this mechanism the role of the MIO in the 
conjugate addition was not clear and the observed reversibility of the reaction was 
difficult to rationalize.   
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A2.5 Structural characterization of MIO-based ammonia lyases 
The first X-ray crystal structure of an MIO-containing enzyme was histidine 
ammonia lyase from Pseudomonas putida, which revealed the chemical nature of the 
active site electrophile (9). The overall structure is composed of multiple parallel !-
helices forming a tetramer arranged as a dimer of head-to-tail dimers.  The active site is 
located at the monomer interface with amino acid side chains from three subunits 
comprising the active site region around each MIO prosthetic group (Figure A2.3). 
Subsequent crystal structures of phenylalanine and tyrosine ammonia lyases provided a 
structural basis for additional substrate specificity (24, 25).  The combined work 
demonstrated that the class has significant structural homology, particularly around the 
active site. One common structural feature is that a large number (typically six) of the 
protein !-helices direct the positive end of their helix dipoles toward the active site (24).  
The culmination of these dipoles results in a significant positive charge in the active site, 
which would favor a reaction pathway with negatively charged intermediates as in the 
E1-cB elimination. In order to probe the nature of substrate recognition, previous 
structures of the histidine and phenylalanine ammonia lyases were used as a guide to 
rationally switch the substrate specificity in a tyrosine ammonia lyase from Rhodobacter 
sphaeroides (RsTAL) to favor L-phenylalanine (25, 26). A single point mutation in the 
active site was made (His89Phe) at a position that forms a hydrogen bond with the 
substrate phenol. Modeling the substrate into the active site showed that an amine adduct 
with the MIO would place the phenol of tyrosine 2.4 Å away from His89, supporting an 
amine activation mechanism (25).  Additional support for the amino-MIO adduct 
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mechanism comes from recent structures of the phenylalanine ammonia lyases from 
Anabaena variabilis and Nostoc punctiforme (27-29).  A double mutant of AvPAL was 
used to generate crystals with ordered electron density around the active site, including 
loops that are typically disordered in other lyase structures, resulting in an improved view 
of the active site.  Catalytic residues can also be identified by the proximity of inherently 
bound cinnamic acid, including Tyr78, which is positioned appropriately to act as the 
enzymatic base.  Docking studies were also used to show that binding of substrate and 
product is consistent with a carbanion elimination mechanism. 
Figure A2.3: Example X-ray crystal structures of MIO-ammonia lyases and aminomutases.  The 
protein monomers (shown) form biologically relevant tetramers where the active site is protected 
by inner and outer loop regions.  The PDB codes are 1B8F, P. putida; 1T6J, R. toruloides; 2O6Y, 
R. sphaeroides and 2OHY, S. globisporus. 
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A2.6 Structural basis for MIO aminomutase activity 
In 2007, the first structure of an MIO-based aminomutase was determined with 
the solution of the tyrosine aminomutase, SgTAM (30).  The structure is highly 
homologous to ammonia lyases, in particular to the tyrosine ammonia lyase, RsTAL (9, 
25).  One feature shared between the two structures is that the active site loops were in an 
ordered, ‘closed’ conformation around the MIO prosthetic group. A conserved tyrosine 
residue (Tyr63 in SgTAM) resides on the inner loop in close proximity to the MIO.  
Modeling of a substrate into the active site placed this residue in the proper position to act 
as a general enzymatic base.  Indeed, mutation of this residue to a phenylalanine results 
in complete loss of activity, an observation also seen in RsTAL (31, 32). 
With available structures of both an L-tyrosine specific ammonia lyase and 
aminomutase, the basis for the different chemistries can be explored.  Comparison of the 
active sites of SgTAM and RsTAL showed similar positions and identity of side chains 
around the MIO (30).  Only one obvious difference is observed at a site adjacent to the 
selectivity switch (His93). At this position, RsTAL has a valine residue (Val409), and 
SgTAM has a tyrosine (Tyr415). A difference of solvent accessibility to the MIO in the 
active site was also noted.  In the ammonia lyase, an open channel leads to the active site 
and no such channel was present in SgTAM. This could enable mutases to sequester the 
substrate and ammonia in the active site, favoring the conjugate addition to form the !-
amino acid.   
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A2.7 Small molecule probes into the mechanism of MIO-enzymes 
Earlier work characterized the mode of irreversible inhibition of histidine 
ammonia lyase by the amino acid L-cysteine in the presence of molecular oxygen. 
 Tanner and coworkers isolated and structurally characterized the adduct formed showing 
that L-cysteine is bound to the MIO through the  !-amine (33).  Heteroaryl-acrylate and 
alanine analogs were demostrated to be inhibitors of both histidine and phenylalanine 
ammonia lyases, a result that was proposed to support a Friedel-Crafts-type mechanism 
(34, 35).  An additional synthetic inhibitor is a conformationally restrained substrate 
analog, 2-aminoindan-2-phosphonate (AIP) (36).  The specificity mutant (His89Phe) of 
RsTAL, as described above, was cocrystallized with AIP to form an approximation of the 
substrate complex (25).  In this structure, the !-amine of AIP formed a covalent adduct 
with the MIO (Figure A2.4).  A variety of cocomplex crystal structures were obtained 
with the wild-type enzyme, the His89Phe mutant and products 4-hydroxycinnamate or 
cinnamate. The trans-alkene of the products is positioned directly over the MIO, 
maintaining the interactions between residue 89 and the aryl ring as predicted. In 
addition, in the absence of substrate/product analogs, the electron density maps show the 
MIO covalently modified by a small molecule, possibly ammonia. This work provides 
further evidence for the ordered release of products from the active site of lyases, as 
biochemically demonstrated (37). 
An analogous approach using cocrystallization with small molecule probes was 
applied to the tyrosine aminomutase, SgTAM. Exploiting the reversibility of the 
chemistry, a stable analog of the product, !,!-difluoro-(S)-"-tyrosine, was used to assign 
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key residues (Figure A2.4) (32).  As with the lyase/AIP structure, the amine of the 
product analog is covalently attached to the MIO.  The general base Tyr63 is well 
positioned to deprotonate at the !- and "-positions and eliminate MIO-bound ammonia 
through an anti-periplanar mechanism.  In addition, cinnamate epoxides were designed 
and synthesized to mimic the coumarate intermediate in the reaction, while providing a 
reactive moiety that could act as a mechanistic ‘trap’ (38).  When incubated with 
SgTAM, the epoxide was converted to the 2,3-diol and the cocrystal structures showed 
the analog bound to the MIO through the 2-hydroxyl group, forming a complex that 
mimics an enzyme-substrate complex. 
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Figure A2.4: Active site structures of MIO-ammonia lyases and aminomutases with bound small 
molecule probes.  Enzyme residues (gray) in proximity to the MIO (red) are illustrated along with 
the observed small molecule (teal).  The PDB codes are 2O7E, R. sphaeroides: AIP; 2O7B,  R. 
sphaeroides: HO-cinnamate and 2QVE, S. globisporus: !,!-diF-!-tyrosine. 
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A2.8 Unified mechanism for MIO-based enzymes 
The recent structural characterization of multiple MIO-enzymes supports an 
elimination/conjugate addition mechanism (Figure A2.5). In this cycle, the !-amine of 
the substrate amino acid forms a covalent adduct with the exocyclic alkene of the MIO 
prosthetic group. The bound amino acid is then deprotonated at the benzylic position by 
an enzymatic base, a tyrosine side chain possibly in the phenolate ionization state.  Upon 
loss of ammonia from the substrate, the cinnamic acid is sequestered in the active site in 
the case of aminomutases, and released in the case of lyases. For aminomutases, the 
ammonia remains bound to the MIO, and, by simple bond rotation, the amine can be 
repositioned for addition into the "-position.  The "-amino acid is then released, 
regenerating the MIO.  The amino-MIO adduct mechanism accounts for the observed 
kinetic isotope effects (7), the ordered release of products (12), and the characterization 
of intermediates and products of the reaction (15). 
Recent work by Walker and coworkers has provided biochemical insights into the 
mechanism.  Deuterium labeling studies were used to demonstrate that the amine and the 
benzyllic hydrogen atom trade positions with facial selectivity in paclitaxel PAM (39).  
They proposed a syn-configuration for the unsaturated intermediate, which would be the 
only way for the amine and proS hydrogen to maintain facial selectivity without the 
substrate rotating during the reaction sequence.  This general mechanistic proposal 
involving retention of the !- and "-nitrogen was also supported by studies on the tyrosine 
aminomutase from andrimid biosynthesis (40). 
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An amine-adduct mechanism does not, by itself, fully resolve the difficultly of 
deprotonating a benzylic hydrogen.  However, the extensively electropositive active site 
formed by !-helical dipoles can stabilize the benzylic anion generated through an E1-cB 
mechanism, effectively lowering the pKa.  In addition, cocomplex structures indicate that 
the enzyme binds substrate in a conformation favoring orbital alignment for a periplanar 
elimination.  A recent publication by Bartsch and Bornscheuer suggests that perhaps 
different mechanisms may occur depending on the nature of the substrate (41).  For PAL, 
the substrate would undergo a Friedel-Crafts-like mechanism, while for TAL the 
Figure A2.5: Unified mechanistic proposal for MIO-based ammonia lyase and aminomutase 
enzymes. The substrate ‘Ar’ corresponds to imidazole, phenyl, or 4-hydroxyphenyl.  
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substrate would go through the amino-MIO adduct mechanism.  Their reasoning is based 
on a conserved glutamate in the active site for PAL and PAM enzymes, which acts by 
blocking binding of the amino group to the MIO; an asparagine is conserved at this 
position for TAL and TAM enzymes, which would allow the MIO to bind to the amino 
group on the substrate. These assumptions are supported via mutations of a single residue 
(Glu484Asn) and the resulting activity towards tyrosine and phenylalanine.  It is 
uncommon for homologous members of the same enzyme class to utilize drastically 
different chemical mechanisms based on the nature of the substrate.   
A2.9 Utilization of MIO-aminomutases in chemoenzymatic synthesis applications 
The chemistry of MIO-dependent aminomutases has led to attempts to exploit 
substrate promiscuity for the production of novel !-amino acids.  Walker and coworkers 
have shown that paclitaxel PAM catalyzes the isomerization of diverse arylalanine 
substrates to the corresponding (R)-!-arylalanines (42).  Both fluorinated phenylalanines 
and phenylalanines substituted with electron-donating groups were turned over with 
increased efficiency over the natural substrate. Interestingly, (S)-styrylalanine was 
converted to (R)-!-styrylalanine, although at a significantly lower reaction rate. Janssen 
and coworkers illustrated another chemoenzymatic application by demonstrating that 
PAM can aminate functionalized (E)-cinnamic acids to produce both !- and !-amino 
acids with high enantiomeric excess (43).  It was found that electronic effects influenced 
the regioselectivity of the reaction with electron-donating groups on the aryl ring favoring 
!-amino acids and, conversely, electron-withdrawing groups preferentially generating !-
amino acids.  For example, in the case of the (E)-methyl- and (E)-nitrocinnamates, 
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amination occurred almost exclusively at the !- and !-positions, respectively. As 
opposed to the high substrate tolerance shown with PAM, the tyrosine aminomutase 
SgTAM has significantly tighter selectivity (15).   
A2.10 Rational engineering of lyase and aminomutase activity  
While some enzymes from this class show a considerable amount of flexibility for 
substrates, the products are generally fixed in terms of lyase and mutase paths.  Lyases 
produce elimination products (cinnamates) while mutases primarily produce one !-amino 
acid enantiomer. With the high degree of homology shared between lyases and mutases, 
determining the molecular basis for the two distinct activities poses a significant 
challenge.  Theoretically, an ammonia lyase could be mutated into an aminomutase and 
vice versa, the latter of which would seem facile since mutases already exhibit lyase 
activity.  Also, one could envision changing the stereoselectivity of mutases to produce 
different !-amino acids.  Towards these ends, Krug and Müller recently reported the 
effects of a variety of mutations of CmdF, which is responsible for the production of (R)-
!-tyrosine for incorporation into the chondramide family of natural products (44).  
Attempts to engineer CmdF into an ammonia lyase by exchanging conserved sequence 
motifs from lyases resulted in no activity or substantially reduced activity with retained 
mutase activity.  One successful mutant was an exchange of a sequence in CmdF for a 
homologous region in MdpC4 (the tyrosine aminomutase found in maduropeptin 
biosynthesis (20)), which surprisingly did exhibit a shift from aminomutase activity to 
ammonia lyase activity. Additionally, a mutation (Glu399Lys) led to an increase in 
enantioselectivity as compared to the wild-type enzyme.  On the basis of these and other 
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studies, it appears that this family of enzymes is quite sensitive to changes in and around 
the active site and that engineering novel activity will not be straightforward. The MIO 
cofactor is a chemically reactive species and even conservative mutations to the active 
site structure results in the abolishment of activity. This could stem from exposure of the 
active site to external nucleophiles or possible disruption of the quaternary structure by 
interfering with the tetramer interface. 
A2.11 Conclusions 
Recent structural biology efforts have provided insight into the chemistry of 
enzymes dependent on the MIO prosthetic group. The use of small molecule probes, 
along with biochemical studies, is consistent with a mechanism where the electrophilic 
MIO reacts with the amino acid and the enzyme orients the bound complex for an E1-cB 
elimination.  The recently described aminomutase subfamily diverts the lyase 
intermediate toward !-amino acid products, resulting in an overall 2,3-amino shift. These 
investigations have provided a structural basis for substrate specificity and defined key 
residues involved in catalysis. Further mechanistic work is necessary to resolve 
ambiguities in the chemical mechanism, particularly in defining the precise role the MIO 
prosthetic group plays in facilitating the catalytic cycle. Members of this enzyme family 
are important catalysts in the production of secondary metabolites and are rapidly 
expanding in both number and scope.  !-amino acids are biosynthetic building blocks in a 
variety of natural products.  The unique chemistry of MIO-based enzymes has the 
potential to be used in the preparation of chiral building blocks and in biosynthetic 
engineering approaches toward novel therapeutics.  
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